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THE GROWING EPIDEMIC OF CHRONIC
HEART FAILURE
Chronic heart failure (CHF) is one of fhe leading health problems in the Western
World [1 -41. This chronic, progressive condition is increasing in both prevalence and
incidence due to the ageing of the population, better chances of survival following
myocardial infarction and the growing incidence of hypertension, hence reaching
epidemic proportions 15,61. In the United States, a total prevalence of 2.5% was
reported in 2004 17}. The Rofterdam Study, a Dutch population-based prospective
cohort study of more than 7,000 patients, indicated point prevalence rates of CHF of
6.4% (1997), 6.7% (1998) and 7.0% (1999) Higher prevalence rates were found in
men than in women, and there was a significant rise in prevalence with age. The
study indicated that almost 1 in 3 individuals aged 55 or older will develop CHF
during their life span  [81. The incidence reported  in the latter study was  14.4/1000
person-years, with significantly higher incidence in men than in women 18]. By
comparison, the Netherlands Heart Foundation reported a prevalence of 163,800-
176,400 and an incidence of 37,400-43,400 in the Netherlands in 2000 191.
Apart from being a common condition, CHF is also associated with high
mortality and morbidity rates, despite impressive advances in treatment during the
last decades 11-4,8-101. In 2,445 patients hospitalised for CHF in the United
Kingdom in the year 2000, all-cause mortality rates 1 -, 2-, and 5-years after hospital
discharge were 37.3%, 52.9%, and 78.5%, respectively [21. In the United States,
deaths from CHF increased between  1994 and 2004 with 28%, whereas hospital
discharges rose with  1 75% [71. In the Netherlands, 5,624 patients died of CHF in
2004 (12% of total cardiac mortality) and 24,460 (8% of total cardiac
hospitalisation) were hospitalised [101.
Taken together, CHF is a chronic and progressive condition that is
associated with high mortality and morbidity, hence deserving attention in clinical
research. All fhe more because studies have shown that patients with CHF also report
impaired quality of life 111-141
QUALITY OF LIFE AND HEALTH STATUS AS
PATIENT-CENTRED OUTCOMES
Quality of life and health status are often used synonymously; however, quality of life
is a broader concept than health status, as it not only assesses the influence of the
disease on the individual's functioning, but also the extent to which this is
10
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bothersome to the individual [151. Quality of life and health status are imporfant
outcome measures in CHF research, because in general CHF patients prefer better
quality of life over prolonged survival [161. In addition, the studying of patient-
centred outcomes, such as quality of life and health status, has been advocated as a
means by which to bridge the gap between scientific research and clinical practice
[171. Patient-centred outcomes are an important aspect of patient-centred care, i.e.,
attending to patients' needs, improving or maintaining their quality of life and giving
them an opportunity to play an active role in medical decision-making [171
Furthermore, impaired quality of life has been linked to worse prognosis in coronary
artery disease (CAD) and CHF [18-201. Thus, knowledge of the determinants of
health status and quality of life in CHF may also help to identify CHF patients at high
risk for worse prognosis, thereby leading to improvements in treatment and
enhancements in secondary prevention.
Recent studies have identified New York Heart Association (NYHA) functio-
nat class, socio-demographic variables, somatic co morbidities and depression as
potential determinants of health status in CHF, whereas clinical disease charac-
teristics, such as left venfricular eiection fraction (LVEF), seem to play a minor role
Ill,21 -261. Apart from depression, little is known about psychological and
psychosocial determinants of patient-centred outcomes, such as health status, in
CHF.
EPISODIC VERSUS CHRONIC PSYCHOLOGICAL
RISK FACTORS
The importance of psychological and psychosocial factors in heart disease has been
increasingly recognised in recent years, but studies have mainly focussed on
depression, also in CHF [27-351 Depression has been shown to predict adverse
prognosis and impaired health status, although some studies did not confirm a
relationship between depressive symptoms and mortality [25,26,29-341. By contrast,
few studies have focused on anxiety in relation to health outcomes in CHF, with
results being inconsistent [30,32,35-371. With the primary focus on mood states, and
in particular on depression, there is a risk of ignoring other potentially important
psychological risk factors, such as personality.
According to the theory of Kop , psychological risk factors in heart disease
can be classified into (1) acute risk factors, (2) episodic risk factors, and (3) chronic
risk factors, based on their duration [38,391. Acute risk factors, such as a fit of anger,
may act as a trigger of cardiac events within a time period of one hour, whereas
11
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episodic risk factors exert an influence from several months up to two years and tend
to reoccur, with depression and anxiety comprising examples of this category of risk
factors. Finally, chronic risk factors, such as personality traits and socioeconomic
status, have an impact of longer than two years 138,391.
A paucity of studies has investigated the role of personality as a chronic
psychological risk factor in CHF, probably because of inconsistencies in research
findings on the Type A Behaviour Pattern (TABP) [40} However, personality is an
important explanatory factor of individual differences in distress and health outcomes
in CAD, and probably also in CHF [41-431. The type-D, or distressed, personality
has been related to poor health status and adverse prognosis in patients with CAD
[e.g. 36,40-42,44-47]. Given that CAD patients are at risk of developing CHF, type-
D personality may also be associated with deleterious health outcomes in this patient
group. Thus, it may be of importance to examine both episodic as well as chronic
psychological risk factors in the context of CHF.
THE NATURE OF TYPE-D PERSONALITY
Personality refers to the organisation of traits, which reflect consistencies in affect and
behaviour of persons [48,491 Negative affectivity and social inhibition are fwo
normal and stable personality traits that are relevant in the context of CAD [50,511
Negative affectivity and social inhibition are theoretically sound maior domains of
personality. Negative affectivity refers to the tendency to experience negative emo-
tions (such as anger, irritability and dysphoria), have a negative view of self, and
scan the world for impending trouble [501 Social inhibition is the tendency to inhibit
the expression of emotions and behaviours in social interactions, because of fear of
reiection or disapproval [51}. Persons with a type-D personality have elevated scores
on both negative affectivity and social inhibition. This means that they have a
tendency to experience a broad range of negative feelings that they are not going to
share with others, because they fear reiection or disapproval [48,52,531
Both statistical procedures (cluster analysis) and specific theoretical
assumptions underlie the construction of the type-D personality concept [48,541.
Research using cluster analysis yielded a number of coping subtypes in patients with
CAD, under which the specific personality subtype that was characterised by high
negative affectivity and high social inhibition [48,54,551. The theoretical deduction
followed the empirically based personality profile by using a median split of scores
on self-report measures of negative affectivity and social inhibition [48,531. This
median split was used following the coping subtypes model developed by
12
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Weinberger [561. A recent study using item response theory confirmed that all items
of the Type-D Scale (DS] 4), the instrument used to assess type-D, have the highest
measurement precision around this cut-off [571.
Evidence shows that negative affectivity and social inhibition, as measured
by  the  DS 1 4,  are  not  the  same as neuroticism and introversion/extraversion,
respectively  [531.  In the validation study  of the D514, evidence  on the construct
validity of the scale in both the general population as well as in cardiac patients and
in  patients with hypertension was provided.  The  D514 was validated against the
NEO-Five Factor Inventory (NEO-FFI), which assesses the Big-five personality Ira its,
namely neuroticism, extraversion, openness, agreeableness and conscientiousness
[53,581. In subiects  from the general population,  the  DS 1 4 negative  affectivity
subscale correlated r=.68 with NEO-FFI neuroticism, while the correlation between
the DS 14 social inhibition subscale and NEO-FFI extraversion was r=-.59. In other
words, the traits were related but not identical. The above-mentioned findings were
replicated in cardiac patients. Negative affectivity correlated  r=.68 with neuroticism,
whereas social inhibition correlated r=-.65 with extraversion [531.
Taken together, these results show that the DS 14 negative affectivity and
social inhibition sub domains are related to NEO-FFI neuroticism and extraversion,
respectively, but that the NEO-FFI and the DS 1 4 measure different construds [531. In
addition, the type-D construct represents the interaction of traits whereas the NEO-
FFI assesses single traits. A recent study confirmed that it is the interaction of the two
DS 1 4  personality traits that is toxic, with social inhibition moderating  the effect of
negative affectivity on prognosis [59]. Furthermore, neuroticism may have negative
connotations, such as "neurotic disorder" 1481. Although type-D personality is an
important determinant of emotional distress, such as anxiety and depression, and
type-D may therefore predispose to psychopathology, the personality configuration
itself is not psychopathological given that it is based on normal trails [481
TYPE-D PERSONALITY: AN EMERGING RISK FACTOR
IN CAD
In recent years, several studies have examined the detrimental effects of type-D
personality on prognosis and other health outcomes in CAD. Among the first was a
study published in the Lancet in 1996 [601. In this study, type-D personality predicted
mortality over a 6-10 year follow-up period in CAD patients, independently of
biomedical risk factors and measures of disease severity, such as impaired LVEF and
three-vessel-disease [60] These findings were replicated  in  1998,  2000,  2004,
13
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2006 and 2007, also in coronary patients with an impaired LVEF, and in patients
treated with percutaneous coronary intervention with drug-eluting stents
136,44,59,61-631. Very recently was shown that type-D personality was also
predictive of worse prognosis in heart transplantation recipients [641. Apart from
being associated with "hard medical outcome", type-D personality has also been
associated with impaired health status and increased psychological distress (i.e.,
depression, anxiety, post-traumatic stress disorder, and vital exhaustion) in cardiac
patients [e.g. 40,45,47,65-681
Recently, some studies have investigated possible physiological and
behavioural mechanisms in explaining the impact of type-D personality on health
outcomes. One very recent study, for example, investigated the association between
type-D and the cortisol awakening response in patients hospitalised for acute
coronary syndrome [691. Furthermore, two cross-sectional studies have examined the
associations between type-D personality and the cytokines TNF-a and its soluble
receptors sTNFRl and sTNFR2, and one recent study focused on type-D and health-
related behaviours in physically healthy persons 170-721. Although the first two
studies were conduded in patients with CHF  [70,711, the potential  impad of type-D
personality on patient-centred outcomes, such as impaired health status and
increased psychological distress (depression and anxiety), and prognosis in CHF is
not known, nor have any prospective studies examined possible physiological and
behavioural mechanisms that may explain the adverse effects of type-D personality
on health outcomes in CHF.
For a more extensive review of the literature on the type-D personality
construct, readers are referred to Chapter 2 of this thesis. Furthermore, a review
article on type-D personality in Dutch is included in the Appendix.
PRESENT RESEARCH AND AIMS OF THIS THESIS
The present thesis examines the role of type-D personality as a chronic risk factor for
patient-centred outcomes and prognosis in CHF, and reports on findings of a
longitudinal follow-up study. Patients for the study were recruited from the cardiology
department of the TweeSteden hospital in Tilburg, the Netherlands. All patients were
consecutive CHF outpatients. The study was approved by the medical ethics
committee. The data for the cross-sectional study described in Chapter 3 were




As mentioned before, until now no studies have reported on the impact of
type-D personality on adverse patient-centred outcomes and prognosis in CHF.
Furthermore, no prospective studies have examined possible physiological and
behavioural mechanisms explaining the adverse effects of type-D personality on
these outcomes in CHF. Therefore, the focuses in the present thesis are on the role of
type-D personality as a determinant of patient-centred outcomes and prognosis, i.e.,
health outcomes, in CHF, and on possible mechanisms explaining the adverse
effects of type-D personality on these outcomes. In Figure l,a schematic overview of
the outline and aims of the present thesis is presented.
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CHAPTER 1
OUTLINE OF THE THESIS
PART A
TYPE-D PERSONALITY AS A PREDICTOR OF
PATIENT-CENTRED OUTCOMES IN CHF
After a general introduction on type-D personality (Chapter 2), the first part of this
thesis (Part A) focuses on type-D personality and its traits, and patient-centred
outcomes in CHF.
An exploratory, cross-sectional study  (n=84)  on  the association between
type-D personality on the one hand, and health and mood status, and depressive
symptoms on the other hand will be described in Chapter 3. This is the first study to
examine the influence of type-D personality on health status, depressive symptoms
and mood status in patients with CHF.
In  a second, prospective study  in  166 CHF patients, the findings  of the
cross-sec:tional study reported in Chapter 3 will be replicated. However, in this study,
health status will be assessed using a broader approach, that is, using both disease-
specific and generic (mental and physical) health status as patient-centred outcome
measures. Furthermore, the aim of this study is to examine whether type-D
personality would predict impaired health status above and beyond depressive
symptoms (Chapter 4).
The relationship between negative affectivity, one of the type-D trails, health
status, cardiac symptoms, perceived disability and functional capacity will be
investigated in an exploratory study of 31 CHF patients who underwent cardiac
resynchronisation therapy (CRT) (Chapter 5). To the best of our knowledge, no
previous study has reported on the influence of personality trails on a broad range of
patient-centred outcomes in patients treated with CRT.
Since anxiety and its determinants are in general less investigated in CHF
than for instance depression, and the predictive role of type-D personality on anxiety
in CHF has not been investigated, Chapter 6 will focus on type-D personality as a
predictor of clinically relevant anxiety, measured with a clinical interview. In this




TYPE-D PERSONALITY AS A PREDICTOR OF
PROGNOSIS IN CHF AND MECHANISMS EXPLAINING
THE ADVERSE EFFECTS ON HEALTH OUTCOMES
The second part of the thesis (Part B) reports on the relationship between type-D
personality and mortality in CHF, and on possible mechanisms explaining adverse
relationships between type-D personality and health outcomes.
Chapter 7 will prospectively investigate the association between type-D
personality and impaired self-management, or more specifically, impaired
consultation behaviour,  in  178 CHF patients. Given their high level of social
inhibition, type-D CHF patients may be at risk for inadequate self-management in
terms of poor consultation behaviour. This failure to consult for cardiac symptoms is
paradoxical given their tendency to experience high levels of negative feelings and to
worry.
A possible physiological mechanism explaining adverse relationships
between type-D personality and mortality is neurohormonal activation (cyfokines).
The relationship between type-D personality and chronic kidney disease on the one
hand, and pro- and anti-inflammatory cytokine levels on the other hand, will be
prospectively investigated in 125 CHF patients in Chapter 8.
Finally, the role of type-D personality in cardiac prognosis will be described
in Chapter 9, as no study has reported on the relationship between type-D
personality and prognosis in the context of CHF. The prognostic value of type-D
personality will be examined in 232 CHF patients.
In the general discussion and summary of the thesis (Chapter 10), the main
findings will be summarised and integrated. Implications for clinical research and
practice will be described and reflections on limitations and strengths of the present
research will be given. Finally, a review article on type-D personality in Dutch is
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Despite significant reductions in morbidity and mortality in recent years due to
improved treatment strategies, cardiovascular disease is the leading cause of death
in the Western World. Psychosocial factors, such as depression, have been shown to
impact adversely on the prognosis of patients with coronary artery disease, but
personality factors have to a large extent been ignored since the controversial
findings surrounding the Type A Behaviour Pattern. This review on type-D personality
highlights the importance of including personality factors in research and clinical
practice, as personality may be an important explanatory factor of individual
differences in multiple clinical outcomes. Type-D personality is defined as a high
score on negative affectivity (a tendency to experience increased negative emotions)
and social inhibition (a tendency not to express these emotions when together with
others). Type-D has been associated with increased depression, fatigue, poor
Chealth-related) quality of life, and increased risk of cardiac morbidify and mortality,
independent of established biomedical risk factors. Type-D personality can be
assessed  with the Type-D 14-item Scale   (DS 1 4). The scale   is a brief, valid  and
standardised instrument that comprises little burden to patients and to clinical
practice. The DS14 has recently been validated in Italian cardiac patients.
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RIASSUNTO
Nonostante negli ultimi anni si sia verificata una notevole diminuzione di morbilit6 e
mortalito, grazie anche al miglioramento nella diagnostica e nella cura, le maiattie
cardiovascolari rimangono la causa principale di morte nelle popolazioni
occidentali.
Si 6 dimostrato che fattori psicosociali, come ad esempio la depressione, giocano un
ruolo negativo nella prognosi delle maiattie cardiovascolari; tuttavia, i fattori legati
alla personalito, a causa dei risultati a volte contraddittori delle ricerche sul Tipo A
(Type A Behaviour Pattern), sono stafi trascurati. Questa rassegna sulla personalita di
Tipo D mette in luce l'importanza dell'inclusione dei fattori di personalita nella
ricerca e nella pratica clinica, poichd la personalit6 pu6 essere un importante fattore
esplicativo di differenze individuali in molteplici esiti clinici.
La personalit6 di Tipo D & una combinazione di due dimensioni : affettivit6 negativa
Ctendenza ad esperire emozioni negative nel tempo e in diverse situazioni) ed
inibizione sociale (tendenza ad inibire emozioni e comportamenti nelle interazioni
sociali. La personalitO di Tipo D 6 stata associata ad un aumento di depressione,
spossatezza cronica, insoddisfacente qualit6 della vita connessa alla salute e
aumentato rischio di morbilit6 e mortalito per malattie cardiovascolari,
indipendentemente da altri fattori di rischio biomedici. La personalitti di Tipo D 6
misurabile con la Scala DS 1 4 costituita da  14-item, uno strumento conciso, valido e
standardizzato che richiede poco tempo a pazienti e operatori.   La   DS 1 4 6 stata




Several studies have shown that psychological distress is associated with the
pathogenesis of cardiovascular disease (CVD) 11,21, but a paucity of studies include
an appraisal of the contribution of personality to the link between distress and CVD
prognosis. Personality factors may have much explanatory power in terms of
individual differences in psychological distress, morbidify and mortality following
somatic disease such as CVD, as will be shown in this review. In part, the exclusion
of personality factors in psychosomatic research can be attributed to inconsistent
results on the Type A Behaviour Pattern (TABP) and CVD.
The type-D (distressed) personality construct, derived from theoretical and
empirical research, is characterised by a high score on two stable persona|ity traits,
i.e., negative affectivity and social inhibition [3-51 Negative affectivity denotes the
tendency to experience negative emotions (such as anxiety, sadness, anger) across
time and situations, with individuals high on this trait scanning the world for signs of
impending trouble [6,71. Social inhibition refers to the tendency to inhibit fhe
expression of these negative emotions in social interactions, i.e., individuals high on
this trait fear the negative iudgment of others and beli#le or hide their difficulties,
thereby generating a condition of social isolation 17,81. In general, individuals with a
type-D personality present with few positive emotions, have low self-esteem, and are
generally dissatisfied with life [51. In addition, type-D persons are more likely to suffer
from depression, chronic tension, anger, pessimism, poor social support, and low
levels of perceived well-being 13-5,91
The present review reports on research on type-D personality in relation to
CVD conducted between  1995  and  2004. For clarity, the studies  have  been
categorised according to the levels of evidence in medical experimentation proposed
by the Italian National Program for Guidelines Ministry of Health (Table  1)  110]
These levels range from I to V, with level I (e.g. randomised controlled trials and
meta-analyses) being the highest, i.e., the best, level of evidence, and level V (e.g.
case studies without a control group) being the lowest. To date, no studies have
looked at interventions targeting type-D personality. Therefore, evidence from level I
and 11 studies is not available.
EVIDENCE LEVEL 111 STUDIES
The study that can be considered a precursor to fhe type-D personality construct was
published in  1995 1111. It was based on a small sample of  105 male survivors of
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myocardial infarclion (MI), and investigated the association between personality and
mortality. The results of the study showed that personality traits might play a role in
the adverse effect of emotional distress on prognosis in post-MI patients. Patients with
a fype-D personality had a 6-fold increased risk of cardiac mortality compared with
non type-D patients, adiusting for biomedical factors, including low exercise
tolerance, previous MI, smoking, and age. Furthermore, adding the personality
variable to biomedical factors in a logistic regression model more than doubled the
sensitivity of the model in terms of its ability to predict mortality. In the latter study,
depression, social alienation, somatisation and the use of benzodiazepines were also
related to prognosis in post-MI patients. The findings indicated a higher prevalence
of the various psychosocial risk factors in the distressed than in the non-distressed.
However, fhe factors did not add to the level of prediction of mortality above and
beyond that of the distressed personality type [ill
Tobie 1 Levels of evidence
Levels of evidence as provided by the Itolion ministry of health
1 Randomised controlled Mals (RCTs) and/or systematic reviews of RCTs
11          One RCT
1/1           Cohort non-randomised studies with concurrenf or· historical controls or their meta-
analyses
IV            Retrospective studies i.'such as case contro/3 or their meta-analyses
V Case series without control group
Vl            Expert opinion (such as guidelines or consensus conferencel
In  1996, an extension of the 1995 study was published [91. The number of
patients included was increased in order to enhance the power of the study, and the
follow-up was extended. Type-D personality was associated with a significantly
increased risk of mortality (type-Ds=27% versus non type-Ds=7%;p< 0.00001). The
influence of type-D on cardiac and non-cardiac death remained substantial
(OR=4.1;95%Cl:1.9-8.8), even after adiusting for left ventricular election fraction
(LVEF), multi-vessel disease, low exercise tolerance, and lack of thrombolytic therapy
after  MI. As shown in Figure 1, type-D  personality  was  a  predictor of all-cause
mortality, independent of the two well-known risk factors for coronary heart disease
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(CHD), i.e., LVEF and multi-vessel disease [91. Another important result of this (and
the previous) study was that neither negative affectivity nor social inhibition alone, but
the synergistic effect of these two trails had deleterious effects on cardiovascular
health; death rates for patients scoring high on only one of these traits did not differ
from patients scoring  low  on  both  tra its.
4 50 •Type-D
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Figure 1. Left ventriculor election fraction (LVEF) and niulti-vessel disease stratified by personality
type
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In 2000, the above-mentioned results were confirmed in a 5-year follow-up
study of 319 patients with established  CHD  [121.  In  a multivariate model, type-D
personality COR=8.9.95%(1:3.2-24.7), LVEF<50% (OR=3.9;95%Cl:1.4-11.1) and
age<55 (OR=2.6;95%Cl:1.0-6.6) were identified as independent predictors of
cardiac mortality and non-fatal MI at 5-year follow-up. Type-D personality was also
a risk factor for a combined endpoint, defined as cardiac mortality, non-fatal MI,
coronary bypass graft surgery (CABG) and percutaneous transluminal coronary
angioplasty (PTCM (OR=4.5.95%(1:2.3-8.5) [121
Two studies have investigated the relation between type-D and prognosis in
special interest groups. The first study was undertaken in patients with a poor LVEF
[131; the second in patients  with  established  CHD who developed cancer  [141.  The
first study, focused on 87 patients with MI and a LVEF550%. Type-D (RR=4.7;
95%Cl:1.9-11.8) and LVEFs30% (RR=3.0;95%Cl:1.2-7.7) were identified as
independent risk factors for cardiac events in a follow-up period of 6-10 years
(mean=7.9 years) [131. The second study, that examined the association between
type-D personality and the development of cancer in male CHD patients, found that
13% of type-D patients developed cancer versus 2% of non type-D patients [14].
Type-D personality (OR=7.2;95%Cl:2.9-18.1) and age (OR=4.6;95%Cl:1.5-14.3)
were identified as independent predictors of the development of cancer. There was
no association between development of cancer and cardiac disease severity as
measured by LVEF [141
A recent sub-study of the Rapamycin-Eluting Stent Evaluated At Rotterdam
Cardiology Hospital (RESEARCH) registry evaluated the impact of type-D personality
on prognosis at 9-month follow-up in 875 consecutive patients with ischemic heart
disease (IHD) following percutaneous coronary intervention (PCI) [15]. The patients
had either received a sirolimus-eluting stent (SES) or a conventional bare stent. In
univariate analysis, patients with a type-D personality had a higher risk of a
composite of death or MI (5.696) compared with non type-Ds (1.3%1
(OR=4.7;95%Cl:1.9-12.0). Type-D personality remained an independent risk factor
for mortality or MI (OR=5.3;95%Cl:2.1-13.7) after adiusting for all other clinical
variables, including stent type. The results of the above-mentioned RESEARCH sub-
study suggest that type-D personality is an independent predictor of prognosis in
CHD, even when patients are treated with the latest advent in interventional
cardiology [151
Taken together, the consistency of these results suggests that type-D




EVIDENCE LEVEL IV STUDIES
A study by Appels and colleagues in 2000 considered the association befween vital
exhaustion (VE) and the inhibition of emotions in patients having suffered a sudden
cardiac arrest  (SCA)  [161.  This study, based  on 99 patients  with  SCA  and  119
controls, identified VE as an antecedent of SCA. Furthermore, the effect of VE was
modified by the inhibition of emotions, with patients who did not express their
emotions being at a 7-fold increased risk of SCA [161.
In 2001, a study of 171 patients with IHD focused on the relation between
type-D personality, gender, VE, and symptoms of angina 1171 Patients scheduled for
coronary angiography (CAG) completed a questionnaire at baseline and 6 weeks
following invasive or medical therapy. Univariate analysis yielded fype-D as an
independent predictor of VE at baseline and at follow-up. Compared with non type-
Ds, type-D patients were at increased risk of VE both at baseline
COR=6.4;95%(1:3.0-9.7) and follow-up (OR=4.7;95%Cl:0.7-8.8). At follow-up,
type-Ds also reported more symptoms of angina pectoris than non type-Ds.
A recent contribution to type-D research was conducted in Denmark [18}.
The obiectives of this study were to investigate whether the Type-D Personality Scale
CDS 1 6)  is a valid and reliable measure in other than Belgian populations, and to
investigate whether individuals with a type-D personality may be at increased risk of
developing pos#raumatic  stress  disorder. The study was based  on  112  first MI
patients and 115 healthy controls, selected af random from the general population.
The study confirmed   the   validity    of   the    DS16,    and    identified   type-D
COR=4.5.95%(1: 1.4-14.6), neuroticism (OR= 1.3,95%(1:1.1-1.5) and diagnosis of
MI (OR=4.0.95%(1.1.4-11.4) as independent predictors of pos#raumatic stress
disorder adiusting for several other variables [181
In another study, Pedersen and colleagues [191 investigated the prevalence
of symptoms of anxiety and depression, and the association between type-D
personality, social support and distress in patients with an implantable cardioverter
defibrillator (ICD) (n=182) and their partners (n= 144). The results showed a higher
prevalence of anxiety symptoms in partners (42%) than in patients (31%), whereas
levels of depression were similar (29% versus 28%). Both in patients (OR= 7.0,
95%Cl:2.3-21.3) and in partners (OR=8.8;95%Cl:3.2-24.1), type-D was an
independent determinant of symptoms of anxiety. Type-D was also independently
associated with depressive symptoms in patients (OR=7.4;95%Cl:2.5-21.9) and
partners (OR=4.4;95%Cl:1.8-11.01).
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The results of the level IV studies indicate that the type-D construct also has
value in arrhythmia research, and again support the notion that personality is an
important explanatory factor of individual differences in distress.
EVIDENCE LEVEL V STUDIES
In 1998, the first level V study on type-D was published [51. The focus of the study
was on the two traits that define type-D, i.e., negative affectivity and social inhibition,
and the development of a brief self-report measure for identifying type-Ds. The aim
of the study was to replicate the 1996 finding that the synergistic effect of these two
fraifs, i.e., type-D personality, is a risk factor in CHD patients [91. The results showed
that the Type-D Scale was a valid and reliable measure with type-Ds reporting more
depressive feelings, lower self-esteem, and more dissatisfaction with life than non
type-Ds [51.
A study of 734 patients with hypertension again focused on the synergetic
effect of negative affectivity and social inhibition that is known as a risk factor in
CHD [71 First, the results showed that negative affectivity and social inhibition and
their lower order traits could be assessed reliably in this patient group. This means
that the type-D construct is not only applicable in patients with established CHD.
Furthermore, there was an association between type-D personality and depressive
affect; 49% of the type-Ds scored high on depressive affect versus 23% of the non
type-Ds [71.
A preliminary cross-sectional study of 42 male patients with chronic heart
failure (CHF) suggested that immune-activation may comprise one link between type-
D personality and cardiac events [201. Denollet and colleagues found that type-D
was independently associated with higher levels of the pro-inflammatory cytokine
TNFa and its soluble receptors TNFRl and TNFR2, which comprise important
prognostic indicators  in CHF [20,211.  In the Denollet  et  al. study, type-D was as
important as ischemic aetiology in immune activation [20]. It has previously been
shown that negative emotions are associated with increased levels of pro-
inflammatory cytokines 1221. The results of another study in healthy subiects (n= 173)
on fhe relationship between fype-D personality and physiological indices, indicated a
relationship between increased blood pressure and social inhibition, and between
reduced heart rate and negative affectivity, in male subieds [231.  Furthermore, both
negative affectivity and social inhibition turned out to be correlated with increased
cortisol levels as a result of stress. These results suggest that the sympathic nervous
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system may comprise another pathway in the relationship between type-D and
outcomes in CVD 1231.
An American study took into consideration type-D personality and other risk
factors that have been associated with an increased risk of mortality in patients with
CVD, using age at initial diagnosis as a proxy for prognosis. Type-D personality was
found not to be significantly correlated with age at initial diagnosis; however, type-D
persons reported more symptoms of depression and anxiety compared to non type-
Ds [24}. A sequel to the latter study, which increased the number of participants by
including more women, identified a significant relation between type-D and younger
age at initial diagnosis of CVD in men [251
Publications on type-D personality based on the level of evidence in
medical experimentation as proposed by the Italian Ministry of Health are shown in
Table 2.
Table 2.   Publications on type-D personality based on fhe level of evidence in medical
experimentation os proposed by the Italian Ministry of Health
Author Publication Evidence Reference
level number
Denollet el al. 1996, Lancet                     3             9
Denollet & Brusaert 1998, Circulation                 3             13
Denoilet 1998,  Psychol Med                                3                          14
Denotlet 1998, Ann Behav Med                   5                   5
Denoflet et al. 2000.  Circulation                                        3                              1 2
Denollet 2000, J Psychosom Res                 5                 7
Appels et al. 2000, J Psychosom Res                 4                  16
Pedersen & Middel 2001.  J Psychosom  Res                                  4                                    1 7
Denollet et al. 2003, Brain Behov Immun              5                 20
Hobra ef al. 2003, J Psychosom Res               5                23
Pedersen & Denollet 2004, J Psychosom Res                 4                  18
Pedersen et 01. 2004, Psychosom Med                       4                        1 9
Pedersen et ol. 2004. J A m Coll Cardiol                       3                           1 5
Ketterer et al. 2004, J Psychosom Res                 5                 25
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TYPE-D PERSONALITY, QUALITY OF LIFE,
AND RESPONSE TO TREATMENT
Qualify of Life
Until now, we have mainly considered the levels of evidence related fo hard
endpoints in CVD , i.e., morbidity and mortality, but response to treatment and
quality of life (QoL) comprise other important endpoints. As emphasised by the
World Health Organization (WHO), the target for the next millennium in terms of
public health is a general improvement in QoL; all health-care professionals are
required to devote attention to this aspect which to dafe only has been considered
secondary [261. Furthermore, in medical research, patients have rated qualify of life
as more important than extended survival [27]. As a consequence, QoL is an
important outcome measure in medical research, also since impaired QoL has been
associated with adverse prognosis [28,291
Two studies have investigated the association between type-D personality
and QoL in CVD patients. In the already cited study by Denollet and colleagues,
type-Ds reported poorer subiective health compared to non type-Ds at 5-year follow-
up [121. QoL was measured with the Health Complaints Scale (HCS) and the Global
Mood Scale (GMS), two psychomefrically sound and sensitive measures of QoL
[30,311. It must be emphasised, however, that the above-mentioned results are
based on a relatively small sample (n=104), and that further studies are warranted
to confirm these associations. A cross-sectional study of 84 patients with CHF found
an association between type-D personality and impaired health status [321. In
univariate analysis, type-D was associated with impaired health status
(OR=2.8;95%Cl:1.1-7.3); after adiusting for clinical and demographic variables,
type-D remained an independent risk factor for impaired health status
COR=3.3.95%Cl: 1.2-9.1) 1321
Response to treatment
The already mentioned results of the Pedersen and Middel study on patients
scheduled   for  CAG   (n=1 71) showed that type-Ds reported more symptoms   of
angina pectoris than non type-Ds following CABG/PTCA or conservative treatment,
despite reduction in symptoms of angina [17]. This means that type-D patients
benefit from treatment, but not to the same extent as non type-D patients, as their
levels of distress and somatic complaints remain significantly higher. Furthermore,
another study showed that fhe convergence of decreased LVEF, younger age and
type-D personality predicts absence of an expected therapeutic response 1121.
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Taken together, these results show that type-D personality is not only
associated with an increase in emotional distress, more cardiac events and poor
QoL, but also seems to moderate the effects of pharmacological and invasive
treatment.
CROSS-CULTURAL RESULTS ON TYPE-D PERSONALITY:
PRELIMINARY RESULTS ON THE DS14
During the third conference on the (Non-) Expression of Emotions in Health and
Disease in Tilburg, the Netherlands (October 2003), a symposium was organised on
the cross-cultural applicability of the type-D construct. Results of five studies on the
validation of the Type-D Scale (D514) in different countries, i.e., Belgian, Hungary,
Germany, Denmark, and Italy were presented 118,33-361. The DS] 4 comprises two
subscales, i.e., negative affectivity and social inhibition, containing seven items each
[331. Both subscales have good test-retest validity and high internal validity, with
Cronbach's a of .88 and .86 for the negative affectivity and social inhibition
.subscales, respectively. The items are answered on a 5-point Likert scale from "false
CO) to "true" (4). A pre-defermined cut-off 210 on both subscales is used to
determine those with a type-D personality [331.
The results of the Hungarian study in the general population (n=12570)
identified type-D personality as a risk factor for cardiovascular disorder, MI, and
cardiovascular morbidity, especially in subgroups in whom more traditional risk
factors were absent (i.e., hypertension, diabetes and smoking) 1341. The German
study (n=2417) confirmed the validity and reliability of the German DS 1 4 in cardiac
patients, psychosomatic patients and healthy factory workers (preliminary datal [351
The prevalence of type-D in cardiac patients was 24%, in psychosomatic patients
62%, and in healthy factory workers 32% [351. The Danish study, which has been
mentioned previously, was conducted in first MI patients and healthy controls. The
DS 1 6 was found to be a valid instrument in both MI patients and healthy persons.
Type-D also was associated with a more than 4-fold increased risk of posttraumatic
stress disorder in this population, confirming that it is a marker of general distress
[181. The validation study of the Italian version of the  DS 1 4 included 145 cardiac
patients [361. The study confirmed fhe validity of the Italian DS 14, of with Cronbach's
a .82 and .80 for the negative affectivity and social inhibition subscale, respectively,
and found type-D to be a predictor of psychological distress 1361
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TYPE-D OR NOT TYPE-D: DO WE NEED ANOTHER
PERSONALITY TYPE8
The emergence of non-psychopathological personality types and their association
with somatic disease dates  back  to  the  1950s when Friedman and Rosenman
discovered that behavioural factors influenced serum cholesterol levels independent
of diet [371 Their observations led to the derivation of the TABP, or Type A as it is
often referred to. The TABP is probably the most well known "personality" construct,
and is defined as a competitive achievement orientation, a sense of urgency, and
hostility; Type B typifies individuals with the absence of TABP. Following identification
of TABP as an aefiological risk factor for CHD, independent of established
biomedical risk factors, TABP was formally recognised as a risk factor of CVD on par
with traditional biomedical risk factors 138,391 However, later studies have shown
mixed findings, and it seems that sub components of TABP (hostility) rather than
global TABP have deleterious effects on health  12,40,411. The following personality
taxonomy that emerged was Type C personality, or the cancer-prone personality
[421. Type C defines those individuals who are cooperative, unassertive, and who
suppress negative emotions 14,421 Type-D personality is the most recent addition to
these non-psychopathological personality dispositions, and may revive research in
personality factors per se.
As a final remark, if is important to note that, although TABP is often
regarded as a personality type, it was defined so as to avoid any association with
general and stable features of personality [431. Hence, it is particularly paradoxical
that inconsistent results in relation to TABP have led to the general exclusion of
personality factors in CVD. By contrast, type-D is a personality construct that is based
on two stable traits, i.e., negative affectivity and social inhibition. So far, this
personality type has been related consistently to hard and soft endpoints in CVD and
other chronic conditions, thereby identifying patients at risk for important events and
impaired QoL.
CONCLUDING REMARKS
The identification of cardiac patients at risk of recurrent cardiac events and impaired
QoL, and the modification of this risk comprise important targets for secondary
prevention. Since psychosocial risk factors have shown to cluster together within
individuals, hence increasing the risk of adverse prognosis substantially, it is
imperative to be able to identify this subgroup of patients. A recent review on the role
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of psychological factors in CVD has suggested that focus on chronic stress in
research  and in clinical practice may facilitate the identification of these patients  Ill.
Chronic psychological risk factors are believed to promote the development of
episodic and acute risk factors [44,451. Type-D personality comprises a chronic
psychological risk factor in so far as Type-D individuals deal with stress in a
particular way. As shown in this review, type-D has substantial explanatory power of
individual differences in cardiac morbidity and mortality. It has been associated with
increased morbidity and mortality in patients with established CVD, comprising a risk
factor on par with traditional biomedical risk factors. Furthermore, it has been
associated with increased psychological distress and impaired QoL, and it has been
shown to moderate the effects of pharmacological and invasive treatment. Type-D
personality has also been shown to be important in other chronic conditions and
diseases, including hypertension 171, cancer [14], and arrhythmias [191
An important question remains, however, namely whether it is at all
possible fo modify the impact of type-D personality given its stable effect on
behaviour. Although two recent trials have produced mixed findings [46,471,
psychosocial interventions successful at reducing emotional distress, depression,
TABP and anger/hostility, have proven to reduce morbidity and mortality in patients
with  CVD [48-511. Type-D patients match this psychological profile  and   may
therefore benefit from similar psychosocial interventions, even though this needs to
be confirmed in future intervention studies.
In conclusion, the DS14 could  be used in research and in clinical practice
in order to identify patients at risk of future cardiovascular events. The scale is a brief
and valid measure that comprises little burden to patients and to clinical practice.
Although the scale was developed in Belgian cardiac patients, its applicability in
other cultures has been demonstrated in recent studies in Denmark, Hungary
Germany, and Italy [18,34-361.
40
TYPE-D PERSONALITY AND CARDIOVASCULAR DISEASE
REFERENCES
1.     Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on fhe pathogenesis
of cardiovascular disease and implications for therapy. Circulation 1999;99:2192-2217.
2.  Hemingway H, Marmot M. Psychosocial factors in the aetiology and prognosis of
coronary heart disease: systematic review of prospective cohort studies. BMJ
1999;318:1460-1467.
3.     Denollet J, De Potter B. Coping subtypes for men with coronary heart disease: relationship
fo well-being, stress, and Type A behaviour. Psychol Med 1992;22:667-684.
4,   Denollet J. Bio-behavioral research on coronary heart disease: where is the person2 J
Behav Med 1993;16:115-141.
5.     Denollet J. Personality and coronary heart disease: the type-D scale-16  (DS16).  Ann
Behav Med 1998;20:209-215.
6.   Watson D, Pennebaker JW. Health complaints, stress, and distress: exploring the central
role of negative affectivity. Psychol Rev 1989;96:234-254.
7. Denollet J. Type-D personality a potential risk factor refined. J Psychosom Res
2000;49:255-266.
8.  Asendorpf JB. Social inhibition: a general developmental perspective. In:Traue HC,
Pennebaker JW (eds). Emotion, inhibition and health. Seattle, WA: Hogrefe and Huber
Publishers 1993:80-99.
9.    Denollet J, Sys SU, Stroobant N, Rombouts H, Gilleberf TC, Brutsaert DL. Personality as
independent predictor of long-term mortality in patients with coronary heart disease.
Lancet, 1996;347:417-421.
10.  PNLG. Come produrre, diffondere e aggiornare raccomandazioni per la pratica clinica.
Manuale metodologico. Milano: Arti Grafiche Passoni: 2002.
11. Denollet J, Sys SU, Brutsaert DL. Personality and mortality after myocardial infarction.
Psychosom Med 1995;57:582-591.
12. Denollet J, Vaes J, Brutsoert DL. Inadequate response to treatment in coronary heart
disease: Adverse effects of Type D personality and younger age on 5-year prognosis and
quality of life. Circulation 2000;102:630-635.
13.  Denollet J, Brutsaert DL. Personality, disease severity, and the risk of long-term cardiac
events in patients with a decreased eiection fraction ofter myocardial inforction.
Circulation 1998;97:167-173.




15.  Pedersen SS, Lemos PA, van Vooren PR, Liu TK, Daemen J, Erdman RA, Smits PC, Serruys
PW, von Domburg RT. Type D personality predicts death or myocardial infarction after
bare metal stent or sirolimus-eluting stent implanfation. A Rapamycin-Eluting Stent
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry sub study. J Am Coll
Cardiol 2004;44:997-1001.
16.   Appels A, Golombeck B, Gorgels A, de Vreede J, van Breukelen G. Behavioral risk factors
of sudden cardiac arrest. J Psychosom Res 2000;48:463-469.
17.  Pedersen SS, Middel B. Increased vital exhaustion among Type-D patients with ischemic
heart disease. J Psychosom Res 2001;51 :443-449.
18.  Pedersen SS, Denollet J. Validity of the Type D personality construct in Danish post-MI
patients and healthy controls. J Psychosom Res 2004;57:265-272.
19.  Pedersen SS, van Domburg RT, Theuns DA, Jordaens L, Erdman RA. Type D personality is
associated with increased anxiefy and depressive symptoms in patients with an implantable
cardioverter defibrillator and their partners. Psychosom Med 2004;66:714-719.
20.  Denollet J, Conroads VM, Brutsoert DL, De Clerck LS, Stevens WJ, Vrints CJ. Cytokines
and immune activation in systolic heart failure: the role of Type D personality. Brain Behav
Immun 2003;17:304-309.
21. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and
cytokine receptors in advanced heart failure: an analysis of the cytokine database from the
Vesnarinone trial (\/EST) Circulation 2001;103:2055-2059.
22.  Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Emotions, morbidity, and mortality:
New perspectives from psychoneuroimmunology. Annu Rev Psychol 2002;53:83-107.
23. Habra ME, Linden W, Anderson JC, Weinberg J. Type D personality is related to
cardiovascular and neuroendocrine reoctivity to acute stress. J Psychosom Res
2003;55:235-245.
24. Ketterer MW, Denollet J, Goldberg AD, McCullough PA, John S, Farha AJ, Clark V,
Keteyian S, Chapp J, Thayer B, Deveshwar S. The big mush: psychometric measures are
confounded and non-independent in their association with age at initial diagnosis of
ischaemic coronary heart disease. J Cardiovasc Risk 2002;9:41-48.
25.  Ketterer MW, Denollet J, Chapp J, Thayer B, Keteyion S, Clark V, John S, Farha Al,
Deveshwar S. Men deny and women cry, but who dies2 Do the wages of "denial" include
early ischemic coronary hearf disease8 J Psychosom Res 2004;56:119-123.
26.   Beller GA. Coroncry heorf disease in the first 30 years of the 21" century: challenges and
opportunities: The 33 annual James B Herrick lecture of the council on clinical
cardiology of the American Heart Association. Circulation 2001;103:2428-2435.
27.  Stanek EJ, Oates MB, McGhan WF, Denofrio  D, Loh E. Preferences for treatment out-
comes in patients with heart failure: symptoms versus survival. J Card Fail 2000;6:225-
232.
42
TYPE-D PERSONALITY AND CARDIOVASCULAR DISEASE
28.  Soto GE, Jones P, Weintroub WS, Krumholz HM, Sperfus JA. Prognostic value of health
status in patients with heart failure after ocute myocardial infarction. Circulation
2004,110:546-551.
29.  Rumsfeld JS, Havronek E, Masoudi FA, Peterson ED, Jones P, Tooley JF, Krumholz HM,
Spertus JA. Depressive symptoms are the strongest predictors of short-term declines in
health status in patients with heart failure. J Am Col! Cardiol 2003;42:1811-1817.
30. Denollet J. Health complaints and outcome assessment in coronary heart disease.
Psychosom Med 1994;56:463-474.
31.  Denollet, J. Emotional distress and fatigue in coronary heart disease: the Global Mood
Scale (GMS). Psychol Med 1993;23:111-121.
32.  Schiffer AA, Pedersen SS, Widdershoven JW, Hendriks EH, Winter JB, Denollet J. The
distressed (Type-D) personality is independently associated with impaired health status and
increased depressive symptoms in chronic heart failure. Eur J Cardiovasc Prev Rehabil
2005,12:341-346.
33.   Denollet J.  DS 14 : Standard assessment of negative affectivity, social inhibition, and Type
D personality. Psychosom Med 2005,67:89-97.
34.  Kopp M, Skrabski A, Csoboth C, Rethelyi J, Strauder A, Denollet J. Type-D personality:
cross-sectional associations with cardiovascular morbidity in the Hungarian population
labstractl. Psychosom Med 2003;65(suppl A):A64.
35.  Grande G, Jordan J, Kummel M, Struwe C, Schubmann R, Schulze F, Unterberg C, von
Kanel R, Kudielka B, Fischer J, Herrmann-Lingen C. Evaluation of the German Type-D
Scale  (DS 1 4) and prevalence  of the Type-D personality pattern  in  cardiological  and
psychosomatic patients and healthy sublects [Germanl Psychother Psychosom Med
Psychol 2004;54:413-422.
36.  Gremigni P, Sommaruga M. Personalit6 di Tipo D, un costrutto rilevante in cardiologia.
Studio preliminare di validazione del questionario italiano. Psicoterapia Cognitiva e
Comportamentale 2005;11:7-18.
37.  Friedman M, Rosenman RH. Association of specific overt behavior pattern with increases
in blood cholesterol, blood clotting time, incidence of arcus senilis and clinical coronary
artery disease. JAMA 1959;169:1286-1296.
38.  Rosenman RH, Brand RJ, Jenkins CD, Friedman M, Straus R, Wurm M. Coronary heart
disease in the Western Collaborative Group Study: final follow-up experience of 8 1/2
years. JAMA 1975;233:872-877.
39.  Cooper T, Detre T, Weiss SM. Coronary-prone behaviour and coronory heart disease: a
critical review. Circulation 1981;63:1199-1215.
40. Matthews KA, Gump BB, Harris KF, Haney TL, Barefoot JC. Hostile behaviors predict




41.    Dembroski TM, Costa PT. Coronary prone behavior: components  of  the  Type A pattern
and hostility. J Pers 1987;55:211-235.
42.  Temoshok L, Heller BW, Sagebiel RW, Blois MS, Sweet DM, DiCIemente R.1, Gold ML. The
relationship of psychosocial factors to prognostic indicators in cutaneous malignant
melanoma. J Psychosom Res 1985;29:39-153.
43.  Dimsdale JE. A perspedive on type A behavior and coronary disease. N Engl J Med
1988;318:110-112.
44. Kop WJ. Chronic and acute psychological risk factors for clinical manifestations of
coronary artery disease. Psychosom Med  1999;61:476-487.
45.   Kop WJ. Acute and chronic psychological risk factors for coronary syndromes: moderating
effects of coronary artery disease severity. J Psychosom Res 1997;43:167-181.
46.  Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan
KR, van Zyl LT, Swenson JR, Finkels MS, Landau C, Shapiro PA, Pepine CJ, Mardekion J,
Harrison WM. (For the Sertraline Antidepressant Heart Attack Randomized Trial
[SADHARTI Group) Sertraline treatment of maior depression in patients with acute MI or
unstable angina. JAMA 2002;288:701-709.
47.  Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czaikowski SM,
DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell LH, Raczynski
JM, Schneiderman N. (For the Enhancing Recovery in Coronary Heart Disease Patients
Investigators [ENRICHD]). Effects of treating depression and low perceived social support
on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart
Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289:3106-3116.
48.  Friedman M, Thoresen CE, Gill JJ, Ulmer D, Powell LH, Price VA, Brown B, Thompson L,
Rabin DD, Breall WS. Alteration of Type A behavior and its effect on cardiac recurrences
in post myocardial infarction patients: summary of the recurrent coronary prevention
proiect. Am Heart J 1986;112:653-665.
49. Davidson K, MacGregor MW, Stuhr -1, Gidron Y. Increasing constructive anger verbal
behavior decreases resting blood pressure: a secondary analysis of a randomized
controlled hostility intervention. Int J Behav Med 1999;6:268-278.
50. Linden W. Psychological treatments in cardiac rehabilitation: review of rationales and
outcomes. J Psychosom Res 2000;48:443-454.
51.    Denollet J, Brutsaert DL. Reducing emotional distress improves prognosis in coronary




TYPE-D PERSONALITY AS A PREDICTOR
OF PATIENT-CENTRED OUTCOMES IN
CHRONIC HEART FAILURE
CHAPTER 3
The distressed (type-D) personality is
independently associated with impaired
hea/th status and increased depressive
symptoms in chronic heart fai/ure
Angaigue A. Schiffer", Susanne S. Pedersen°, Jos W. Widdershovent, Eric H. Hendrikst Jobsf
8. Wintert johan Denofter
-CoRPS - Center of Research on Psychology in Soniatic diseases. Tilburg University, Tilburg, the
Netherlands
- Department of Cardiology, TweeSteden Hospital,  Tilburg,  the Netherlands




Chronic heart failure (CHF) is a serious condition that is associated with impaired
health status and a high prevalence of depressive symptoms. To date, little is known
about the deferminants of health status and depressive symptoms in CHF. Therefore,
the aim of this study was assessing whether type-D personality is associated with
impaired health status and increased depressive symptoms in CHF patients,
independent of disease characteristics.
Methods
Eighty-four patients  (63  men  and 21 women, mean age=65.91: 12.1  years) with
systolic  CHF  completed four questionnaires fo assess type-D personality  (DS 1 4),
health status (MLWHFQ), depressive symptoms (CES-D) and mood status (GMS)
when visiting an outpatient heart failure clinic. Information on clinical variables was
obtained from the patients' medical records.
Results
Type-D patients were more likely to experience impairment in health status
(18/38=47%) as compared to non type-Ds (11/46=24%), p=.027. They also more
often reported symptoms of depression, i.e. 18/38=47% versus 6/46=13%,
p=.001. When controlling for severity and aetiology of CHF, and age and gender,
type-D remained a significant associate of health status (OR=3.3;95%Cl:1.21-9.09)
and depressive symptoms (OR=7.1;95%Cl:2.23-22.39).
Conclusions
Type-D personality was associated with impaired health status and increased
depressive symptoms in CHF patients. These preliminary findings demonstrate the
value of including personality factors in CHF research.
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INTRODUCTION
Chronic heart failure (CHF), which is the end-stage of most heart diseases, is an
important cause of cardiac morbidity and mortality, and has been labelled as an
emerging epidemic 11,21. CHF has also been related to impaired health status and
quality of life, and to co morbid depression [3-71. Quality of life is a frequently used
outcome measure in medical research and some patients have rated it as more
important than extended survival [81 Depression has been associated with increased
risk of morbidity, morfa|ify, (re)hospitalisation, and poor health status in CHF
13,6,9,101
However, most studies have focused on the prevalence of depressive
symptoms in hospitalised patients with CHF [61 Gottlieb and colleagues were among
the first to determine the prevalence of depression in outpatients with heart failure,
and found depression to be a common co morbid condition [61 Moreover, little is
known about the determinants of health status and depression in CHF, although
studies have shown that markers of CHF severity cannot explain differences in quality
of  life  14,6,111.   Furthermore,  to our knowledge, the determinants  of mood status
have not been examined in CHF. Taken together, these findings suggest that we may
need to expand our focus beyond looking at traditional risk factors, as knowledge of
these determinants may lead to an expansion and refocusing of the treatment
strategies used in CHF.
Personality may be an important determinant of individual differences in
health status and depression in CHF that largely has been overlooked. Neuroticism,
for example, has been shown to be an independenf predictor of increased mortality
in patients with CHF [121. The adverse affect of type-D, or distressed, personalig on
health outcomes in patients with coronary heart disease (CHD), including high-risk
patients with decreased left ventricular function following myocardial infarction, is
also well-documented 113-151. A high score on two stable personality traits, i.e.,
negative affectivity (the stable tendency to experience negative emotions and affect
across time and situations) and social inhibition (the stable tendency to inhibit the
expression of these negative emotions in social situations), defines .type-D personality
le.g. 13,16]. Type-D personality is associated with increased risk of morbidity,
mortality and impaired quality of life in patients with acute coronary syndromes (ACS)
113-171. A recent study also showed  that  type-D  individuals  with an implantable
cardioverter defibrillator (ICD) suffered from more anxiety and depressive symptoms
compared with patients with non type-D personality [181 Although patients with CHD
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are at risk of developing CHF, to our knowledge no study has examined the effect of
type-D personality on health and mood status in patients with CHF.
Thus, the obiective of the current study was to examine whether type-D
personality is associated with impaired health and mood status, and increased
depressive symptoms in unselected outpatients with CHF.
METHODS
Study popu/ation
Consecutive unselected patients (n=121) with a diagnosis of systolic heart failure,
visiting the heart failure outpatient clinic of the TweeSteden teaching hospital in
Tilburg, the Netherlands, were asked to participate in the current study, and 84
patients agreed. Patients (11 with other life threatening co morbidities (e.g cancer),
(2) older than 80 years, (3) with a history of diastolic heart failure, (4) incapable of
understanding and reading Dutch, or (5) with cognitive impairments, were excluded
from this study.
Clinical variables
Socio-demographic variables included gender and age. Information on severity (New
York Heart Association (NYHA) functional class and left ventricular eiection fraction
(LVEF)) and aetiology (ischemia) of heart failure was obtained from the specialised
heart failure nurse or the treating cardiologist. Information on clinical variables
Chypertension, diabetes mellitus, smoking, hypercholesterolemia, and adipositas) and
medication was obtained from the patients' medical records.
Type-D personality
Type-D personality was measured with the 14-item Type-D Scale (DS14)  [191. The
scale comprises two subscales, negative affectivity and social inhibition, containing
seven items each. Examples of items measuring negative affectivity are "I often make
a fuss of unimportant things", and "I often feel unhappy" "I often feel inhibited in
social interactions", and "I find it hard to start a conversation" are examples of items
of the social inhibition subscale. The items are answered on a 5-point Likert scale
from 0 ("false")  to  4   ("true").  A  pre-determined  cut-off  210  on both subscales  is
used to determine those with a type-D personality [191. Both subscales have good
test-retest validity and high internal validity with Cronbach's a of .88 and .86 for the
negative affectivity and social inhibition subscales, respectively [191
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Hea/th status
The Minnesota Living with Heart Failure Questionnaire (MLWHFQ), a disease
specific instrument,  was  used to assess health status  [20]. This questionnaire consists
of 21 items that are answered on a 6-point scale. The reliability of the scale is good
with Cronbach's a of .95 1201. A higher score on the MLWHFQ represents a poorer
health status. The MLWHFQ is a frequently used measure to assess health status in
CHF patients.
Depression and mood status
Depressive symptomafology was assessed with the Center for Epidemiologic Studies
Depression Scale (CES-D), a measure thaf frequently has been used to measure
depressive symptoms in CHF [21,221. The 20 items are answered on a 4-point Likerl
scale ranging from 0 ("rarely or none of the time") to 3 ("most or all of the time"). A
higher score on the CES-D indicates more depressive symptoms, with a score 216
indicating likely depressive symptomatology. The CES-D has a high internal
consistency, as measured by Cronbach's a (ranging from .85-.90), and scores
correlate highly with other self-report measures of depressive symptoms [231
The 20-item Global Mood Scale (GMS) was used to evaluate mood status,
defined as negative and positive affect 1241. Each subscale consists of 10 items that
are answered on a 5-point Likert scale ranging from 0 ("false") to 4 ("true"). The
scale has a high internal consistency with Cronbach's a of .90 [241.
Procedure
Patients were approached by letter and asked to fill in the four questionnaires.
Patients who had not returned the questionnaires within two weeks received a
reminder telephone call. This study was conducted at the heart failure outpatient
clinic of the TweeSteden hospital as part of daily clinical practice. Patient
participation was voluntary.
Statistical analyses
Discrete variables were compared with the chi-square test and continuous variables
with the Student's t test. Univariate and multivariate logistic regression analyses were
used to assess the association between type-D personality and the outcome
measures health status, depressive symptoms and mood status. Prior to running
logistic regression analyses, the scores on the questionnaires were recoded into
discrete variables. The highest tertile on the MLWHFQ indicated impaired health
status, whereas fhe highest tertiles of the both subscale of the GMS indicated
increased negative affect and increased positive affect, respectively. In multivariate
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analyses, we adiusted for NYHA functional class, LVEF, aetiology of CHF, gender
and age. All statistical tests were two-failed; p<0.05 was used for all tests to indicate
statistical significance. Odds ratio (OR) with 95% confidence intervals (Cl) are
reported. All statistical analyses were performed using SPSS 11.5 for Windows.
RESULTS
Patient characteristics
Patient characteristics are listed in Table  1. No significant differences were found
between type-D and non type-D patients on demographic and clinical variables
(p<0.05). Thus, type-D personality was not a function of NYHA functional class,
LVEF, or aetiology of heart failure. Furthermore, no significant differences were found
between type-Ds and non type-Ds on the prescription of drugs (p<0.05; results not
shown).
Toble  1.    Patient characteristics
Type-D Non type-D                p
Male gender                 26                          37                          .21
Age (mean iSD) 6 6.7=1 3.2 65.2111.2 .55
Ischemic aetiology             22                               27                               .94
NYHA° Class m and IV            14                                           23                                          .23
LVEP (mean .+St)) 27+8 24f10 .20
Smoking                        10                            9                              .46
Hypertension                            15                                          22                                          .44
Diabetes Mellitus             8                              8                              .67
Hyped,pidemia                        16                                           18                                          .78
Adspos,fas                      9                              16                            .27
UNYHA New York Heart Association funclional class.
·"LVEF, Left ventncular election fraction.
Data are presented as n unless otherwise stated
Type-D patients reported impairment in health status more often than non
type-Ds (18/38=47% versus 11/46=24%, p=.027). They were also more likely to
suffer from depressive symptomatology, i.e. 18/38=47% versus 6/46=13%,
p=.001 (Figure 1).
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Type-D personalify, health status and depressive symptoms
In univariate analysis, type-D personality was associated with impaired health status
and more depressive symptoms (Figure  1 ). Age, gender, NYHA classification,  LVEF
and aetiology of CHF were not significantly related to these endpoints in univariate
analyses (Table 2)
Table 2. Relationship befween clinical and demographic factors, health status and depressive
feefings (unadiusted analyses)
Impaired health status Depressive feelings
OR       p         OR       p
NYHA' closs 1.3 0.571                  1.1                     0.835
LVEF 0.97 0.190 0.98 0.636
Aefiology 0.6 0.334 1.3 0.625
Mole gender 1.6 0.356         1.8           0.268
Age 1.0 0.610 1.0 0.938
'NYHA,  New York Heart Association funcfional class
V_VEF, Leff ventricular election frochon
When adiusting for severity and aetiology of CHF, age, and gender, type-D
personality was independently related to health status (OR=3.3;95%Cl:1.21-9.09)
and depressive symptoms (OR=7.1;95%Cl:2.23-22.39) (Table 3)
Type-D personality and mood status
In univariate analyses, type-D patients were more likely to experience negative affect
and less likely to experience positive affect (Figure 1 ) Type-D personality remained a
significant associate of negative affect (OR=3.4;95%Cl:1.26-9.23) and positive
affect (OR=0.3;95%Cl:0.09-0.81) when controlling for severity and aetiology of
CHF, and demographic variables (Table 3). However, lower NYHA functional class
COR=3.7:95%Cl:1.07-12.61) and younger age (OR=0.9;95%Cl:0.91-1.00) were
also independently associated with more positive affect in multivariate analysis (Table
3).
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Table 3. Type-D personality as o determinant of health status, depressive symptoms and niood sfafus (adiusted analyses)
Impaired health status
' Depressive feelings· Negative affect' Positive affect'
OR (950.Cl)              p        OR (95%Cl)              p          OR (95%CO p       OR (95060)               p
Type-D 3.32(1.21-9.09) .02- 7.07 (2.23-22.39) .001.. 3.4 1 (1.26-9.233 02* 0.26 (0.09·0.8 U .02'
NYHA'
1.19(0.39-3.59) .76 1.15(0.34-3.90) .82 0.69 (0.22-2.10)        .51     3.67 (1.07-12.61) .04'111  &  IV
LVEP' 0.96 (0.90-1.03) .25 0.96(0.89-1.04) 33 0.97(0.91-1.04) .39 1.04 (0.97-1 12) 23
Aefiotogy 0.58 (0.2 h 1.65) .58 1.29 (0.43-3.94) .65 0.68(0.24-1.91) .47
2.52 (0.82- 7.72)                    .1 1                            Male
1.54 (0.49-4.84) .46 1.26 (0.37-4.28) .72 1. 15 (0.37-3.60)          .81       0.27 (0.06-1.13) .07          6
gende,
JE
Age 1.00(0.96-1.04) .91 0.99(0.94-1.03) .50 1.00(0.96-1.04) 99 0.95 (0.91 -1.00,1 04-
'NYHA New York Heart Association functional class                                                                                            
                                                                                    .
"LVEF. Left ventricular election fraction                                                                                                                                                                            7
'Minnesoto Living with Heart Failure Questionnaire (MLWHFQ), a high score indicates impaired healfh status
-'Center for Epidemiologic Studies Depression Scale (CES-Dj; a high score indicates more depressive symptoms 51<-'Global Mood Scale (GMS), subscole negative affect; a high score indicates more negative affect rn I
-'Global Mood Scale (GMS), subscale positive affect, a high score indicates niore positive affed  T
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DISCUSSION
As mentioned by Albus et al., there is evidence that psychological factors such as
type-D personality contribute to the development and adverse outcomes in CHD
[251. To our knowledge, this is the first study to examine the influence of personality
on health status and mood status in patients with CHF. Type-D patients were more
likely to have poor health status, increased depressive symptoms, and impaired
mood status compared with non type-Ds. These associations remained significant
when adiusting for severity (NYHA functional class and LVEF) and aetiology of CHF,
gender, and age. Characteristics of CHF, i.e., NYHA functional class and LVEF, were
not related to any of the outcome measures. This means that clinical measures of
CHF are not related to health and mood status, and depressive symptoms, but type-
D personality is.
The results of the current study concur with studies having investigated the
role of personality on quality of life in patients with ACS. These patients are at risk of
developing CHF. In a prospective study of patients with ACS, type-D personality was
found to be a predictor of impaired quality of life at 5-year follow-up 1131.  In ACS
patients, personality factors, such as type-D, have also been related to hard medical
outcome [13-151, as has neuroticism in patients with CHF (1121 Furthermore, a
recent study showed that fype-D patients treated for arrhythmia with ICD therapy
experienced more anxiety and more depressive symptoms than non type-Ds treated
with ICD Il 81
In previous research on depression and CHF, there has been a focus on the
prevalence of depressive symptoms, and on the association between depression and
prognosis in CHF 19,11,261. Only one study has examined the role of depressive
symptoms as a predictor of health status in patients with CHF [31 Rumsfeld and
colleagues found depressive symptoms to be a strong predictor of worsened health
status in CHF, adiusting for baseline health status and over 20 patient variables [31
Ruo and colleagues found similar results among patients with CHD 1271. Recently,
Gottlieb et al. found the presence of depression in patients with CHF to be
associated with reduced qualily of life scores [61. No study, however, examined which
factors are important in determining the depressive feelings that are so common in
CHF.
Furthermore, although some studies have suggested an association
between depression and personality traits such as neuroticism [281 or alexithymia
[29}, and between depression and personality pathology [30}, no study has
examined the role of a normal personality construct as a possible determinant of
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depressive feelings in CHF patients specifically. We found type-D personality, a
personality type that is not characterised as psychopathology, to be an important
associate of depressive feelings in patients with heart failure.
This study has a number of limitations. First, the cross-sec:tional design of
the study does not allow for determination of cause and effect. Second, the number
of pafients was relatively small, which limits generalisation of the results and the
number of variables that can be controlled for in statistical analyses. Third, we did
not include information on pacing techniques and other types of CHF treatment,
because all patients included in this study were optimally treated by a cardiologist
and a specialised heart failure nurse. Fourth, there is an overlap between symptoms
of heart failure and depression. A diagnostic interview with a psychologist would
provide better information on this issue.
Despite these limitations, this study is the first to investigate the role of type-
D personality as an associate of health and mood status in heart failure patients.
Moreover, the study was based on an unselected group of outpatients.
In conclusion, these preliminary findings suggest that fype-D personality
may be associated with adverse health status, increased depressive symptoms, and
impaired mood status in patients with CHF. The results also demonstrate that it may
be worthwhile to include personality factors in future studies of patients with CHF, as
personality may be an important explanatory factor of individual differences in
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Little is known about the role of personality as a determinant of health status in
chronic heart failure (CHF). We examined whether type-D personality exerts a stable,
independent effect on health status  in  CHF  over  12  months,  controlling  for
depressive symptoms.
Methods
Consecutive systolic CHF patients (n=166; 75% men; mean age 66+9) completed
the DS 14 and the BDI at baseline, and the MLWHFQ (disease-specific health status)
and SF-36 (generic health status) at baseline and 12 months.
Results
There was a general improvement in disease-specific (p=.008) and mental (p=.06)
health status  over 12 months, but type-D patients reported significantly lower
disease-specific (p<.001) and mental (p<.001) health status as compared to non
type-Ds. Type-D personality was not related to generic physical health status. The
negative impact of type-D personality on disease-specific {p=.89) and mental
(p=.69)  health  status was stable, as indicated  by the non-significant interaction
effects. In multivariable analyses, type-D personality was an independent predictor of
disease-specific (11=.20;p=.003) and mental (B=:25;p=.001) health status,
controlling for depressive symptoms, disease characteristics, socio-demographic
variables, relevant medication, and baseline health status. Depressive symptoms was
an independent predicfor of disease-specific (11=.20;p=.012) and generic physical
health status Ill=-.24;p=.001). In logistic regression analyses, type-Ds had a more
than 2-fold risk of impaired disease-specific health status and a close to 4-fold risk of
impaired mental health status.
Conclusions
Type-D personality and depression were independent, stable predictors of impaired
health status over 12 months. Because healfh status is an important patient-centred
outcome and related to prognosis in CHF, counselling of patients at high risk for
impaired health status is indicated.
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INTRODUCTION
Chronic heart failure (CHF) is a serious condition, with increasing incidence and
prevalence, and deleferious effects on prognosis and health status [1 -41. Impaired
health status is a predictor of poor prognosis in CHF [51, but it is also emphasised by
patients as an important treatment goal on its own, with patients generally preferring
better health sfafus over prolonged survival [61 Hence, the study of health status,
representing a patient-centred outcome, and its determinants is important for
secondary prevention in order to identify high-risk patients. The study of patient-
cenfred outcomes has also been advocated by others, as a means by which to bridge
the gap between research and clinical practice [71
Several studies have focused on functional status, as indicated by (self-
rated) New York Heart Association (NYHA) class [8,91, age [8,10,111, sex 18,11,12},
and somatic co morbidity [8] as important determinants of health status in patients
with CHF. Depression has also been identified as a potential determinant [e.g.
13,141. By contrast, a paucity of studies has investigated personality in the context of
health status and CHF, probably because of the inconsistencies in findings in
research on the Type A Behaviour Pattern (TABP) 1151 However, personality factors
may explain individual differences in health outcomes above and beyond
demographic and clinical risk factors [161.
Type-D personality is an emerging risk factor that has been associated with
poor prognosis and health status across different cardiovascular patient groups
[17,181 Type-D personality is defined by a high score on the two stable personality
traits negative affectivity and social inhibition [161. Type-D patients tend to
experience increased levels of anxiety, irritation, and depressed mood across
situations and time, while not sharing these emotions with others because of fear of
reiection or disapproval [161 Type-D personality has been associated with impaired
health status in patients with coronary artery disease, and in heart transplantation
recipients [15,19,201. Preliminary findings from a cross-sectional study suggested
that type-D may also affect health status in CHF patients [211, but no prospective
studies have examined whether this effect remains stable over time. Furthermore, it is
unknown whether type-D personality predicts disease-specific and generic health
status in CHF above and beyond depressive symptoms.
Therefore, the aims of this study were to examine (1) whether type-D
personality has a stable effect on both disease-specific and generic health status in
CHF over a 12-month period, and (2) whether type-D personality is an independent
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determinant of disease-specific and generic health status  at 12-month follow-up,
when adiusting for depressive symptoms.
METHODS
Patient population, design and procedure
Between October 2003 and October 2005, consecutive CHF patients from the
cardiology unit of the TweeSteden teaching hospital in Tilburg, the Netherlands, were
recruited for the current study. Of 287 patients, 228 (79.4%) agreed to participate.
However, since we used a prospective design and patients died and left the study
during follow-up, final analyses are based on  166 out of 228 patients (Figure 1).
Number of participating n=228
patients at baseline
n-12      Excluded due to missing
questionnaire scores
n= 4 Excluded during follow-upA
n =18 Died during follow-up
-   n -28 Refused participation at 12-
month follow-up
Included patients n=166
Figure  1. Flow chart of patient seIection
A These patients were excluded due to medical  (e.g.  cerebrovascular accident during the study)
or logistic reasons (e.g. moving abroad).
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All patients were treated following the most recent guidelines for CHF
[1,2,22}. Inclusion criteria were: (1) diagnosis of systolic CHF with a left ventricular
election fraction (LVEF) 540%, (2) 580 years of age, and (31 stable on medication
for at least one month prior to inclusion. We excluded patients with (1) a diagnosis of
diastolic heart failure, (2) who were unable to read, write or understand Dutch, and
(3) who had life-threatening co morbidities (e.g. cancer or a myocardial infardion
(MI) one month preceding inclusion), or (4) severe cognitive impairments (e.g.
dementia).
The study was approved by the hospital medical ethics committee and
carried out conform to the Helsinki Declaration. Every patient received oral and
written information about the study and provided written informed consent.
Participation was voluntary and patients were free to withdraw at any time during the
study.
The treating cardiologist or CHF nurse informed patients about the study
and asked them to participate. If they agreed, they were called by the investigator in
the same week to make an appointment for assessment. During the first visit, patients
were given additional information about the study and were asked to complete a set
of questionnaires  at  home and return  them  in a self-addressed envelope.  Af  12-
month follow-up, patients were invited to the hospital again and received a set of
questionnaires to complete at home once more. All questionnaires were checked for
completeness. Patients who had left open several questions were called to obtain the
answers or they were mailed a copy of the items and were asked to complete them.
In case the questionnaires were not returned within two weeks, patients received a
reminder telephone call or letter.
Measures
Health status.
In the current study, both disease-specific as well as generic health status were
assessed at baseline and at 12-month follow-up.
We used fhe Minnesota Living with Heart Failure Questionnaire (MLWHFQ)
to assess disease-specific health status [23,241. The MLWHFQ is a 21-item measure
of health status that is frequently used in CHF patients [241. The 21 items are
answered on a 6-point Likerf scale, ranging from "no" (0) to "very much" (5). A
higher score on the MLWHFQ represents a poorer health status [231. The MLWHFQ




The Short-Form Health Survey (SF-36) is a 36-item measure of generic
health status, with higher scores indicating better generic health status, except for the
bodily pain subscale where a high score indicates the absence of pain [25-271. The
SF-36 can be divided into eight subscales, namely (1) physical functioning, (2) role
limitations due to physical functioning, (3) role limitations due to emotional
functioning, (41 mental health, (5) vitality, (6) social functioning, (7) bodily pain, and
(8) general health. Subscale scores can be obtained by summing the items together,
dividing the outcome by the range of scores, and finally transforming the raw scores
to Z-scores, ranging  from  0  to  100.  The  subscales  can be summarised  into  a
physical component summary score (PCS) and a mental component summary score
(MCS)  127].  In a recent study, the two-factor  structure of the SF-36 was validated  in
patients with somatic diseases [28], and therefore the two component summary
scores were used in this study. The Dutch version of the SF-36 is a reliable and valid
instrument for use in chronic disease populations. The mean Cronbach's a across
the eight subscales is .84 [261.
Type-D personality .
Type-D personality  was   measured  with the Type-D Scale  (DS1 4)   1161.   The
questionnaire consists  of 14 items  that are divided  into two subscales, namely
negative affectivity and social inhibition. Items are answered on a 5-point Likert scale
from "false" (0) to "true" (4). A standardised cut-off 210 on both subscales indicates
type-D caseness [161 Emons and colleagues showed recently that the items of the
D514 had highest measurement precision around the mentioned cut-off [291. The
two DS 14 subscales have good psychometric qualities, with Cronbach's a=.88/.86
and 3-month test-retest reliability r=.72/.82 for the negative affectivity and social
inhibition subscale, respectively [161. Recently, the stability of type-D personality over
18  months was shown in post-MI  patients  [301.  The  DS 14 was administered  at
baseline.
Depressive symptoms.
The presence of depressive symptoms was assessed at baseline with the Beck
Depression Inventory (BDI), a commonly used questionnaire to measure depressive
symptoms in clinical research and in patients with cardiovascular disease (CVD)
131,321. The 21 items are answered on a 4-point scale, ranging from "0" to "3".A
higher total score on the BDI indicates more depressive symptoms. A standardised
cut-off 210 denotes those with likely depressive symptomatology [311. The BDI is a
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valid and reliable measure of depressive symptoms, with Cronbach's a=.81 in non-
psychiatric samples [321.
Socio-demographic and clinical characteristics.
Socio-demographic variables, including sex, age, marital status, and educational
level, were obtained through four purpose-designed questions in the questionnaire.
Information on clinical variables, including LVEF, NYHA functional class, aetiology of
CHF (ischemic/non-ischemic), co morbidities (diabetes mellitus, rena| insufficiency,
hyperlension and hyperlipidemia), and medication (ACE inhibitors, ARB's, diuretics,
spironolactone, digitalis, beta-blockers, long-acting nitrates, aspirin, statins, and
psychopharmaca) were obtained from the medical records or the treating
cardiologist/CHF nurse. Smoking status was assessed by means of self-report.
Statistical analyses
Discrete variables were compared with the chi-square test and continuous variables
with Student's t test for independent samples. In order to adiust for multiple
comparisons, multivariate analyses of variance (MANOVA) for repeated measures
were performed to examine whether there were differences in disease-specific health
status CMWLHFQ), mental health status (SF-36) and generic physical health status
(SF-36), and between type-D and non type-D patients and depressed and non
depressed patients on these outcomes, over a 12-month period. Post-hoc ANOVA's
for repeated measures were performed to evaluate differences in mean scores on
disease-specific and generic health  status at baseline and  at 12-month follow-up.
Type-D personality and depressive symptoms were entered (separately) into the
ANOVA's to compare type-D and non type-D patients, and depressed and non-
depressed patients  on both disease-specific and generic health  status  over a  12-
month period. Univariable and multivariable linear regression analyses were used to
examine predictors of disease-specific and generic health status at 12 months. Prior
to regression analyses, independent continuous variables were recoded into
dichotomous variables. In the multivariable linear regression analyses, we entered
type-D personality [e.g. 15,19-211, depressive symptoms [13,14], age [8,10,111, sex
[8,11,12}, NYHA functional class [8,91, diuretics, spironolactone, long-acting nifrates
and psychopharmaca, since these variables have been identified as potential
determinants of impaired health status in the CVD literature, or were significant in
univariable analyses in the current study. Since LVEF is a measure of disease severity
and may be a potential confounder of health status, LVEF was added as a covariate
in the multivariable analyses. Finally, we controlled for baseline health status. To
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enhance clinical interpretabilily, multivariable logistic regression analyses were
performed as secondary analyses, dichotomising the health status scores using the
highest tertile. All analyses were performed using SPSS  12.0.1 for Windows.
RESULTS
Of 287 patients, 228 (79.496) agreed fo participate. There were significant
differences between participants and non-participants on age, sex, hyperlipidemia
and use of aspirin. Participants were younger (mean age=65.61:9.2 versus
70.618.3,p<.001), more often male (75.3% versus 50.9%;p=.001), more likely to
have hyperlipidemia (53.6% versus 32.1%;p=.004), but less likely to be prescribed
aspirin (45.2% versus 64.3%;p=.010) as compared to non-participants.
Baseline characteristics
Of 166 patients, 38 (23%} patients had a type-D personality, and 52 patients (31%)
had significant depressive symptoms. Baseline characteristics, stratified by type-D
personality, are shown in Table 1. There were no significant differences between
type-D and non type-D pafienfs on any of the demographic and clinical baseline
characteristics Call ps>.05)
Type-D personalify, depressive symptoms and health status
The results of the MANOVA for repeated measures indicated a significant overall
improvement in disease-specific, mental, and generic physical health status over time
(f(1,165)=13.040;p<.001). When including type-D personality and depressive
symptoms as covariates, we found a main effect for both type-D personality
(F(1,164)-28.8201<.001) and depressive symptoms (F(1,164)=81.160;p<.001)
on these outcomes.
In posthoc analyses, ANOVA's for repeated measures showed a significant
general improvement in disease-specific health status (F(1,164)=7.101;p=.008)
over 12 months. However, type-D  patients  reported significantly lower disease-
specific health status compared with non type-D patients (F(1,164)=25.482;
p<.001) (Figure 2). The interaction effect type-D by time was not significant
(F(1,164)=.020;p=.89), indicating that fype-D personality exerted a stable effect on
disease-specific health status over a 12-month period. There was also a significant
main effect for depressive symptoms (F(1,164)-72.315;p<.001), and the negative
effect of depressive symptoms on disease-specific health status was stable over time,
as indicated by the non-significant interaction effect depressive symptoms by time
(F(1,164)=2.688.p=.103).
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Table 1.    Baseline characteristics stratified by type-D personality
Total sample Type-D Non Type-D         p
tn -38) (n = 1283
Demographics
Age, Mean (SD) 66 (9) 67 (91 65 (9) 0.30
Mate sex 125 (75) 3 1 (821 94 (73) 0.39
Living with a partner· 123 (74) 27 (711' 96 l75) 0.68
Lower Education 54 (33) 17 (45) 37 (29) 0.08
Clinical variables
LVEF'%,  mean (SDJ 30 (7) 31 (7) 30 (8) 0.44
NYHA- class 111 and IV 76 (46) 22 (58j 54 (42) 0.09
Ischemic aetiology 89 (54) 19 (50) 70 (55} 0.71
Smoking 38 (23) 7 (18} 3 1 (241 0.52
Co morbidities
Diabetes 43 (26) 10 (26) 33 (26) 1.00
Renal insufficiency 21 (13) 6 (16) 1 5 (1 2) 0.58
Hypertension 56 (34) 14 (37) 42 (33) 0.70
Hyperlipidemio 89 154; 22 (58) 67 (52) 0.58
Medication
ACE-inhibifors 127 (771 31 (82) 96 (751 0.52
ARB's 22 (13) 5 (13) 17(13) 1.00
Diur·etics 127 (77) 33 (873 94 (731 0.13
Spironoloctone 38 (23) 8 (21) 30 (23) 0.83
Digitalis 52 (31 3 13 (34) 39 (31 J 0.69
Beta-blockers 110 (66) 25 (66) 85 (663 1.00
Long-acting nitrates 31 (19) 9 (24j 22 (17) 0.35
Aspirin 75 (451 19 (50) 56 (44) 0.58
Statins 84 (51) 2 1 M 63 (49) 0.58
Psychopharmaca 24 (15) 7 (18) 17(13) 0.43
Numbers are presented as n (96) unless otherwise stated
<LVEF=Left ventricular election fraction
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Furthermore, scores on mental health status (the MCS of the SF-36) did not
change significantly over time, although there was a trend (F{1,164)=3.648,p=.06)
for an improvement in mental health status  over 12 months.  The main between-
subiects effect for type-D on mental health status was significant (F(1,164)=45.311;
p<.001), with type-D patients reporting worse mental health status as compared to
non type-D patients (Figure 2). The interaction effect for type-D by time was not
significant (F(1,164)=.164,p=.69), again indicating a stable effect of type-D
personality on the MCS scale over time. The main effect of depressive symptoms on
mental health status was significant (F(1,164)=34.459;p<.001) and stable over
time, as indicated by the non-significant interaction-effect depressive symptoms by
time (F(1,164)=1.660;p=.20).
Scores on generic physical health status (the PCS of the SF-36) did not
change significantly over time (p=.79), neither was there a significant main between-
subiects effect for type-D personality (p=.12) (Figure  2). The interaction effect for
type-D by time was also not significant (F(1,164)=.833,p=.36) However, there was
a significant main between-subiects effect for depressive symptoms FO,164)-
38.970;p<.001). This main effect was stable over time, as the interaction-effect
depressive symptoms by time was not significant (F(1,164)=.244;p=.62).
independent predictors of health status at 12 months
In univariable linear regression analyses, type-D personality, depressive symptoms,
NYHA functional class, diuretics, spironolactone, long-acting nitrates,
psychopharmaca, and baseline health status were significant predictors of disease-
specific and/or generic health status (Table 2). In multivariable linear regression
analyses, type-D personality remained an independent predictor of disease-specific
(11=.20,1=3.0, p=.003) and mental (B=-.25;t=-3.5, p=.001) health status,
adiusting for depressive symptoms, NYHA class, diuretics, spironolactone, long-
acting nitrates, psychopharmaca, baseline health status, age, sex, and LVEF. Type-D
personality was not an independent predictor of generic physical health status (p=
.82). Depressive symptoms independently predicted disease-specific and generic
physical health status (Table 3).
In secondary analyses, we dichotomised health status as an outcome
measure in order to enhance clinical interpretability as advocated by others [331, and
to compare the results with those of other studies on type-D personality te.g. 341. The
results of the logistic regression analyses are displayed in Table 4.
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Table 2.    Significant predictors of impaired disease-specific and generic health status af  12 months (univariable analyses)                                                          >
-0
-1
Disease-specific Mental health Generic physical health rn
health (MLWHFQ) (SF-36;MCSJ (SF-36:PCS) 70
4.
B                   P                   B                   P                   B                   P
Type-D personality .34 .    .00 1 ..44 <.001 11.5. n.5
Depressive symptoms .46 <.001 ..34 <.001 .43 ...001
NYHA functional class 23 .003 n.s. 0.5. .31 (.00 1
Diure ics .19 .015 .21 .006 ..16 .039
Spironolactone n.s. n.s. n.s. n.s. 16 041
Long ·acting nitrates .19 012 /1.S. n.s. ..27 k  . 00 1
Psychopharmaco 29 <.001 n.5. n.5 ..23 003
Baseline health status .48 <.001 -.48 < .001 -.49 <.001
MLWHFQ= Minnesota Living with Heart Failure Questionnaire,SF-36= Shor·f-Form Health Survey,·MCS =Mental Componenf Scale;
PCS . Physical Component Scale. NYHA=New York Heart Association clossification,·n.s. =not significant
Table 3.     Independent predictors of impaired disease-specific and generic health sfofus af 12 months (mulfivanable hnear analyses)
Disease-specific Mental health Generic physical health
health (MLWHFQ) (SF-36;MCS) (SF-36:PCS)
B P B P B P
Type-D personality .20 .003 25 .001 n.s. n.s.
Depressive symptoms .20 .012 n.s. /1.5. - 24 .001
NYHA functional class n.s. n.s. n.s. n.s. . 18 .009                  K
2%
Diuretics fl.S. n.s. ..14 .042 n. s. 0.5.                                    U
Cl
rn
Spironolactone n.s. n.5. n.s. n.s. n.s. n.s. -0
Pclm
Long-acting nifrafes n.s. n.s. n.s. n.s. n.s.
n.s.                    0
Psychopharmaco .14 .045 11.5. n.s. n.s. Z
>
Baseline health status .27 .001 .33 <.001 -.33 <.001                    ZC
I
Age n.s. n.s. n.s. n.s. n.s. n.s. m>
4
Sex n.s. n.s. n.s. n.s. n.s. n.s.                                    I
LVEF                          .14 .033 11.s. n.s. n.s.
n.s                          
LVEF=Left ventricular election  fraction,MLWHFQ=Minnesota  Living  with  Heart Failure  Questionnaire;SF-36=Short-Form Health Survey;                       C
i/3MCS-Mental Component Scale,PCS=Physical Component Scale;NYHA=New York Heart Associahon classification, n.s. =not significant
Z
(--)
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Table 4.     Independent predictors of impaited disease-specific and generic health status at  12 months (niultivariable logistic analyses) I
3>
3Disease-specific Mental health Generic physical health rn
health (MLWHFQJ (SF-36.MCS) (SF 36;PCS) 70
4.
OR (95%Cl) p OR (95°.Ct)     p                OR (95°·i,Clj      p
Type-D pet·sonality 2.5 (.98-6.61) 06 3.8 (1.4-10.2) .001 n.s. n.s.
Dept·essive syniptoms 3.2  < 1.3-8.1) .01 n.s. n.s. 32(1.3-7.8) .009
NYHA functional class n.5. 11.S. n.5. n.. 2.4 (1.0-5.5) .04
Diuretics 3.3 (1.1-9.9) .04 n.s. 11.5. n.5. 11.s
Spironolactone /1.S. n.s. n.s. 0.5. ns n.s.
Lolig-acting tiifrates n.s. n.s. n.s. fl.S. /1.5. n.5
Psychopharniaca n.S n.s n.s. n.s. n.s. fl.S.
Baseline health status 3.4 (1.4-8.1) .007 9.6(3.7-24.81 00 1 3.9 (1.7-9.0) .002
Age 11.s 11.5. 11.5. n s. n.5 /1.5.
Sex n.s. n.s. n.s. H.S. n.s. f l. S.
LVEF 1.1 (1.0-1.2) .02 n.s. n.s. n.s. n.s.
LVEF-Left ventriculat  efection fraction.MLWHFQ -Minnesota Living with Heart Fa,ture Questionnaire.SF-36»Short-Forni Health Survey;
MCS = Mental Component Scale,·PCS =Physical Component Scale,NYHA=New York Heart Association classification,n.s. · · not significant
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DISCUSSION
This is the first prospective study fo examine the effect of type-D personality and its
stability over time on disease-specific and generic health status in patients with CHF,
while adiusting for depressive symptoms. Although there was a general improvement
in health status over time, type-D patients reported significantly poorer disease-
specific and mental health status as compared to non fype-D patients. Thus, type-D
personality exerted a stable, negative effect on disease-specific as well as on mental
health status over a 12-month period. When controlling for potential confounders,
including depressive symptoms, measures of disease severity, and baseline health
status, type-D personality remained a significant independent predictor of disease-
specific and mental health status. We found type-D patients to have a more than 2-
fold risk of impaired disease-specific health status, and a close fo 4-fold risk of
impaired mental health status. In this study, we found no general improvement in
generic physical health status over time; neither was there a significant relation
between type-D personality and this outcome measure.
Personality as a determinant of individual differences in CHF patients'
health status has largely been overlooked, as there is only one cross-sectional study
on the relationship between type-D personality and health status in this patient group
[211. This study found that type-D was a significant associate of impaired health
status adiusting for disease severity 121]. In the current study, this finding was
replicated in a larger sample, using a more broad measure of health status and a
prospective design.
Apart from type-D personality, we also found depressive symptoms to be an
important predictor of impaired health status. This result is consistent with other
studies focusing on depression as o determinant of health status in CHF [e.g
13,14,35,361 However, in the current study was shown that personality was also an
important determinant that predicted individual differences in health status above
and beyond depressive symptoms. Therefore, our results elaborate on findings from
previous studies on determinants of health status in CHF. Furlhermore, the results
also support the notion that depressive symptoms and type-D personality are different
forms of psychological distress. A recent sub study of the Myocardial Infarction and
Depression Intervention Trial (MIND-IT) showed that type-D personality was less
confounded by disease severity than post-MI depression [371. This may help to




In previous studies, type-D personality has been associated with impaired
health status and quality of life, for instance in patients surviving heart
transplantation, and in patients treated with percutaneous coronary intervention or
coronary artery bypass surgery [15,17-20,341. Although the studies by Pedersen and
colleagues [15,201, and Al-Ruzzeh and colleagues [341 found that type-D personality
was an independent predictor of mental and physical health, we found no
association between type-D personality and generic physical health status in the
current study. Our sample of patients with CHF may be different from the patient
samples in other studies in that patients in the present study are chronically ill with
hardly any options left concerning invasive interventions. Hence, the generic physical
health status may have been largely a function of the severity of CHF in the current
study.
There was an overall significant improvement in disease-specific and
mental health status over time, which suggests general treatment benefits or better
adiustment to the disease. However, the subgroup type-D patients reported
significantly lower health status as compared to non type-D patients, with this
negative effed being stable over a 12-month period. These results indicate that type-
D personality is not a temporal psychological risk factor for impaired health status in
CHF, but an enduring one, and that type-D patients do not only need optimal
pharmacological treatment but also more intensive psychological coaching and
intervention. Vulnerable patients, such as type-D patients (but also patients with
significant depressive symptoms) should be offered coaching, with the aims of
improving self-management abilities [381, learning to better adiust to their disease,
and extending their social network and sources of social support. Impaired self-
management [381, maladiustment to the condition of CHF, and low social support
[391 could be possible behavioural mechanisms explaining the relationship between
type-D personality and impaired health status in CHF. Since impaired health status
has been associated with death and (re)hospitalisation in patients with heart disease
[5,33,40}, efforts such as counselling of subgroups of patients at high risk for
impaired health status are warranted.
A number of limitations must be considered in interpreting the results of this
study. First, study participants were required to visit the outpatient c|inic to be
included in the study, and hence the sample could be biased by mobility and
younger age. Second, there were several differences on clinical variables between
participants and non-participants, as participants were more often male, younger,
had more often hyperlipidemia and used less often aspirin. Third, we used self-report
measures to assess health status and self-report may be prone to socially desirable
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behaviour. Strengths of the study are its prospective design, the use of a broad
measure of health status, since a disease-specific as well as a generic instrument was
used, and the controlling for confounders, including depressive symptoms, disease
severity, and baseline health status.
In conclusion, we found type-D personality to be a stable, independent
predictor of disease-specific and mental health status in patients with CHF over a 12-
month period, also when adiusting for depressive symptoms. Since health status is an
important patient-centred outcome, with patients generally preferring better health
status over prolonged survival, and impaired health status being associated with
poor prognosis 15-7,33,401, high-risk patients, such as type-D patients, require a
form of behavioural and psychosocial intervention in addition to their management
of CHF. Furthermore, it seems timely now to include personality factors in
cardiovascular research, as we need more studies that lead to a fuller understanding
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Cardiac resynchronisation therapy (CRT) is a promising treatment in chronic heart
failure (CHF) However, a subgroup of patients still report impaired health status,
cardiac symptoms and feelings of disability following CRT. The aims of this study
were to examine (1) whether CHF patients treated with CRT improved in patient-
centred outcomes and functional capacity, and (2) whether personality traits exert a
stable effect on these outcomes over 2 months.
Methods
Analyses are based on 31 patients (65% male; mean age 70+8) with CHF treated
with CRT. Two weeks before and 2 months after CRT, patients completed the Type-D
Scale (negative affectivity, i.e. tendency to experience negative emotions, and social
inhibition, i.e. tendency to inhibit self-expression), the Minnesota Living with Heart
Failure Questionnaire (disease-specific health status) and the Health Complaints
Scale (cardiac symptoms and perceived disability), and performed the 6-minute
walking fest (functional capacity)
Resu/ts
There was an improvement in disease-specific health status (p<.001), cardiac
symptoms (p=.001), perceived disability (p<.001 ), and functional capacity
(p=.007)  in all patients  over 2 months. However, high negative affectivily  patients
reported significantly lower disease-specific health status   (p=.046),   and    more
cardiac symptoms (p=.035) and perceived disability (p=.015) as compared to low
negative affectivity patients. There was no significant main effect for negative
affectivity on functional capacity. High negative affectivity patients still reported lower
disease-specific health status (p=.06) and significantly more perceived disability
(p=.04) when adiusting for left ventricular election fraction, gender and age. The
effects for negative affectivity on patient-centred outcomes, as measured by Cohen's
effect size index, were moderate to large.
Conclusions
Patient-centred outcomes improved over a 2-month period in patients treated with
CRT, but negative affectivity exerted a stable, negative effect on health status, cardiac
symptoms and perceived disability. Personality traits should be taken into account




Cardiac resynchronisation therapy (CRT) has been used extensively over the last years
in patients with advanced systolic chronic heart failure (CHF) and a prolonged QRS
interval. Such patients commonly have a delayed myocardial activation, leading to a
dyssynchronic contraction pattern of the left ventricle. This dyssynchrony results in
hemodynamic alterations and ensures symptoms to the patients, such as dyspnoea
11,21. Large-scale clinical trials have shown  that CRT exerts positive effects  on
mortality, morbidity, quality of life, functional status, and exercise capacity in CHF [l-
71. However, a subgroup of patients still report significant symptoms and high levels
of disability following CRT, and are labelled as non-responders 18,91
When evaluating the effects of CRT, New York Heart Association (NYHA)
class and health status are most frequently used as indicators le.g. 2,5,101, whereas
the effects on a more broad range of patient-centred outcomes have not been
reported. Little is also known about improvements in patient-centred outcomes
following CRT. Patient-centred care refers to attending to patients' needs, improving
or maintaining their quality of life and giving them an opportunity to play an active
role in medical decision-making [111. One key component of patient-centred care is
assessment of patient-centred outcomes. Examples of such outcomes are health-
related qualify of life and symptom burden [11 1
The distressed, or type-D, personality has been shown to influence a
number of health outcomes in patients with heart disease, including mortality,
morbidity, quality of life and health status [12-151 Type-D personality is defined by
two normal and stable personality traits, namely negative affectivity (the tendency to
experience a broad range of negative feelings) and social inhibition (the tendency
not to share these feelings in social interaction) [16-191. Thus, patients with this
disposition experience increased negative emotions, while not expressing these
emotions in social interaction because of fear of reiection or disapproval [16,171
Not only type-D personality, but also its two traits negative affectivity and social
inhibition have been shown to be determinanfs of individual differences in health
outcomes [12-261. To date, no study has reported on the association between
negative affectivity, social inhibition and type-D personality, and patient-centred
outcomes in patients treated with CRT.
Therefore, the aims of the present study were to examine (1) whether CHF
patients treated with CRT experience general improvements in patient-centred
outcomes (disease-specific health status, cardiac symptoms, perceived disability) and
functional capacity (6-minute walking test performance) over a 2-month period, and
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(2) whether negative affectivity, social inhibition, or both (i.e., type-D personality)
exert a stable negative effect on these outcomes.
METHODS
Patient population, design and procedure
Between October 2003 and December 2006, all CHF patients who were eligible for
CRT at the cardiology department of the TweeSteden teaching hospital in Tilburg, the
Netherlands, were approached for participation in the current study. All patients were
treated according to the most recent guidelines for CHF [27,281 These patients
received either an Insync-111® (Medtronic) or Frontier-11® (St Jude) device. These
devices provide atrial-driven biventricular pacing with the use of a standard right
ventricular lead and a left venfricular lead.
Inclusion criteria for CRT, and thereby for the current study, were (l )
diagnosis of systolic CHF, (2) being on optimal medical therapy, (3) NYHA functional
class 111 or IV, with a QRS duration 2120msec, and (4) left ventricular eiection
fraction (LVEF)540%. In addition, (5) at least one of the following echocardiographic
criteria had to be fulfilled: an aortic pre-eiection delay>140msec, an interventricular
mechanical delay>40 msec, or delayed activation of the posterolateral left ventri-
cular wall [3,291. For the current study, patients who were unable to read, write or
understand Dutch, who had life-threatening co morbidities (e.g. cancer or a
myocardial infarction one month preceding inclusion), severe cognitive impairments
(e.g. dementia), or who participated in another study on psychological determinants
of health outcomes in CHF, were excluded.
Of 91 patients, 55 fulfilled all criteria and were asked to participate in the
current study, of whom 41 (74.5%) agreed. However, since we used a prospective
design, final analyses are based on 31 patients who had complete data at baseline
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Figure  1.  Flow chart of patient selection
'These patients  were excluded because of diagnosis  of dementia  after  inclusion  (n =2),  no
resynchronisation therapy after all (n= 1 j. and failure of successful implementation (n = 1)
The study was approved by the hospital medical ethics committee and
carried out according fo policies to protect human subiects formulated by the World
Medical Association and described in the Helsinki Declaration. Every patient received
verbal and written information about the study and provided written informed
consent. Participation was voluntary and patients were free to withdraw at any time
during the study without further explanation or consequences. The specialised heart
failure nurse informed patients about the current study and asked them to participate.
If they agreed, they were called by the investigator in the same week to make an
appointment for assessment (mean time between assessment and CRT=2
weeks;SD=2 weeks). During the first visit, patients were given additional information
about the study and the CRT implantation procedure. They were asked to perform
the 6-minute walking test (6MWT) and complete a set of quesfionnaires at home.
The questionnaires were returned in self-addressed envelopes. Two months following
CRT (mean time between CRT and follow-up assessment=8 weeks;SD=3 weeks),
patients were asked to return to the hospital and the assessment procedure was
repeated.
All questionnaires were checked for completeness, and patients who had
left open several questions were called to obtain the answers. In case the
87
CHAPTER 5
questionnaires were not returned within one week after assessment, patients received
a reminder telephone call or letter.
instruments (patient-centred outcomes)
The Minnesota Living with Heart Failure Questionnaire (MLWHFQ) was used to
assess disease-specific health status from the patient's perspective [30}. The
MLWHFQ is a subiective measure that is frequently used to measure disease-specific
health status in CHF patients  [311. The 21  items are answered on a 6-point scale,
ranging from "no" (0) to "very much" (5), with a higher score on the MLWHFQ
representing a poorer disease-specific health status [301. The items ask about the
impact of physical and psychological symptoms and the effect of heart failure on
physical and social functioning. In addition, medication side effects are captured
[321. The MLWHFQ has solid psychometric properties, with Cronbach's a ranging
from .91-.96 [30-32}. The fota| score is the best measure of the patient's health
status 1321.
Cardiac symptoms and perceived disability were measured with the Health
Complaints Scale (HCS). Originally, the scale was developed to create a sensitive
outcome measure in the context of coronary heart disease [33]. This questionnaire
consists of two 12-item subscales, measuring cardiac symptoms that frequently occur
in patients with heart disease, and perceived disability, respectively. The cardiac
symptom subscale contains items measuring cardiac and pulmonary symptoms,
fatigue and sleep problems, whereas the perceived disability subscale contains items
focusing on health worry (anxious concerns about ones health) and illness disruption
(concerns about the extent to which illness interferes with ones life). The items are
answered on a 5-point Likert scale ranging from "not at all" CO) to "extremely" (4)
[331. The HCS is a valid, internally consistent (Cronbach's a 2.89), and stable (test-
retest reliabilit,2.69) measure, and has good construct validity [33,341.
Furthermore, it has been shown that the HCS is sensitive to detect treatment effects
[331. A higher score on the subscales of the HCS means more symptoms and more
perceived disability.
Disease-specific health status and health complaints were measured af
baseline and 2 months following CRT.
Functional capacity
We used the 6MWT as a measure of the patient's functional capacity. The 6MWT
has good infrasubiect reproducibility and reliability 135,361. Patients were asked to
walk six minutes at their own pace, without talking to the investigator. The
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investigator encouraged patients with standardised statements, such as "You are
doing well." Other conversation was not allowed. The walking test was interrupted
when patients were too tired or reported too many symptoms to walk any further. The
patients  were  permitted  to  stop  and   rest when necessary during  the  test  135,371
Functional capacity was measured at baseline and 2 months following CRT.
Personality traits
Negative affectivity, social inhibition, and type-D personality were assessed with the
Type-D Scale (DS14) [171. The questionnaire consists of two subscales of seven items
each, measuring the two normal and stable personality traits negative affectivity and
social inhibition 1171. The  14  items are answered on a 5-point Likert Scale ranging
from "false" (0) to "true" (4). Examples of items measuring negative affectivity are "1
often feel unhappy" and "I am often irritated" Examples of items measuring social
inhibition are "I often feel inhibited in social interactions" and "I am a closed kind of
person" Type-D personality is defined as a standardised cut-off 210 on both
subscales of the DS 1 4, i.e., the negative affectivity as well as the social inhibition
subscale. High negative affectivity and high social inhibition are defined as a score
of 210 on the negative affectivily or social inhibition subscale, while scoring low on
the other scale [171. Recently was shown  that the items  of the  DS 1 4 had highest
measurement precision around the mentioned cut-off [381. The negative affectivity
and social inhibition subscales have good internal consistency (Cronbach's
a=.88/.86) and good 3-month fest-retest reliability (r=.72/.82) [171. The construct
validity of negative affectivity and social inhibition has been confirmed against the
Big-Five personality traits neuroticism and extraversion,   respectively   [171
Furlhermore, a recent study in 475 patients with myocardial infarction indicated that
type-D personality was a stable construct over an  18-month period [391. The DS 1 4
was administered at baseline.
Clinical variables and socio-demographic characteristics
Information on clinical variables (aetiology, LVEF, NYHA, co morbidities, current
medication, height and weight) was collected at baseline and obtained from the
medical records or the treating cardiologist/heart failure nurse. Socio-demographic
variables included gender, age, marital status, educational level and work status,
and were measured by purposed-designed questions in the questionnaire. Life style




Discrete variables were compared with the chi-square test and continuous variables
with Student's f test for independent samples. In order to adiust for multiple
comparisons, multivariate analyses of variance IMANOVA) for repeated measures
were performed to examine whether there were differences in (a) patient-centred
outcomes, i.e., disease-specific health status (MLWHFQ), cardiac symptoms and
perceived disability (HCS), and (b) between low/high negative affectivity (cut-off
210), low/high social inhibition (cut-off 210) and type-D personality (yes/no) [171
on these outcomes over time. Differences on 6MWT performance over time were
evaluated with an analysis of variance CANOVA) Post-hoc ANOVA's for repeated
measures were performed to evaluate differences in mean scores on the patient-
centred outcomes at baseline and 2 months following CRT. Personality traits were
entered into the ANOVA's to examine between-group differences on all outcome
measures. Analyses of covariance (ANCOVA) were used to examine whether
negative affectivity exerted a stable effect on disease-specific health status, cardiac
symptoms, perceived disability and functional capacity, adiusting for baseline LVEF,
gender and age.
Finally, Cohen's effect size index (d) was used to evaluate the influence of
negative affectivity and gender on all outcome measures 1401 Gender is an
individual difference variable that is often included in cardiovascular research [411
An effect size (ES) of 0.20 is considered small, of 0.50 moderate, and of 20.80
large [401. Ali analyses were perlormed using SPSS 14.0 for Windows.
RESULTS
Base/ine characteristics
Of 31  patients, 11  (36%) had elevated scores on negafive affectivity and 18 patients
158%) were significantly socially inhibited. The prevalence of type-D personality in this
sample was 26% (8/31).
Baseline characteristics for the complete sample and stratified by negative
affectivity are shown in Table 1. High negative affectivity patients differed from low
negative affectivity patients on educational level in that patients high on negative
affectivity were more often on lower educational level.
CRT and patient-centred outcomes
The results of the MANOVA for repeated measures indicated a significant overall




Tab/e  1.    Base/ine characteristics stratified by negative o ffectivity
Total sample High NA Low NA          p
(n=31)            (n- 11)            Crt -20)
Demographics
Age, Mean (SD; 70 (85 70(8) 70(9) 95
MaTe sex 20 (651 6 (55) 14 (70) 39
Living with a partner 23 (741 8 (731 1 5 (75) 89
Lower Education 9 (29) 6 (55) 3 (15) .02
Retired 23 (741 9 (82) 14 (70) .47
Working 3 (10) 1 (91 2 (10) .94
Clinical variables
NYHA-' class m 28 (90) 9 (82.1 19 (95) 23
LVEF-' 98, mean (SD) 27 (8) 28 111) 26 (6) 71
Ischemic aetiology 20 (651 9 (82) 1 1 M .14
Life style
Smoking· 7 (23) 3 (27) 4 (20) .64
Physical activity 1 2 (39J 3      (27J 9      (45/ 33
BMI'. mean (SDi 28 14) 30 (53 27 (3) .55
Co niorbidifies
COPD It (36) 5 0,161 6 (30) .39
Diabetes mellitus 7 93) 4 (36) 3 (151 .17
Renal insufficiency 6 (19) 2 (18) 4 (201 90
Hypertension 19(61) 6 (551 13 M .57
Hyperlipidernia 17 (551 8 (73j 9 (45} .14
PADS 6 (19) 3 (27) 3 (15) .41
Medication
ACE-inhibitors 24 (771 7 (64) 17 (85) .17
ARB's 12 (391 6 (55) 6 (30J .18
Diurefics 23 174) 9 (82) 14 (703 .47
Spironolactone 5 (16} 1 (9) 4 (201 .43
Digitatis 8 (26J 4 (36) 4 (20) 32
Beta-blockers 18 M 6 (55) 12 (60) 77
Long-acting nitrates 11 86) 4 (36) 7 (35) .94
Aspifin 20 (652 6 (55) 14 (70) .39
Statins 14 (45) 5 (461 9 N .98
Psychopharmaca 9 (29) 4 136) 5 (25) .51
Data ore presented as n (96) unless otherwise indicated
Negative  affectivity,'New  York Heart Association functional  doss; 'Left  ventricular  election
fraction; 'Body mass index. 'Chronic obstructive puhnonary disease.°Peripheral arfery disease
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ANOVA for repeated measures showed a significant general improvement
in disease-specific health status, as measured with the MLWHFQ over 2 months in
patients treated with CRT (F(1,30)=25.665;p<.001). There was also a main effect
for time on both subscales of the HCS, indicating an improvement in cardiac
symptoms (F(1,30)=13.789;p=.001) and in perceived disability (F{1,30)-15.685;
p<.001)overtime.
In Table 2, mean scores on the patient-centred outcomes at baseline and 2
months following CRT are shown.
Table 2.  Mean scores on patient-centred outcomes and functional capacity of baseline and 2
months following CRT
Mean (SD) Mean (SD)        F             p
Baseline 2 months
Health status' 47.5 (16.4) 32.2 (17.7) 25.665 <.001
Cardiac symptomsl       21.0 (12.6) 13.9(12.7) 13.789 .001
Perceived disabilitys             23.8  (1 1.6 3 1 7.0(1 3.7) 15.685 <.001
Functional capacity''          120.0 (95.21 200.0 (160.03 8.538 .007
'Minnesota Living with Heart Failure Questionnaire
-Health Complaints Scale
-'6-minute walking test (in meters;
Personality and patient-centred outcomes in CRT
When including personality traits (that is negative affectivity, social inhibition, and
type-D personality) as between-subiects factors in the MANOVA's for repeated
measures, we found a main effect for negative affectivity on disease-specific health
status, cardiac symptoms and perceived disability (F(1,29=6.810;p=.01). This effect
for negative affectivity was Cal stable over time, given the fact that the negative
affectivity by time interaction effect was non-significant (p=.70), and (b) the same for
all patient-centred outcome measures used, i.e., the negative affectivity by scale
interaction was also non-significant (p=.85). Neither social inhibition nor type-D
personality were significantly associated with any of the outcome measures.
In the ANOVA for repeated measures, we found that high negative
affectivity patients treated with CRT reported significantly lower disease-specific
health status compared to low negative affectivity patients (F(1,29)=4.363;p=.046)
(Figure 2). The interaction effect negative affectivity by time was not significant
(F(1,29)=.050;p=.82), indicating that negative affectivity exerted a stable effect on
disease-specific health status over a 2-month period. Compared to low negative
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affectivity patients, high negative affectivity patients also reported more cardiac
symptoms (F(1,29)=4.879:p=.035) and more perceived disability (F(1,29)=6.715;
p=.015), as measured with the HCS over 2 months (Figure 2). The non-significant
interaction effects for negative affectivity by time for both cardiac symptoms
(F(1,29)=.970;p=.33) and perceived disability (F(1,29)=.022;p=.88) indicated a
stable negative effect for negative affectivity on cardiac symptoms as well as on
perceived disability over the follow-up period.
Effects on functional capacity
Functional capacity, as measured with the 6MWT, improved significantly during the
course of 2 months (F(1,30)=8.538;p=.007) (Table 2). However, there was no
significant between-subiects difference between high and low negative affectivity
patients on the 6MWT (p=.33) (Figure 2), neither was there an interaction effect for
negative affectivity   by  time (p=.36) There  were  also   no main effects for social
inhibition or type-D personality on functional capacity.
Effect of negative affectivily on outcomes (adiusted analyses)
When adiusting for LVEF, gender and age (ANCOVA), high negative affectivity
patients still reported lower disease-specific health status (F(1,1)=3.813;p=.06) and
significantly more perceived disability (F(1,1)=4.894;p=.04) as compared to low
negative affectivity patients. There were no significant main between-subiects effects
for negative affectivity on cardiac symptoms (p=.11) nor on functional capacity
(p=.37), when adiusting for disease severity, gender and age (Table 3). There were
no significant between-subiects effects for LVEF, gender and age, but male patients
had near significant better functional capacify as compared to female patients
(F(1,1)=3.833;p=.06) (Table 3).
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Table 3   Effect of negative affectivity on patient-centred outcomes ot-,d functional capacity
,adiusted analyses,
Health La·dtoc Perceived Functioflal
Ste„uS' symptoms' disability' Capacity
F p F P F p F         p
NA. 3.813 0.06 2802 0.11 4.894 0.04 0.839 0.37
LVEF· 1.319 0.26 0.053 0.82 0.151 0.70 1.005     0.32
Gender 0  129 0.72 1.314 0.26 0.809 0 38 3.833     0.06
Age 0.039 0.85 0.755 0.39 0003 096 0.259 0.62
Negative offectivily
-Left ventriculat election froction
'Minnesota Living with Heart Failure Questionnaire
  Health Compic,in Is Scale
6-minute walking rest
Effects of negative affectivify versus gender
Negative affectivity had moderate to large effects on the patient-centred outcomes at
baseline and 2-month follow-up, but a small effect on functional capacity, as
measured by Cohen's effect size index. The effects of negative affectivity on disease-
specific health status, cardiac symptoms and perceived disability were larger than the
effect of gender on these outcomes (Figure 3).
DISCUSSION
To our knowledge, this is the first study to examine the influence of
personality traits on a broad range of patient-centred outcomes in patients treated
with CRT. We found a general improvement in patient-centred outcomes, i.e.,
disease-specific health status, level of cardiac symptoms, perceived disability, and in
functional capacity over a 2-month period in these patients. However, negative
affectivity had a stable, negative effect on patient-centred outcomes, with patients
high on negative affectivity reporting lower disease-specific health status, more
cardiac symptoms and more perceived disability as compared to low negative
affectivity patients. There was no difference between high and low negative affectivity
patients on functional capacity. When adiusting for disease severity (LVEF) and socio-
demographics, negative affectivity still exerted a substantial negative effect on
disease-specific health status and perceived disability. The effects of negative
affectivity on the patient-centred outcomes were moderate to large, as indicated by
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Cohen's effect size index [401 Type-D personality (concurrent high negative
affectivity and social inhibition) and social inhibition were not associated with the
patient-centred outcomes or functional capacity.
CRT is a promising treatment option for patients with advanced CHF, as it
has been shown in prospective clinical trials to reduce mortality and morbidity, and
to improve quality of life and functional status [1 -7,42-451. However, not all patients
experience improvement following CRT [441. In this context, it is important to identify
which clinical parameters predict poor treatment response [45,461, but it might be of
equal importance fo gain knowledge about those patients that still report cardiac
symptoms and perceived disability following CRT. Furthermore, it has been shown in
previous research in patients with an implantable cardioverter defibrillator that
psychological variables are at least as important as disease-characteristics in
predicting quality of life [471
Some authors stress that soft endpoints (such as measures of complaints
and 6MWT performance) are less appropriate for measuring effects of CRT [44],
whereas others emphasise that there is an urgent need to focus on patient-centred
outcomes in cardiovascular research, such as health status and symptoms [11].
Negative affectivity is a stable personality trait that is defined as the tendency to
experience a broad range of negative feelings even in the absence of overt stress.
High negative affectivity persons focus on the negative side of others and the world,
and have a negative self-view [181 Research has shown that persons high on
negative affectivity report more symptoms, although the relationship between
negative affectivify and actual morbidity or mortality is not clear [17,48,491. As
Kroenke points out, subiective symptoms may guide diagnosing and treatment in
medical settings [501 Therefore, the subgroup of high negative affectivity post-CRT
patients, who report more impaired disease-specific health status and more health
complaints as compared to low negative affectivity patients, may incorrectly be
labelled as "non-responder" or "having no benefit from CRT" However, these
patients do improve on outcome following CRT, although they do not reach the
same level as low negative affectivity patients, as they report more health complaints.
Furthermore, there were no differences between high and low negative affectivity
patients on functional capacity, whereas high negative affectivity patients do perceive
more disability as compared to low negative affectivify patients. Therefore, it may be
that persons high on negative affectivity are sensitive for the encouraging statements
that the investigator is allowed to give during 6MWT performance, but in general feel
more disabled. An alternative may be that these patients report more impaired
disease-specific health status, more symptoms, and feel more disabled both before
97
CHAPTER 5
and after CRT, but are not different from low negative affectivity patients on more
oblective measures, such as 6MWT performance. In a recent study in patients with
atrial fibrillation (AF) was shown that negative emotions influenced patients' AF
symptoms report more than obiective indicators of AF [511 Taken together, it is
possible that high negative affectivity patients report more health complaints,
although they do not differ on clinical measures of disease severity. Further research
is warranted to explore this.
In previous research, type-D personality has been shown to predict negative
outcome Ie.g. 12-15,20-22,52,531. In this study, no differences between type-D and
non type-D patients on any of the outcome measures over a 2-month period was
found. This may be due to the relatively small sample size, with only eight patients
being identified as type-D, and the relatively short follow-up period of two months.
Limitations and strength
This study is exploratory and has several limitations. First, there was no control group
and it is not possible to attribute the general improvements in disease-specific health
status, cardiac symptoms, perceived disability, and functional capacity to CRT.
Second, the sample size was small, which may be a reason for not finding an effect
of negative affectivity on cardiac symptoms in adiusted analyses. Third, the follow-up
period was relatively short. Fourth, we had only information on LVEF and NYHA class
at baseline and were therefore not able to study the influence of personality traits on
LVEF and other echo parameters over time. We were therefore also not able to
assess whether CRT had resulted in changes in echo parameters. However, the focus
of the study was on patient-centred outcomes.
Despite these limitations, this is the first study examining the effect of
personality traits on patient-centred outcomes in patients treated with CRT.
Furthermore, the study focuses on patient-centred outcomes and their determinants,
which may help to close the gap between research and clinical practice [111
Conc/usions
In conclusion, we found general improvements in disease-specific health status,
cardiac symptoms, perceived disability and functional capacity over a 2-month
period in patients treated with CRT. However, patients high on negative affectivity
reported lower disease-specific health status, and more cardiac symptoms and
perceived disability as compared to patients low on negative affectivity. Large-scale
studies with a longer follow-up period are needed to further explore the relationship
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Chronic heart failure (CHF) is a debilitating condition associated with poor outcome,
including increased anxiety. However, anxiety and its determinants have not yet been
studied systematically in CHF. We examined whether type-D personality and de-
pressive symptoms would predict clinically significant anxiety at 1 -year follow-up.
Methods
Consecutive patients with sysfolic CHF (n=149; 79% men; mean age 66+8.6)
completed the Type-D Scale (DS14), the Beck Depression Inventory, and the Anxiety
Sensitivity Index at baseline. A clinical interview (Hamilton Anxiety Rating Scale) was
used to assess clinically significant anxiety at 1 -year follow-up.
Resu/ts
At 12-month follow-up,  26%  (9/35) of type-D patients  had clinicaily significant
anxiety versus only 6% (7/114) of the non type-Ds (p=0.001).
In univariable analyses, type-D personality (OR=5.3;p=0.002) and anxiety sensitivity
(OR=4.5;p=0.009), but not depressive symptoms (p=0.27), predicted clinically
significant anxiety. Type-D remained an independent predictor of anxiety at 1 -year
(OR=5.7;p=0.01), controlling for depressive symptoms, anxiety sensitivity, socio-
demographic and clinical variables. Adding type-D in a hierarchical logistic
regression model, comprising standard and psychological risk factors, enhanced the
level of prediction of clinically significant anxiety substantially (-2LL=75.16
X2=26.46;p=0.009)
Conclusion
Type-D personality, but not depressive symptoms, predicted
1-year clinically significant anxiety. The Type-D Scale could be used to identify CHF
patients at high risk of anxiety, as these patients may be at increased risk of adverse
prognosis and impaired quality of life.
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INTRODUCTION
Chronic heart failure (CHF) is a maior health problem, with the incidence and
prevalence of this potentially fatal disorder increasing tantamount to an epidemic
Il,21.  Despite an impressive development of various treatment options, CHF is still
associated with poor prognosis and functional capacity, frequent (re)hospitalisation,
and escalating health costs [1 ,3,41. Importantly. CHF is also associated with
increased psychological distress 15,6], and there is an urgent need to focus on this
patient-centred outcome and its determinants in CHF [71
Depression has received the most attention in CHF, with only few studies
focusing on anxiety [8,91 However, there is evidence to suggest that 8-16% of CHF
patients suffer from clinically significant anxiety, such as generalised anxiety disorder
or panic disorder [10,111 Moreover, anxiety in heart patients is frequently under-
recognised in clinical practice [121. Although anxiety has been linked in some
(although not all) studies to prognosis, morbidity, and functional status in CHF 113-
161, few studies have investigated the determinants of anxiety, and all of these have
been  cross-sectional  [10,1 7,181. In these cross-sectional studies, higher  New  York
Heart Association (NYHA) functional class [10,18J, co morbid physical conditions
[101, and lower perceived control   [1 71   were  associated with increased levels  of
anxiety.
The distressed (type-D) personality may be another important, but over-
looked, determinant of anxiety in CHF patients. Type-D patients have elevated scores
on two normal and stable personality traits, namely negative affectivity (tendency to
experience negative emotions) and social inhibition Ctendency to inhibit self-
expression in social interaction) [191 (Table   1 ). Type-D personality   has   been
associated with several negative outcomes in patients with cardiac disease, such as
worse prognosis and impaired quality of life Ie.g. 20-221 Type-D personality is also
independently associated with an increased risk of depressive symptoms and anxiety
in patients with an impaired pumpfunction, in patients with an implantable
cardioverter defibrillator (ICD), and in coronary patients [e.g. 6,23-251
Increasing our knowledge of the prevalence and deferminants of anxiety
may enhance secondary prevention and further improve management of CHF
[9,101.  However, to date no prospective study has directly examined  the relationship
between type-D personality and anxiety in CHF patients. Hence, the obiective of this
1-year follow-up study was to examine whether type-D personality would predict
clinically significant anxiety in CHF patients.
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Table  I.    Definition, symptoms ond assessnient of negotive affectivity (NA) ond social inhibition
51)
NA                                               St
Definition tendency to experience tendency to inhibit
negative emotions across negative emotions in sociat
time and situations contact because of fear of
disapproval
Symptoms frequent worrying, inhibited, insecure when
(examples) scanning fhe world for wifh others
danger, low self-esteem
Assessment NA subscale of the DS 14- St subscole of the DS 14
Items I often make o fuss about "1 am a closed kind of
(examples) unimporiont things" '1 person"  "1  find  if hard to
often feel unhappy start a conversation
I                                                                                                                                                           ./
Type-D Persons who score 210 on the NA and the SE subscale
of the DS 14.
'Type-D Scale
METHODS
Study population and procedure
Consecutive CHF outpatients visiting the cardiology clinic of the TweeSteden tea-
ching hospital in Tilburg, the Netherlands, were approached for inclusion in the
current study. CHF patients with a left venfricular eiection fraction (LVEF) 540% and
pharmacologically stable one month preceding inclusion were asked to participate in
this study. Patients older than 80 years, with diastolic heart failure, incapable of
understanding and reading Dutch, or with cognitive impairments or life-threatening
co-morbidifies were excluded. The patients were treated following the most recent
guidelines for the treatment of CHF [261, and were informed about the study by a
cardiologist or a specialised heart failure nurse. If patients agreed to participate, they
were called the same week to set up a first appointment to complete a set of
psychological questionnaires. All patients provided written informed consent and
participation was voluntary. The hospital's medical ethics committee approved the
study protocol, and the study was carried out according to the Helsinki Declaration.
During the first visit, patients were given a booklet with a series of self-
report questionnaires asking about psychological and socio-demographic
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information. Patients were asked to fill out the questionnaires at home and return
them in a self-addressed envelope. At  1 -year follow-up, patients were interviewed
about their anxiety levels in the past week, and again received a set of questionnaires
to complete at home. All questionnaires were checked for completeness. Patients
who had left open several questions were called to obtain the answers or they were
mailed a copy of the items and asked to complete them. In case the questionnaires
were not returned within two weeks, patients received a reminder telephone call.
In total we asked 231 patients for participation in this study. The response
rate  was  82%,  as 190 patients agreed to participate. However, because patients
died and  left the study during follow-up, final analyses are based on 149 patients
(Figure 1 ).
Number of patients asked n=231
for participation
··- n=41 Refused to participate
n=3   -  Excluded due to missing BDI*
and ASI'-scores
-n=5 Excluded during follow.up»
-·      11 -1 6 Died during follow-up
-  n=17 Refused participation at follow-
UP
Included patients n=149
Figure 1. Flow chart of patient selection
17-hese patients were excluded due to medical (e.g. cerebrovasculor accident during the study)






The Type-D Scale (D514), consisting  of two seven-item subscales, i.e., negative
affectivity and social inhibition, was used to assess type-D personality 1191. The  14
items are answered on a 5-point Likert scale from "false" (0) to "true" (4) Patients
are defined as type-D when scoring 210 on both subscales.  The  DS 1 4  has good
internal consistency with Cronbach's a=.88/.86  for the negative affectivity  and  the
social inhibition subscale, respectively.  The  DS 1 4 measures two temporally stable
personality traits, indicated   by good test-retest  reliability   (r=.72  for the negative
affectivity subscale and r=.82 for the social inhibition subscale). Furthermore, the
two subscales are independent from changes in mood [191. Finally, the construct
validity of negative affectivity and social inhibition against neuroticism and
extraversion, two important personality traits, has been confirmed  [191. The DS14
was administered at baseline.
Potentia//y confounding variables
We also assessed depressive symptoms and anxiety sensitivity at baseline to control
for any confounding effects of these psychological variables on clinically significant
anxiety. The Beck Depression Inventory (BDI) was used to measure depressive symp-
toms [271. This 21-ifem questionnaire is a commonly used self-report measure of
depressive symptoms in clinical research. There are four response options for each
item, ranging from 0-3. The scale has good internal consistency with Cronbach's
a=.81 in non-psychiatric samples [5]. Using a cut-off 210, the  BDI  has sensitivity
and average specificity against a clinical diagnosis of depression [281
Anxiety sensitivity may also be associated with anxiety in chronic conditions
1291. Anxiety sensitivity refers to the extent to which a person experiences anxiety-
related sensations as fearful or to have a catastrophic outcome [30-321. The 16-item
Anxiety Sensitivity Index (ASI) was used to measure anxiety sensitivity [30,321. The 16
items are answered on a 5-point Likert scale from "very little" CO) to "very much" (4)
[30,321. The internal consistency of the ASI is acceptable with Cronbach's a ranging
from.80-.90 [301
Clinically significant anxiety at follow-up
The severity of anxiety symptoms was rated by a clinical interview, namely the
Hamilton Anxiety Rating Scale (HARS), a standardised psychiatric interview that is
widely used in research and in clinical trials for the evaluation of anxiety 133,341. This
14-item interview rating scale assesses and quantifies severity of anxiety along two
symptom dimensions, i.e. psychic anxiety and somatic anxiety [35]. Each item is rated
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on a 5-point scale by a clinical psychologist [331. The interrater reliabilities of the
HARS are 0.74, 0.73 and 0.70 for the total, psychic, and somatic subscales,
respectively  [351. A cut-off 217  on the  HARS  indicates mild to severe anxiety,  that  is
clinically significant anxiety [331. The interview was conducted at 1 -year follow-up.
Demographic and clinical characteristics.
Socio-demographic information was obtained from separate questions in the
questionnaire and comprised sex, age, marital status, and educational level.
Smoking status (yes/no) was also assessed by means of self-report. Information on
LVEF, NYHA class, aefiology of CHF, risk factors, co morbidities and medication was
obtained from the patients' records or treating cardiologist.
Statistical analyses
Discrete variables were compared with the chi-square test, whereas Student's f test
for independent samples was used to compare continuous variables. Logistic
regression analyses were performed to assess the impact of type-D personality,
depressive symptoms, anxiety sensitivity, and clinical and demographic variables on
clinically significant anxiety at 1 -year follow-up. Prior to logistic regression analyses,
NYHA class, aetiology of CHF, marital status, and educational level were recoded
into dichotomous variables. Furthermore, BDI-scores and ASI-scores were also used
as dichotomous variables, using the pre-determined cut-off of 10 for the BDI [5,36],
and the highest tertile for the ASI. Finally, HARS scores were dichofomised using a
cut-off 217, indicating mild to severe anxiety [33,351. Dichotomisation was used in
order fo enhance clinical interpretabilily [37,38}. In secondary analysis, multivariable
linear regression analysis with continuous variables was performed. Finally, a
hierarchical logistic regression model was used to identify the model that best
predicted outcome. All analyses were performed using SPSS 12.0.1 for Windows.
RESULTS
Patient characteristics
At baseline, 35 patients (23.5%) were classified as type-D and 47 patients (31.5%)
as having probable depression (BDI 210). There were no significant differences (all
ps>0.05) between type-D and non type-D patients on baseline characteristics,
including medication (Table 2). The mean score was 8.63:6.2 (range 0-34) for self-
reported depression and 12.1 + 9.7 (range 0-47) for anxiety sensitivity.
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Table 2.   Baseline characteristics stratified by fype-D personality
Total Type-D Non type-D     p
sampie Crt =35) (n= 1 1 4)
Demographics
Age, mean (SD) 66 (8.6) 68 18. N 66 (8.8) 0.22
Mole sex, n (%) 118 (79) 29 (83) 89 (78) 0.54
Primary school. n (98) 54 (36) 16 (46) 38 (33) 0.18
Living with a partner, n (%) 113 (76) 27 (77) 86 (75) 0.84
Clinical variables
LVEF' %, mean (SD) 30 (7) 29 (71 30 (7) 0.32
NYHA' class Ill and IV, n 1%) 72 (48) 22 (63) 50 (44) 0.05
Ischemic oetiology, n (961 8 1  (54 J 18 (51) 63 (55) 0.69
Smoking 36 (24) 6(17) 30 (26) 0.27
Co morbidifies
Precious cardiac history: n (%) 85 (57) 19 (54) 66 (58) 0.71
Diabetes, n (96; 36 (243 9 (263 27 (24) 081
Renal insufficiency, n (%) 18(12) 5 (14) 13(11) 0.65
Hypettension, n (06) 49 (333 11   (31 j 38 (33) 0.83
Hyperlipidemio, n (961 80 (54) 20 (57) 60 (53 0.64
Medication
ACE-inhibitors, n (96) 118 (79) 27 (77) 91 (80J 0.73
AH-antagonists, n (96) 22 (15) 5 (14) 17(15) 0.93
Diuretics, n (96) 1 19 (80) 32  (91 j 87 (76) 0.05
Spironolactone, n (96) 36 (24) 6(17) 30 (26) 0.27
Digitalls, n (96) 49 (333 13 (37) 36 (31) 0.54
Beta-blocked, n (%) 98 (66) 24 (691 74 (65) 0.69
Long-acfing nitrates, n (96) 32 (22) 9 (26J 23 (20) 0.49
Aspirin, n (96) 67 (45)' 17 (49) 50 (44) 0.62
Statins, n (%) 71 (48) 18 (5lf 53 (47) 06 1
Psychopharmaco, n (%; 21 (14} 7 (20) 14(12) 0.25
'
LVEF=Left ventricular election frodion
'NYHA=New York Heart Association functional class
'Previous  cardiac  history=myocardial  infarction,  coronary  artery  bypass  graff surgery, percu-
taneous coronary infervention
Preva/ence of mi/d to severe anxiety
The prevalence of clinically significant anxiety at 1 -year follow-up in this sample was
11%. A significantly greater proportion of type-D patients displayed clinically
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significant levels of anxiety (i.e., HARS rating  217) at 1-year follow-up 0(2=10.7;
p=0.001) compared with non type-Ds. Of type-D patients, 26% (9/35) had clinically
significant anxiety versus only 6% (7/114) of the non type-Ds. One-year anxiety
levels, stratified by type-D personality and depressive symptomatology, are displayed
in Figure 2.
• No I Yes
8 30










0 t- -I                i--
Type-D personality Depressive symptoms
Figure 2.   Clinicolly significant anxiety at  1 -year follow-up,  stratified  by type-D  personality and
self-reported depressive symptoms at baseline
..p<0.01
Univariable predictors of anxiety at one year
In logistic regression analyses, hypertension was the only clinical baseline
characteristic  that was associated with severity of anxiety  at  1 -year follow-up
(OR=3.0;p=0.04). None of the other socio-demographic or clinical variables were
associated with clinically significant anxiety at follow-up (Table 3). Type-D personality
and anxiety sensitivity were significant predictors of clinically significant anxiety, with
type-D patients having a more than 5-fold risk (OR=5.3) and patients with increased
anxiety sensitivity a more than 4-fold risk (OR=4.5) of being anxious at follow-up
(Table 3). In contrast, depressive symptoms were not associated (p=0.27) with
clinically significant anxiety at 1 -year follow-up.
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Table 3.    Univariable predictors of clinically significant anxiety at  1 -year follow-up
Odds ratio 9598(3                p
Type-D personality 5.3 1.80-15.53 0.002*
Depressive symptoms 1.8 0.63 - 5.19 027
Anxiety sensitivity 4.5 1.46-13.60 0.009-
Age 1.0 0.9 6  - 1.0 9 0.47
Male sex 1.8 0.60 - 5.85 0.28
Low educatiotial level 0.5 0.19 1.50 0.23
Living with a partner 0.4 0.09-1.93 0.26
LVEF'                                  1.1                 0.96 - 1.13 0.29
NYHA·dassification 0.6 0.21 - 1.77 0.36
Ischeniic aetiology 1.6 0.57 - 4.59 0.37
Smoking                                  1.1                   0.32 - 3.49 0.93
Previous cardiac history 1.8 0.58 - 5.33 0.32
Diabetes 0.7 0.19 2.6l 0.59
Renal insufficiency                     1.1                 0.28 5.01 0.96
Hypertension 3.0 1.04 - 8.59 0.04*
Hyperlipidemia 2.0 0.67 6.20 021
''Left ventricular election fraction
5,New York Heart Association functional class
Sign ficant odds ratios are presented m bold face
'P < 0.05
..p.0.01
Multivariable predictors of anxiety at one year
In mulfivariable logistic regression analysis, type-D personality was an independent
predictor of clinically significant anxiety  at  1 -year follow-up (OR=5.7;p=0.01),
adiusting for LVEF, NYHA class, aetiology of CHF, smoking, hypertension, age, sex,
educational level, marital status, depressive symptoms, and anxiety sensitivity (Table
4). None of the other variables was associated with clinically significant anxiety,
including depressive symptoms and anxiety sensitivity, although there was a trend for
living with a partner (p=0.08) to reduce anxiety and for hypertension (p=0.09) to
enhance it (Table 4). When performing multivariable linear regression analysis with
continuous variables, we also found type-D to be the only significant determinant of
clinically significant anxiety at 1 -year follow-up (11=.35, p<.001).
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Table 4.     Multivoriable predictors of Clinically significant anxiety of  1-year follow-up
Odds ratio 95"ocl                              p
Type-D personality 5.7 1.45 - 22.73 0.01.
Depressive symptoins                          1.1                         0.24 - 4.91 0.92
Atixiefy sensitivity 2.9 0.72- 12.02 0.13
Age                    1.1         0.96- 1.14 0.30
Maie sex 2.4 0.52-- 10.71 0.27
Low educational level 0.6 0.17 -2.14 0.44
Living with a partner 0.2 0.0 3 -1.2 6 0.08
LVEP                                      1.1                  0.97 - 1.20 O. l 8
NYHAB classification 0.5 0.13 - 2.0 6 0.36
Ischemic cetiology 1.8 0.50 - 6.27 0.38
Smoking 1.6 0.36 - 7.07 0.54
Hypertension 3.1 0.85- 11.49 0.09
ALeft ventricular election fraction
5New York Heart Association futicfiond class
Significant odds ratios are presented in bold face
-p < 0.05
In order to examine whether the addition of psychosocial variables
increased the level of prediction of anxiety severity at  1 -year above and beyond
demographic and clinical factors, we conducted a hierarchical logistic regression
analysis, entering socio-demographic and clinical variables in the first step
(-2LL=89.40 X2=12.22;p=0.20). In the second step, we added depressive
symptoms, but this addition did not enhance the predictive level of the model (-
2LL=87.69 X2=13.93;p-0.18), whereas the addition of anxiety sensitivity in the
third step significantly improved the prediction of anxiety (-2LL=81.84
)(2=19.78,p=0.048). In the final step, the addition of type-D personality enhanced
the   level of prediction   of anxiety severity   at   1 -year substantially   (-2LL=75.16
)(2=26.46:p=0.009)
DISCUSSION
This is the first study examining the relative impact of type-D personality, depressive
symptoms, and anxiety sensitivity on severity of anxiety at 1 -year follow-up in patients
with CHF. We found that type-D personality incurred an almost 6-fold increased risk
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of  clinically   significant  anxiety  at   1 -year follow-up, adiusting for depressive
symptoms, anxiety sensitivity, and socio-demographic and clinical baseline charac-
teristics, including LVEF, NYHA class and aetiology of CHF. Only type-D personality
and anxiety sensitivity, but not depressive symptoms, added to the level of prediction
of clinically significant anxiety at 1 -year follow-up compared with socio-demographic
and clinical baseline characteristics. Previous studies in ICD patients and coronary
patients (with a reduced pump function) also found a relationship between type-D
personality and anxiety [21,23-251.
Type-D personality is defined as having a high score on the two stable
personality traits negative affectivity and social inhibition. Inhibited individuals are
more vulnerable for developing anxiety [391, and given that negative affectivig
already increases the risk of anxiety, the combined effect with inhibition may further
exacerbate the anxiety-risk.
In CHF patients, severe anxiety has been related to reduced physical activity
[401. Furthermore, in other groups of heart patients, anxiety has been associated with
impaired quality of life [41,421, more symptoms [121, and self-reported recurrent
cardiac events 1121. With respect to the relationship between anxiety and mortality,
mixed results  have been found  as some [21,43-451,  but  not  all Il 3,14,41,42}
studies have found a higher mortality risk in anxious heart patients. More research to
clarify these inconsistent results is warranted, also in CHF patients.
According to Norman and Lang, anxiety sensitivity may be a contributor to
anxiety in patients suffering from chronic disease [291 However, in our study of
chronically ill patients, anxiety sensitivity was a significant predicfor of anxiety in
univariable analysis, but not in multivariable analysis. It might be that type-D perso-
nality explained away the association between anxiety sensitivity and anxiety in this
sample, and that anxiety sensitivity mediates the relationship between type-D and
anxiety. Further research on this topic is needed.
Previous studies have shown that higher NYHA class is associated with
increased levels of anxiety  and a higher prevalence of anxiety disorders   [10,181
However, in the current study we did not find a relationship between any of the
clinical variables and severity of anxiety at 1 -year follow-up in multivariable analysis.
These differences in results may be attributed to differences in study design, with
previous studies being cross-sectional, whereas we used a prospective design. In
addition, the above-mentioned studies did not take into account the influence of
personality, although type-D personality has in several previous studies been
associated with worse outcome [e.g. 6,20-23].
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This study has a number of limitations. First, some of the anxiety symptoms
may overlap with traditional symptoms of CHF, such as shortness of breath.
However, the assessment of anxiety levels was done by experienced health
psychologists, trained by a heart failure nurse in distinguishing pure physical
symptoms from anxiety-related complaints. Second, the patients in the current study
were asked for participation by a cardiologist or heart failure nurse, which may have
led to a selection bias. Third, depressive symptoms were assessed by means of self-
report. However, the BDI has been shown to have good sensitivity and specificity
compared with the golden standard of a clinical diagnosis of depression [28].
Fourth, anxiety assessment with the HARS was performed by more than one health
psychologist and we only administered the interview once per patients; therefore, we
have no information on interrater reliability, although previous research on the HARS
has shown acceptable interrater reliability [35]
This study also has several strengths. First, the severity of anxiety was not
measured by means of self-report, but with a sfandardised clinical interview.
Furthermore, we used a prospective design to examine the relationship between
baseline characteristics and psychosocial factors, and severity of anxiety. Third, the
response rate in this study was high, with 82%. Finally, we were able fo identify those
patients who are at high risk of developing psychological distress, such as anxiety.
This is in line with the advice of Krumholz and colleagues that there is an urgent
need to focus on patient-centred outcomes in cardiovascular disease, including
emotional distress and their determinants [71
Recently, Zerhouni advocated that a personalised approach to medicine is
needed, because every individual patient has his or her unique genetic endowment
and behaviour [461 Screening patients for type-D personality fits well into this
personalised approach to medicine. Knowing which individuals are at risk for
developing psychological distress provides a window of opportunity to intervene at
an early stage, thereby preventing the development of psychopathology or emotional
problems. More intense coaching on anxiety at an early stage of those patients
identified with a type-D personality may be important, as anxiety in some studies has
been associated with increased risk of mortality [21,43-451, impaired quality of life
[41,421 and more health care consumption [451. Therefore, in clinical practice, these
high-risk patients should be offered psycho-education and some form of counselling.
It may be true that changing personality characteristics is very difficult, but
this should not be the primary goal of counselling in the context of type-D. Targets of
counselling could be improvement of self-management abilities [47], consolidation
of the type-D patient's social network, and improving coping abilities. In a recent
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study 1471, heart failure patients with a type-D personality were shown to be at
increased risk for displaying inadequate self-management behaviour, because they
have the tendency not to consult medical services in case of relevant symptoms.
Furthermore, type-D patients typically do not share their emotions with others Ie.g
19,201, but this is not to say that they do not feel a need to talk to others about
negative emotions; they only avoid sharing their emotions due to fear of reiection
and disapproval, which makes social inhibition different from introversion. A
supportive, stimulating social network may therefore be of great importance to type-
D patients. Finally, counselling should be directly focused on coping styles, as type-
Ds cope with negative emotions by not sharing them with others. There is a need to
evaluate this ineffective coping style with the patients.
In previous research, it has been shown that type-D patients benefit from
behavioural interventions, although to a lesser degree than non type-Ds 1201.
However, this does not imply that no efforts of counselling for type-D patients should
be made. The reverse is true, in fact, since type-D patients are at high risk for
experiencing emotional distress, such as anxiety and depression; hence, they may
benefit more from counselling than non type-D patients although they are unlikely to
reach the same symptom levels as non type-D patients.
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Self-management and adequate consultation behaviour are essential for successful
treatment of chronic heart failure (CHF). Patients with a type-D personality,
characterised by high social inhibition and negative affectivity, may delay medical
consultation despite elevated symptom levels, and may be at an increased risk for
adverse clinical outcomes. We therefore examined whether type-D personality
predicts poor self-management and failure to consult for evident cardiac symptoms
in CHF.
Design/methods/patients
178 CHF outpatients (age580) completed the DS 14 (Type-D Scale) at baseline, and
the Health Complaints Scale (symptoms) and European Heart Failure Self-care
Behaviour Scale (self-management) at 2-month follow-up. Medical information was
obtained from the patients' medical records.
Resu/ts
At follow-up, type-D patients experienced more cardiac symptoms (OR=6.4;95%
Cl:2.5-16.3,p<.001) and more often appraised these symptoms as worrisome
(OR=2.9;95%Cl:1.3-6.6,p<.01) as compared to non type-D patients.
Paradoxically, fype-D patients were less likely to report these symptoms to their
cardiologist/nurse, as indicated by an increased risk for inadequate consultation
behaviour (OR=2.7;95%Cl:l.2-6.0,p<.05), adiusting for demographics, CHF
severity/aetiology, time since diagnosis and medication. Accordingly, of 61 CHF
patients that failed to consult for evident cardiac symptoms, 43% were type-D (26
patients).  Of the remaining CHF patients,  only  14%  (16  patients)  had  type-D
personality.
Conc/usion
In conclusion, CHF patients with a type-D personality display inadequate self-
management. Failure to consult for symptom elevation may partially explain the
adverse effect of type-D personality on cardiac prognosis.
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INTRODUCTION
Because of the ageing population and increasing rate of chronic medical diseases,
finding the best management for these conditions is an important goal in health care
Ill. Chronic heart failure (CHF) is a serious chronic condition that has been
associated with high mortality and hospitalisation rates, limited functional capacity,
impaired health status and escalating health costs, despite recent developments in
treatment options [2-51
Poor self-management, or self-care, is associated with an increased risk of
adverse clinical outcome in CHF [61. Self-management is the individual's ability to
manage the symptoms, treatment, and life style changes inherent in living with a
chronic condition, such as CHF [71; it is the process whereby individuals act on their
own behalf to promote health [81. One important aspect of self-management is
consultation behaviour, i.e., consulting a physician when experiencing cardiac
symptoms 191
Some patients with CHF may delay consulting medical services for relevant
symptoms. This patient delay, which refers fo fhe period between the onset of
symptoms and the moment of consultation [10], may contribute to adverse clinical
outcomes in CHF. The decision to seek help is influenced by the individual's
appraisal of the seriousness of the symptoms [11,121. However, symptom appraisal
is a necessary, but not sufficient condition for seeking help. Consultation behaviour is
also influenced by attitudes to help seeking behaviour [131, such as concerns about
the consequences of disclosing personal feelings and thoughts. For example,
myocardial infarction patients who did not talk with someone about their symptoms
had longer delays in help seeking [141 Hence, patients with CHF who are inhibited
in disclosing symptoms to their cardiologist or heart failure nurse may also be more
likely to delay medical consultation.
Type-D patients tend to inhibit self-expression in social interactions, as
indicated by a high score on social inhibition [15,161. Given their high level of
inhibition, type-Ds may be at risk for inadequate self-management in terms of poor
consultation behaviour. This failure to consult for cardiac symptoms is paradoxical
because, given their tendency to experience negative feelings and to worry [15,161,
type-Ds may experience concerns about their health status. Hence, the obiective of
this predictive study was fo examine the role of type-D personality in poor self-





Study population and procedure
The sample included 178 consecutive outpatients with CHF from the TweeSteden
teaching hospital in Tilburg, the Netherlands. Inclusion criteria were: (1 ) sysfolic heart
failure, (2) left ventricular election fraction (LVEF) 540%, and (3) pharmacologically
stable one month preceding inclusion. Patients (11 older than 80 years, (2) with a
history of diastolic heart failure, (3) incapable of understanding and reading Dutch,
(4) with cognitive impairments and life-threatening co-morbidities, or (5) diagnosed
psychiatric disease (except depression and anxiety) were excluded. Patients were
treated for CHF by a cardiologist and a specialised heart failure nurse according to
the most recent guidelines [31. The hospital's medical ethics committee approved the
study protocol, and the study was carried out according to the Helsinki Declaration.
All patients provided written informed consent.
The cardiologist or specialised heart failure nurse selected CHF patients for
inclusion in the study on the basis of the above-mentioned criteria. Patients were
informed about the study and asked to participate by their treating cardiologist. If
patients agreed to parlicipate, they were called the same week to make an
appointment for completing a set of psychological questionnaires. Participation was
voluntary. During the first visit, patients completed the Type-D Scale  (DS14)  [161.
During a second visit, two months later, the patients filled out the Health Complaints
Scale (HCS;symptoms) [171, and the European Heart Failure Self-care Behaviour
Scale (EHFScBS;self-management)  1181.  Patients who did  not return the question-
naires within two weeks received a reminder telephone call. The response rate in the
present study was 94%.
Self-management and consultation behaviour
The EHFScBS is a disease-specific measure of CHF patients' self-management
behaviour [181. The questionnaire consists of  12 items that are answered on a 5-
point Likert scale ranging from "1 completely agree" (1) to "1 don't agree at all" (5). A
high total score indicates less self-care behaviour. Cronbach's alpha for the total
scale is .81  1181.
Principal component analysis (PCA) with varimax rotation was used to
determine the structure of the EHFScBS at 2-month follow-up. Factors with an
eigenvalue >1 were retained according to Kaiser-Meyer-Olkin criterion (KMO).
KMO and Bartlett's test of sphericity were used as fit indices. PCA at 2-month follow-
up revealed a 4-factor solution (Table 1 ). KMO (0.75) and Bartlett's test of sphericity
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Table  i.    Facets of seff-management at 2-month follow-up
Rotated Factor Solution
Items of the EHFScBS" Factor I Factor 2 Factor 3 Factor 4
4.     lf my feet/legs become more swollen than usual, 1 contact my doctot or nurse. 0.87 0.04 0.09 0.04
3.      If my shortness of breath increases, 1 contact my doctor or nurse. 0.85 0.07 -0.03 -0.01
8.    If I experience increased fatigue, I contact iny doctor or nurse. 0.84 0.26 0.07 0.01
Z
5.     If 1 gain 2 kg iii 1 week, 1 contact my doctor or nurse. 0.73 0.15 0.19 -0.03                         0
Z
12.    I exercise regularly. 0,07 0.70 -0.28 -0.01                 00
9.     I eat a low salf diet. 0.15 0.63 0.21 O.10                  3
C
6.      Ilimit the amount of fluids I drink (not more than  1.5-2 1/day). 0.30 0.52 0.22 0.07                          5
24
2.     If I get short of breafh, 1 fake it easy. 0.19 -0.11 0.77 -0.13                                      0
Z
7.    1 foke rest during the day. 0.01 0.28 0.64 0.18                     Z
10.   / take my medication as prescribed. 0.11 0.02 0.30 0.66
6
1 1.   1 get a flu shot every year. -0.05 0.27 -0.09 0.65
18.    I weigh myself every day.                                                                                         0.05            0.42 0.23 -0.56                                                    Z
'1The European Heart Failure Self-core Behaviour Scale                                                                                                                              EN
 teni  1 could not be assigned to any of the factors because of ambiguous factor loodings                                                                                                     8
Factor loadings ore presented in bold face                                                                                                                                             -4I
n
M                                                                                                                                                                                                                                                                                                          I
\0 -77
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0(2(66, n-178)=483.5, p<.001) indicated that PCA was adequate for this data.
Only one specific facet of self-management was found, i.e., consultation behaviour
(e.g. "If my feet/legs become more swollen fhan usual, I contact my doctor or
nurse"). Cronbach's alpha for this factor was .86, and .46,.37,.28 for the three
other factors, respectively (Table 1 ). Therefore, we constructed a 4-item "consultation
behaviour" subscale as a specific component of self-management that should be
studied  in  its  own  right,  in addition to the EHFScBS total scale ITable 1, factor  1 ;
items 3,4,5,8). The mean score of the consultation behaviour subscale was 9.8
(SD=4.9), and the scores were normally distributed. A relative lack of consultation
behaviour was defined as a score above median split of this 4-item subscale.
Type-D personality
The DS 14 was used to assess type-D personality [161. The DS 14 consists of two 7-
item subscales, i.e., negative affectivity and social inhibition [161. The 14 items are
answered on a 5-point Likert scale ranging from "false" (0) to "true" (4). A
sfandardised cut-off of 210 on both subscales indicates those with a type-D
personality. Both subscales are internally consistent, with a Cronbach's alpha of .88
for the negative affectivity subscale and of .86 for the social inhibition subscale, and
have good test-retest reliability with  r=.72  and  .82,  respectively  [161.  In the present
study, 24% (42/178) of fhe patients were classified as type-D.
Cardiac symptoms
The HCS contains  a  1 2 item self-report subscale of cardiac  symptoms  that  are
frequently experienced by patients with established hearf disease 11 71 These include
cardiopulmonary symptoms (5 items; e.g. "shortness of breath"), fatigue (4 items;
e.g. "feelings of exhaustion"), and sleep problems (3 items; e.g. "disturbed sleepl·
The HCS contains also a 6-item subscale representing health worry {e.g. "worrying
about health", "the idea that you have a serious illness"). Patients indicate how
much they suffer from a particular symptom on a 4-point Likert scale ranging from
"not af all" (0) to "extremely"(4). All scales have a high internal consistency with
Cronbach's alpha 2.89 and test-retest reliability rk.69 [171
Clinical variables
Clinical variables included LVEF, New York Heart Association (NYHA) functional
class, aetiology of CHF, medication, and time since diagnosis of CHF. Information
on clinical variables was obtained from the patients' medical records and from the
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treating cardiologist. Socio-demographic information included sex, age, marital
status, and educational level.
Statistica/ Ana/yses
Prior to statistical analyses, NYHA class, aetiology of heart failure, educational level
and marital status were dichotomised according fo: NYHA class 111/IV versus NYHA
class 1/11, ischemic versus non-ischemic aetiology, low versus high educational level,
and partner versus no partner, respectively. The EHFScBS, the consultation behaviour
subscale, and the HCS were recoded info dichotomous variables using a median
split, reflecting respectively good versus poor self-management, good versus poor
consultation behaviour, and cardiac versus no cardiac complaints. For comparison
between two groups, we used the chi-square test for discrete variables and the t test
for independent samples for continuous variables.
Logistic regression analyses were used to determine whether type-D was an
independent predictor of respectively cardiac symptoms, health worry, self-
management, and consultation behaviour, adiusting for gender, age, marital status,




Patient characteristics stratified by type-D personality are presented in Table 2. There
were significant differences between type-D and non type-D patients only with respect
to medication, i.e., diuretics 0(2(1, n=178)=5.8, p<.05) and calcium antagonists
C)(2(1, n=178)= 3.2, p<.01) were more often prescribed to type-D patients.
Type-D and cardiac symptoms
Type-D personality was an independent predictor of cardiac symptoms at two months
COR=6.4;95%Cl:2.5-16.3, p<.001), adiusting for socio-demographic variables,
LVEF, NYHA class, ischemic aetiology, time since diagnosis, use of diuretics and use
of calcium antagonists. Apart from type-D personality, younger age (OR=0.9;95%
Cl:0.9-1.0, p<.01), lower educational level COR=3.0.95%Cl:l.1-8.5, p<.05), and
NYHA class 111/IV (OR=2.2;95%Cl:1.1-4.5, p<.05) also independently predicted
cardiac symptoms at two months.
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Table 2.   Baseline characterisfics stratified by fype-D personal ty
Total Type-D Non type-D    p
Sample frI=42) (n - 1 36)
Age, mean (SDJ 66.6 (8,4) 68.2 (7.8) 66.1 (8.6) .16
Male sex, n (%) 140 (79) 33 (79) 107 (79) .98
Lower educational level. n (96) 154 (871 39 (93) 1 15 (853 .17
Having no partner, n (06) 43 (24) 12 (29) 3 1  (23 J .45
LVEP %, mean (SD) 29.9 (671 28.9 (66) 30.2 (6.7) .32
NYHA' class ill and 1V, n (96) 96 (54) 28 (671 68 (50) 06
Ischemic aetiology, n (96) 100 (56) 24 (57) 76 (56) 86
Time since diagnosis, mean (SD; 3.9 (4.1) 3.4  (4.1 1 4.0 (4.11 .34
ACE-inhibitor users, n (963 142 (80) 33 (791 109 (80) .82
All-antagonist users, n (%) 30 (17) 8(19) 22 (16) .66
Diuretic users, n (%) 142 (80) 39 (93) 103 (76) .02'
Digitalis users, n (%) 56 (32) 15 (36) 41 (303 .50
Beta-bfocker users, n (°:) 116 (65) 31 (741 85 (63) .18
Long-acting nitrate users, n (98)        44 (25) 14 (33) 30 (22) .14
Short-acting nitrate users, n (%) 17(10) 7 07) 10(7) .07
Calcium antagonist users, n (96)        16 (9) 8 (19) 8 (6) .01.
Anhcoagulant users, n (96) 77 (431 17(41} 60 (44) .68
Aspirin users, n Bo) 80 (45) 19 (45) 61 (453 .97
Statine users, n (86) 84 (47} 20 (48) 64 (47) 95
'LVEF=Leff  ventricubi election  fraction
E·NYHA--New York Heart Association functional class
*p<.05
Type-D patients  had  a mean score  of  17.2  (SD  9.7)  on the cardiac
symptoms scale of the HCS compared to 9.6 (SD 8.7) for non type-D patients
(p<.001). Type-Ds scored also significantly higher on cardiopulmonary symptoms
(p=.002), fatigue (p<.001), sleep problems (p<.001), and health worry (p=.001)
as compared fo non type-Ds. Finally, type-D personality was an independent
predictor of health worry adiusting for all other variables at follow-up. Type-D
patients were at a 3-fold increased risk to worry about their cardiac symptoms
COR=2.9;95%CI: 1.3-6.6, p<.01) compared fo non type-D patients.
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Type-D, self-management and consultation behaviour
When the total score of the EHFScBS was used as an outcome measure, socio-
demographics, severity of CHF, and type-D personality were not significantly related
to overall self-management at 2-month follow-up. Male sex (OR=2.0;95%Cl:0.9-
4.5, p=.07) and lower educational level (OR=2.4;95%Cl:0.9-6.8, p=.07) had a
near significant effect.
However, type-D was an independent predictor of displaying little
consultation behaviour at follow-up when adjusting for all other variables, including
LVEF and NYHA class (OR=2.7:95%Cl:1.2-6.0, p<.05) (Table 3). In contrast to
their high levels of cardiac symptoms and health worry, type-D patients were at a
more than 2-fold increased risk of failing to consult for these symptoms compared
with non type-D patients (Table 3). There was also a tendency for patients without
partner to be low in consultation behaviour (p=.06).
Table 3.   Predictors  of  displaying  little consultation behaviour af 2-month follow-up
Cmultivariable anaiysts)
Odds rotio 95%0                p
Male sex 1.34 0.61 - 2.95 .47
Age 0.99 0.9 5 - 1.0 3 .60
Having no poffner 2.10 0.96 --4.59 .06
Lower educational level 2.05 0.81-5.20 .13
NYHA* cbss lil and IV 0.74 0.39 - 1.44 38
LVEFB 1.00 0.95 - 1.05 85
Ischemic aetiology 0.91 0.47-1.77 .79
Time since diagnosis 1.08 0.99 - 1.17 07
Diurefics users 0.80 0.36-1.76 .59
Calcium antagonist users 0.77 0.24 - 2.44 .66
Type-D 2.67 1.19-6.00 .02*
 ''New York Heart Association functional class
BLeff ventricular ejection fraction
'P<.05
Subgroups at risk for inadequate consulting
CHF patients, who experienced clinically evident cardiac symptoms but were less
likely to consult for these symptoms, were considered to be at risk for inadequate
consulting as a clear indicator of poor self-management. In post-hoc analysis,
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patients who reported cardiac symptoms but displayed poor consultation behaviour
were compared to all other patients. Multivariable logistic regression analysis
revealed that fype-D personality was an independent predictor of reporting cardiac
symptoms while failing to consult (OR=5.1.95%Cl:2.3-11.6,p<.001). Hence, of 61
CHF patients that failed fo consult for evident cardiac symptoms, 43% were type-D
(26 patients).  Of the remaining CHF patients, only  14% (16 patients) had a type-D
personality (Figure   1 ) Additionally, there   was a significant effect for lower
educational level (OR=4.2;95%Cl: 1.1-16.0,p<.05)
50 p < 0.00132 
8                                                               26/61
340           10
a
  30                                   8/29
20
10                     8/88
0
Sympit-j Sympll--1/Consult! · i Sympt<-r)/Consultl-}
Figure  1.   Percentage of CHF patients with ci type-D personality, stratified by cardiac symptoms
and consuhation behaviour
Synipt(- 1: Dercentage of type-D palienfs without relevant cardiac sy,Tiptoms.
Synip,( ·· : ·Consulf·f - :·  percentage  of type-D  pafients  with  relevant  cardiac  symptonis  who
succeed to consult.
Symot( _ 3 'Consult'-i:  percentage of type-D patients with  relevant cardiac symptoms who foil to
consu/t
DISCUSSION
To our knowledge, this is the first prospective study to investigate the role of
personality, and type-D personality in particular, as a determinant of self-
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management behaviour in patients with CHF. The present findings indicated that
type-D patients experienced more cardiac symptoms at follow-up as compared to
non type-D patients. Type-Ds also reported high levels of health worry, indicating
that they appraise these symptoms as serious. Paradoxically however, type-D patients
were less likely to contact their doctor or nurse. Hence, type-D patients are at risk for
failing to report their elevation of CHF symptoms to health care professionals, in
spite of the fact that they appraise them as worrisome.
Previous studies have shown the adverse effect of type-D personality on
prognosis in patients surviving myocardial infarction [15,19], in patients with
decreased LVEF 1201, and patients that were treated with percutaneous coronary
intervention [211. Although there is preliminary evidence that immune-activation [22]
or dysfunctional stress-reactivity [231 may comprise links between type-D personality
and cardiac events, the underlying mechanisms responsible for the association
between type-D and cardiac prognosis are largely unknown. The results of the
current study indicate another possible, behavioural, link between type-D personality
and prognosis, namely inadequate consultation behaviour.
Type-D patients do not have psychopathology per se, but are characterised
as being high on both social inhibition and negative affectivity [15,161 Social
inhibited individuals often report fo be socially isolated or to lack a close confidanf.
Social isolation has been associated with adverse outcome in patients with heart
disease, and this association cannot be explained by factors such as disease severity,
demographic variables and distress [24,251 Social inhibition may result in non-
adherence to treatment. Dickens and colleagues found that coronary patients without
a close confidant were more likely to have further cardiac events, and speculated
that these patients may be less likely to seek treatment for heart disease, thereby
increasing the risk of adverse clinical outcome [261. One aspect of social inhibition is
feeling insecure and less competent when communicating with others [15,161 Those
socially inhibited patients may fear re ection or a negative reaction from their doctor
and may for this reason not go to see a doctor when it is necessary. Furthermore, as
Pereira and colleagues stated, there may be a mediating role for passive coping
strategies, such as denial, in the relationship between inhibition and poor adherence
to  treatment [27]. Therefore, type-D patients  may  have a somewhat more passive
and avoidant coping style while dealing with upcoming problems.
Apart from inhibition, negative mood states are related to poor prognosis
as well as unhealthy behaviours [28-321. In a recent study by van der Wai and
colleagues for instance, it was found that compliance in CHF was negatively related
to depressive symptoms [321. The results of our study indicate that type-D personality
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is a risk factor for the delay fo consult a doctor or nurse, despite clinically evident
symptoms of CHF and associated high levels of health worry.
This study has a number of limitations. First, there may be a bias in the
selection of patients. The cardiologist or heart failure nurse asked patients for
participation in the study. So the interaction pattern may influence the selection.
Second, the follow-up period is relatively short. It would be interesting to look at the
impact of type-D personality on long-term self-management behaviour and to
investigate whether self-management, and consultation behaviour in particular,
comprises a mechanism linking type-D to adverse prognosis. Third, data on self-
management were obtained by means of a self-report questionnaire, and self-report
may be prone to socially desirable behaviour. However, as Jaarsma and colleagues
indicate, the EHFScBS is a valid and reliable scale to measure the self-management
behaviours of CHF patients Il 81.  Furthermore, strength of the current study is that it
is the first to examine the role of personality in consultation behaviour, an aspect of
self-management, in CHF patients in a prospective design.
In conclusion, the results of the current study show that CHF patients with a
type-D personality are less likely to seek medical assistance in the case of elevated
cardiac symptoms in contrast to non type-Ds. Paradoxically, type-Ds do experience
more cardiac symptoms and worry more about these symptoms. Because of the still
increasing health-care costs associated with chronic illness [331, it is important to
identify determinants of high hospital and mortality rates in several patient groups.
Improved self-management may help to reduce hospitalisation among patients with
CHF !341. Further research on the role of personality factors in self-management
behaviour, health care utilisation and prognosis is warranted. Finally, as Jones
mentions, self-management is an essential component of the management of
chronic illness and the quality of self-care is important for the quality of life of
patients [351. This means that it is important to know which CHF patients need more
intensive interventions, such as more education, to improve self-management
abilities. The findings of the present study suggest that type-D patients may be in
need of such a behavioural intervention program.
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Interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a) and soluble TNF-a receptors 1
(sTNFRl) and 2 (sTNFR2) are powerful predictors of mortality in chronic heart failure
(CHF). However, little is known about (i) the origins of pro-inflammatory cytokine
production and (ii) the determinants of substantia| interpatient variability in immune
activation. We prospectively examined type-D personality Ctendency to experience
and inhibit emotional distress) and chronic kidney disease (CKD) as predictors of
cyfokine production in patients with CHF.
Methods
At baseline, 125 CHF patients were assessed for type-D personality. At 1 -year follow-
up,  we measured serum levels  of  IL-6, TNF-a, sTNFRl, sTNFR2,  and  the  anti-
inflammafory cytokines interleukin-10 (IL-10) and interleukin-1 receptor antagonist
(IL-lra).
Results
At 1-year follow-up, type-D patients had significantly elevated levels of sTNFRl
0-0.009) and sTNFR2 (p=0.001), and decreased levels of IL-10 (p=0.006) as
compared to patients without type-D or CKD. Patients with CKD also had elevated
levels of sTNFRl and sTNFR2 (p<0.0001), but their level of IL-10 was not
decreased. Type-D personality and CKD predicted increased sTNFRl/IL-10 and
sTNFR2/IL-10 ratios (all pssO.007); type-D also predicted an increased IL-6/IL-10
ratio (p=0.013). Spironolactone and older age were also associated with elevated
pro-/anti-inflammatory cyfokine ratios. Adiusting for these variables, the odds to
have elevated ratios Chighest 20%) was still increased in type-D patients COR=3.92,
19.88 and 3.12, respectively).
Conclusion
Type-D personality and CKD independently predict unfavourable cytokine profiles,
and play a role in the interpatient variability in immune activation among patients
with CHF.
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INTRODUCTION
Chronic heart failure (CHF) is a multi-system disorder that carries a high mortality risk
and affects the renal, neuroendocrine and immune systems [1-4]. Tumor necrosis
factor-a (TNF-a) and inferleukin-6 (IL-6) are pro-inflammatory cytokines involved in
CHF progression [3-8}, and are major prognostic indicators of atherosclerosis [9],
worsening of CHF 110,111, and CHF-related mortality [7,121 Plasma levels of the
soluble TNF-a receptors  1  (sTNFRl) and 2 (sTNFR2) reflect exposure fo TNF-a over
longer periods of time, and consistently have emerged as important predictors of
mortality in patients with CHF [5-81. Clinical implications of these findings may be
enhanced by progress in understanding (i) the balance between pro- and anti-
inflammatory cytokines, and (ii) the origins of cyfokine production in CHF. Anti-
inflammatory cytokines such as interleukin-10 (IL-10) and interleukin-1 receptor
antagonist  (IL-1 ra) dampen the effect  of  TNF-a,  IL-6  and  other  inflammatory
responses  in the cardiovascular system 113,141, but their role in  CHF  is not clear [31
Little is also known about the determinants of substantial inter-patient variability in
immune activation in CHF.
Patients with chronic kidney disease (CKD) are often excluded from
cardiovascular research 1151 However,  CKD is related to higher IL-6 and TNF-a
levels [16-191 and poor clinical outcomes in CHF [20-231, and should therefore be
considered in subgroup analyses of inflammation in CHF. Psychological factors may
also contribute to poorer CHF outcomes 12,241 and inter-patient variability in
inflammation [251, although their relationship with TNF-a and IL-6 levels is unclear
[26-291 Preliminary findings suggest that psychological distress may be related to
high levels of TNF-a, sTNFRl and sTNFR2 in CHF [30-331, and the few studies
reporting on IL-10 suggest that psychological distress is also associated with IL-10
levels [32,34}. Given their cross-sectional study design and small sample sizes
(ranging from 18 to 42 patients [30,32-341, mean n=32), the implications of these
reports are uncertain.
A recent study showed that IL-6, TNF-a, sTNFRl/sTNFR2, IL-10 and IL-lra
were all related to increased risk of death and CHF following myocardial infarction
[51. We therefore prospectively examined whether type-D personality and CKD would
predict serum levels of these pro- and anti-inflammatory cyfokines at 1 -year follow-




Study population and procedure
The sample comprised 165 consecutive CHF outpatients  (75% male;  mean  age
65.7.+8.9 years) from the TweeSfeden teaching hospital in Tilburg, the Netherlands.
Patients with a left ventricular eiection fraction (LVEF) 540%, 580 years, and
pharmacologically stable one month preceding inclusion, were included in the study
between October 2003 and January 2005. Patients with diastolic CHF, inadequate
proficiency of the Dutch language, cognitive impairments, life-threatening co
morbidities (such as cancer), clinical signs of acute infections, or use of anti-
inflammatory medication were excluded. Of 206 patients, 165 (80%) agreed to
participate. Final analyses are based on 125 patients (Figure  1 ), since patients were
lost to follow-up, had missing blood data or constituted outliers, i.e., one sTNFR2
and two IL-6 outliers (defined as >3 standard deviations (SD) of the mean).
Number of patients
n=165included at baseline
11 = 6 Died during 1 -year follow-up
n-  13        Refused participation at 1 -year
n= 15 Missing blood data
n -· 3 sTNFR2 and IL-6 outliers
n=3 Excluded patients-
Included patients n=125
Figure 1. Flow chart of patients included in the study
AThese patients were excluded due to niedical le.g. cerebrovascular accident during the study)
or logistic reasons (e.g. moving abroad)
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All patients were treated following the most recent guidelines for the
treatment of CHF [35,361, and were informed about the study by a cardiologist or a
specialised heart failure nurse. All patients provided written informed consent and
participation was voluntary. The hospital's medical ethics committee approved the
study protocol, and the study was carried out according to the Helsinki Declaration.
The study design was prospective. Patients completed a psychological questionnaire
assessing type-D and socio-demographic information at baseline. Blood samples
were collected at baseline and one year. Patients were asked to comp|ete the
questionnaire at home and return it in a self-addressed envelope. All questionnaires
were checked for completeness. Patients who had left open several questions were
called to obtain the answers or they were mailed a copy of the items and asked to
complete them after all. In case the questionnaires were not returned within two
weeks, patients received a reminder telephone call or letter.
Assessment of type-D personality
All patients completed the Type-D Scale (D514) at baseline [371. This scale consists
of  14  items  that are divided  into two subscales measuring negative affectivity
Ctendency to experience negative emotions) and social inhibition (tendency to inhibit
self-expression in social interaction). The two subscales have good psychometric
qualities, with Cronbach's a= .88/.86 and 3-month test-retest reliability r=.72/.82
for the negative affectivity and social inhibition subscale, respectively. According to
previously published findings, a standardised cut-off 210 on both subscales
indicates type-D caseness [371
Diagnosis of CKD
According to the 1</DOQI guidelines 1381, the MDRD formula was used to determine
glomerular filtration rate (GFR). CKD was defined as either kidney damage or having
a decreased kidney function, as assessed by a GFR of <60 ml/min per 1.73m2 at
baseline.
Pro-/anti-inf/ammatory cytokines at fol/ow-up
Blood was allowed to clot at room temperature and centrifuged. Serum samples
were stored at -80°C in anticipation of further processing. TNF-a (sensitivity: 0.75
pg/mi), sTNFRl and sTNFR2 (sensitivity: 0.08 ng/mi), IL-6 (sensitivity: 0.82 pg/mI),
IL-10 (sensitivity: 2.30 pg/mi) and Ill ra (sensitivity: 0.0794 ng/mi) were measured
using quantitative enzyme-linked immunosorbent assay (ELISA). ELISA-kits were
purchased from DiaMed Eurogen (Turnhout, Belgium). All tests were measured in
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accordance with the manufacturer's recommendations. The sensitivity of all tests was
calculated by the mean of six zero-values + three SDs extrapolated on the standard
curve. Values below sensitivity (detection level) were raised to sensitivity value. The
intra-assay variation was less than 10%, and the inter-assay variation less than 11%.
C/inica/ covariates
Demographic variables included sex and age. Smoking status was assessed by
means of self-report. Information on clinical variables at baseline and follow-up,
including LVEF, NYHA class, aefiology of CHF (ischemic/non-ischemic), risk factors
(body mass index, hypertension, diabetes and hyperlipidemia), and medication (beta-
blockers, aspirin, spironolactone, diuretics, ACE-inhibitors, statins, digoxin) were
obtained from the patients' medical records or the treating cardiologist
Statistical analyses
Linear regression analyses, adiusting for sex and age, were used to analyse
differences in mean continuous measures of pro- and anti-inflammatory cytokines at
1-year follow-up in  (i)  type-D  patients  and (ii) patients with co morbid CKD, as
compared to reference group of patients without type-D or CKD. Fourteen type-D
patients also had CKD; these patients were included in both the type-D and CKD
groups. Pearsonts correlations and principal components analysis (varimax rotation)
were used to examine the relationships among pro- and anti-inflammatory markers.
In order to estimate the influence of type-D and CKD on the balance between pro-
and anti-inflammatory activity, three ratios of pro versus anti-inflammatory cytokine
levels (sTNFRl/IL-10, sTNFR2/IL-10, and IL-6/IL-10) were calculated. Logistic
regression analysis was used to estimate the risk for an elevated pro-/anti-
inflammatory cytokine ratio (defined by the 20% of CHF patients with the highest
ratios) in type-D patients, after adiustment for relevant clinical covariates. All tests
were two-failed, and all analyses were performed using SPSS 12.0 for Windows.
RESULTS
Base/ine characteristics of iype-D and CKD patients
Af baseline, type-D CHF patients did not differ from non type-D patients on clinical
or demographic characteristics, except for NYHA class and diuretics, with type-D
patients more likely to be classified in NYHA-111/IV (Table  1 ) However, type-D and
non type-D patients did not differ in mean LVEF (p=.46) or ratio of LVEF<25%
(p=.45). As expected, CKD patients  were more likely  to be treated  with  diuretics
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(p=.02) and were somewhat older (p=.05), but did not differ from non-CKD
patients on any other baseline characteristic.
fable 1.    Baseline characteristics strotified by type-D and chronic kidney disease
Type-D-/CKD- Type-D- p value CKD r p value
C„ =52) (n = 32) (n = 55)
Demographics
Mole sex 79% (41 J 796 (241 0.68 69% (38) 0.25
Age 270 yrs 29% 1'15) 41 9„< 13,) 0.27 47"b (26) 0.05
CHF characteristics
fschemic oetiology 5098 (26) 50% 1 161 1.00 64% (35) 015
History of MI 42% (22) 50% C 16) 0,49 539, (29) 0.28
LVEF (%.M /SDJ 30 : 7",0 29 t 7% 0.46 31    698       081
LVEF < 25% 33% (17) 25% (8) 0.45 24% (13) 0.30
NYHA class 111/IV 47/0 (221' 72% (23) 0.008 58% (32) 010
Risk Factors
BMI 230 23% (12) 310 041 248·,(13) 0.95I  C 10)
Smoking 25% (13) 19% (6) 0.51 18°4 (10) 039
Hypertension 37% (19; 31% (10) 0.62 36% (20) 0.98
Hyperlipidemia 520'                                            :0 (29) 0.93m (271 53% (17) 0.92         53°'
Diabetes 19% C 103 28% (93 0.34 27% (153 0.33
Medication
Beta-blocker 629 (32) 72° (23) 0.33 7  lai (39) 03 1
Aspirin 46°· (241 504 (161 0.73 380„(21) 0.40
Spironokclone              17°0 (9)               1 9% (6) 0.87 26%  C 14 3 0.31
Diurefics 67% (35) 91% (29) 0.02 86% (473 0.02
ACE-inhibitor 77't'o (40) 78% (2% 0.90 78% (43) 0.88
Stafins 48% (253 47% (15) 0.92 490„ (27) 0.92
Digoxin 31% (16) 38% C  21 0.53 33% (181 0.83
Type-D-/CKD-:patients with a non type-D personahly and no chronic kidney disease;Type-
D -:patients   with   a   type-D   personalify;CKD+:patients   with   chronic kidney disease.   All
myocardioi inforction, LVEF:leff ventricular ejection fraction, NYHA:New York Head Associnfien,
BMI: body mass index.
Cytokine levels at 1 -year follow-up
At  1 -year follow-up, type-D patients  had  significantly elevated levels of sTNFRl
(p=.009) and sTNFR2 (p=.001), and decreased levels of IL-10 (p=.006) as
compared to the reference group of patients without type-D or CKD (Table 2). CKD
patients had elevated levels of sTNFRl (p=.0001) and sTNFR2 (p=.0001), but they
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did not have decreased levels of IL-10 (p=.31) as compared to the reference group.
There were no statistical differences with reference to TNF-a,  IL-6 and Ill ra as a
function of personality or CKD.
Table 2.     Pro- and anti-inflammatory cyfokine levels at  1 -year follow-up
Type-D-/CKD- Type-D+ CKD +
(n =52) fn= 323 (n=55)
Mean +SD Mean+SD p-value MeoniSD p-value
Pro-Inflommotory
sTNFRl (pg/mi) 3598 11495 4988 +2627 .009 5159 +2271 .0001
sTNFR2 (pg/mi) 2064 + 972 3356 2 1849 .001 3234 11871 .0001
TNF-a (pg/mI) 6.22 -4.73 6.72 14.37 62 7.35 +4.52 .21
IL-6 (pg/mlf 2.02 1 1.82 2.59 i 2.05 .20 2.20   1: 1.70 .62
Anti-Infiammotory
IL- 10 (pg/mi) 4.02 13.06 2.72  2 1.00 .006 3.47 z2.38 31
IL-l ra tpg/mt) 289 i 232 220 +175 .12 328 +312 .46
Type-D-/CKD-  pohents  with  a non fype-D personality  and no chronic kidney  disease;Type-D + :
patients with a fype-D personality, CKD+:patients with chronic kidney disease.
Relationships among cytokine markers
sTNFRl and sTNFR2 correlated positively with TNF-a and IL-6, and the correlation
among TNF-a receptors was r=.61 (Table 3, left). These markers shared 5%-37% of
variance, indicating  that  they were related,  but  not  identical. IL-lra correlated
positively both with TNF-a and IL-10. IL-10 was unrelated to any of the other
cytokine measures.  Ill ra and  Ill 0 shared  only a small  part of the variance  (696).
Principal components analysis confirmed that sTNFRl, sTNFR2 and IL-6 reflect the
dimension of pro-inflammatory activity (Table 3, right), as indicated by factor
loadings between  .63  and  .87.  IL-10,  and  IL-1 ra reflected the anti-inflammatory
dimension, with factor loadings of respectively .80 and .70. TNF-a had similar
loadings on both factors and was not a pure marker of one domain.
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Table 3.    Relationship among pro-  and anti-inflammatory cytokine markers of  1-year follow-up
in patient  with CHF (n - 1253
Correlations Factors
sTNFRi sTNFR2 IL-6 TNF-a IL- 10 Factor 1 Factor 2
sTNFR 1 - .87 -.07
sTNFR2 .61* .78 .14
IL-6 .37* .27* - .63 .11
TNF-a .28' .22- .27* - .44 .46
IL- 1 0 -.08 .06 .04 .1 4                 - - .1 7 .80
IL-l ra .14 .29* .15 .27- .24* .25 .70
Cytokine  levels  with  a  factor loading  >.60 ore presented in  boldface.
*P<.05.
Pro-/anti-inflammatory cytokine ratios
The results from the factor analysis were used to compose three ratios of pro- versus
anti-inflammatory activity (sTNFRl /IL-10, sTNFR2/IL-10 and IL-6/IL-10)  to  estimate
the influence of type-D and CKD on the balance in pro-/anti-inflammatory adivily
(Table 4). CKD was associated with increased sTNFRl/IL-10 (p=0.004) and
sTNFR2/IL-10 (p=0.007) ratios, but not with IL-6/IL-10 ratio (p=0.39). Type-D
personality predicted increased sTNFRl/IL-10 (p=0.003), sTNFR2/IL-10
(p=0.0001) as well as IL-6/IL-10 (p=0.013) ratios at 1 -year follow-up, adiusfing for
clinical variables (Table 4). Spironolactone was independently associated with the
sTNFRl /IL-10 ratio, and beta-blockers with the sTNFR2/IL-10 ratio.
Type-D, CKD and cytokine imbalance
Next, the highest 20% of proportions of CHF patients with an elevated pro-/anti-
inflammatory cytokine ratio, stratified by type-D personality or CKD, were contrasted
with a "low risk" reference group, consisting of all other non type-D, non-CKD
patients. Type-D personality predicted a significantly increased risk of elevated
sTNFRl/IL-10 (p=0.04), sTNFR2/IL-10 (p=0.001), and IL-6/IL-10 ratios (p=0.05),
adiusting for clinical and demographic variables (Figure 2). CKD also predicted
elevated sTNFRl/IL-10 (p=0.012) and sTNFR2/IL-10 (p-0.002) ratios, but not IL-
6/IL-10  ratios  (p= 0.16).
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Table 4.    Multivariable prediction models of pro-/anti-inflammatory cyfokine ratios
Cytokine Ratio Mulfivoriable Analyses
Mean = SD ing/mIj Variables p.value
INFR 1  IL  10
Reference group-            1224  - 708
CKD 1850 · 987 CKD .004
Type-D 1971 1132 Type-D .003
Mole sex 42









Reference group'         674 - 389
CKD 1127 -725 CKD .007
INe-D 1330 = 794 Type-D .0001
Mate sex 98
Age 270, 08






Spironoloctone                    13
s,TNFR2 'el· 10
Reference group'         0 64   ·_0.64
CKD 078 -067 CKD 39
Type-D 1 04  + 0.88 Type-D .013
Alole sex .46






Aspilin                       1 1
Sp,ronolactone 83
*Reference group consists of patients without Type-D and without CKD.
CKD:  chronic  kidney disease. Type-D:  type-D personalify;LVEF:  left ventricular election  h·action,
N¥HA:New York Head Association,BAll:body mass index.
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Figure 2.  Percentage  of patients with an elevated pro-/anti-inflammatory cytokine ratio,
stratified by type-D personality and CKD
CKD: chronic kidney disease.
Low risk refers to the reference group of patietits without fype-D and without CKD.




In a final multivariate prediction model, including older age, spironolactone
and beta-blockers, type-D personality was associated with a more than three-fold
increased risk of elevated sTNFRl/IL-10 (OR=3.92) and IL-6/IL-10 (OR=3.12)
ratios at follow-up (Table 5, top) Type-D personality independently predicted an
even greater increased risk of elevated sTNFR2/IL-10 ratios (OR=18.88). CKD was
significantly associated with elevated sTNFRl/IL-10 (OR=4.23) and sTNFR2/IL-10
(OR=7.75) ratios (Table 5, bottom) Older age, spironolactone and beta-blockers
were also related to elevated sTNFRl /IL-10 and sTNFR2/IL-10 ratios (Table 5).
Table 5. Type-D personality (A) and chronic kidney disease (8) as predictors of a pro-/anti-
inflammatory cytokine imbalance
Elevated Ratio (M Type-D personolify Odds Ratio i95'A,Cll p-value
(Highest 20%)
sTNFR 1 /IL- 10 Type-D 3.92/1.11-13.871 .034
Age 270 y 0.65 10.17-2.541 54
Spironolactone 5.68 (1.45-22.341 .013
Bela-blocker 0.37/0.10-1.361 .13
sINFR2//L- 1 0 Type-D 18.88£3.61-98.851 .001
Age 270 y 7.94 11.79-35.271 .006
Spirono/actone 2.77 10.53-14.421 23
Beta-bloc:ker 0.19 IO.04-0891 .036
IL-6/IL-10 Type-D 3.12 Il.03-9.391 .044
Age 270y 2.22 IO. 73-6 783                     16
Sptionolactone 1.44 (0.37-5.591 .59
Beta-blocker 1.13 lO.34-3.811 .84
Elevated Ratio (B) Chronic kidney Odds Ratio /9596Cll p-value
CHighest 20%) disease
sTNFR 1 /IL-10 CKD 4.23 fl.44-12.451 .009
Age 270 y 0 70 CO.26-1.941 .49
Spironolactore 2.24 10.76-6.581 .14
Beta-biocker 0.48 CO. 17-1.311 .15
sTNFR2/IL- 10 CKD 7.75 205-29.30j .003
Age 270 y 4.0 4  /1 39-11.781 .01
Spironoloctone 0.94 10.27-3.321 .93
Beta-biocker 0.73 10.24-2.261 .60
IL-6/IL· 10 CKD 1.79 CO.63-5.061 .28
Age 270 y 2 09 CO. 77-5.733 15
Spironolactone 0.84 IO.24-2.891 .78
Beta-blocker 0.90 p.31 2.571 84
Type-D: type-D personality; CKD: chronic kidney disease.
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DISCUSSION
The present study is the first to examine prospectively the relationship between type-D
personality and cytokine levels in CHF. In addition, the present study reports novel
resu|fs on the predictive qualities of CKD in the determination of cytokine levels. Both
type-D personality and CKD were associated with pro- and anti-inflammatory
cytokine imbalance after  1-year  follow-up   in  CHF patients. Moreover, type-D
personality and CKD were found to be equally significant, independent predictors of
cytokine imbalance after adiustment for maior confounding baseline clinical
characteristics, such as LVEF.
There is increasing evidence that cytokines (and thereby immune activation)
play an important role in the pathogenesis of heart failure 14,39,401. In response to
cardiac stress, due to e.g. left ventricular pressure or volume overload, cells within
the myocardium synthesise and release TNF-a. TNF receptors 1 and 2 are present
on the cell surfaces of human myocardial cells. The release of TNF-a triggers these
surface receptors to release their extra cellular domain into the circulation, which
then become the soluble receptors sTNFRl and sTNFR2. These bind fo circulating
TNF-a, serving as a "slow-release reservoir". Other pro-inflammatory cyfokines, such
as IL-1 and IL-6, also play a role in the progression of CHF [6,401, and predict
mortality in CHF patients. sTNFRl and sTNFR2 have shown to be strong, long-term
predictors of death and heart failure in cardiac patients [5-8}.  Univariate results of
the present study showed that levels of both soluble TNF-a receptors, but not of
TNF-a, differed significantly between CHF patients with and without type-D per-
sonality, and between CHF patients with and without CKD. Because the soluble TNF
receptors are shed in response to TNF-a release, increased levels of these receptors
in CHF patients with a type-D personality may represent increased activation of TNF-
a at a local level. Concurrently, serum TNF-a levels were equivalent in type-D and
non type-D patients, potentially reflecting the down-regulation of TNF-a activity by
the increased levels of soluble TNF receptors in type-D CHF patients.
IL-10 is an immunomodulator that down-regulates the production of TNF-a
[41], IL-1 [41], and IL-6 [421, and enhances the shedding of soluble TNF receptors
[431. The current results show that IL-10 is decreased in type-D CHF patients and
unchanged in CHF patients with CKD. Combined, this reflects an imbalance in the
cyfokine profile, i.e., too much pro-inflammatory cytokines (reflected by increased
sTNFRl, sTNFR2  and IL-6 levels) as compared  to the levels of anti-inflammatory
cyfokines (that either were decreased or invariant (i.e., IL-10, Ill ra)) at 1 -year follow-
up. These results indicate the plausibility that the observed cytokine imbalance may
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explain the link between type-D personality or CKD on the one hand, and cardiac
morbidity and mortality on the other hand.
In two previous cross-sectional studies was found that type-D personality
was associated with increased circulating levels of TNF-a and TNF-a receptors
[30,311. The findings of the current study build on these and other previous findings
that emotional distress such as psychological stress [441 and vital exhaustion [281 is
associated with increments in cytokine levels in both cardiac patients and healthy
volunteers. For depression however, results have been inconsistent. Although there
are multiple studies testifying to a significant relationship between depression and
cytokine levels in cardiac patients 125,32-34,451, other studies did not [29,46,471. In
a study of 37 cardiac patients for example, no association was found between IL-1 B
levels and depressive symptom severity or depression diagnosis [461. In addition,
depression was not related to IL-6 in patients two months after hospitalisation for an
acute coronary syndrome [291. In a cross-sectional study of women with coronary
heart disease, depressive symptoms did not correlate significantly with IL-6 or Ill ra
[471
Recent evidence suggests that hypothalamus-pituitary-adrenal (HPA)
dysfunction and associated increased cortisol levels may contribute to the pro-
inflammatory state of cardiac patients with a type-D personality [481. Although
cortisol is universally considered to have anti-inflammatory effects, it actually may
have anti-inflammatory as well as rather unexpected pro-inflammatory properties that
can co-exist at the same time [49]. Prior exposure to stress or cortisol may have a
priming effect on the subsequent inflammatory response to an immune challenge
[50,511. Animal research shows that acute stress increases plasma levels of IL-6 and
TNF-a  [501,  and  that  treatment with glucocorticoids 12 hours prior to immune
challenge increases IL-6 and TNF-a production [521. Finally, while glucocorticoids
may reduce the expression of pro-inflammatory cytokines under certain conditions,
they often simultaneously increase the expression of the corresponding cytokine
receptor 1491
CHF often is complicated by the additional diagnosis of CKD 117,23,53},
since the kidney is the main organ affected when cardiac function is compromised
[541. It was recently shown that inflammation, as assessed by higher levels of sTNFRl
and 2, may mediate this association [17j. However, to date, a temporal relationship
between renal impairment and worsening heart failure has not been established [231
The present study is the first to report that presence of CKD in CHF patients at
baseline is a strong, independent predictor of an unfavourable cytokine profile (too
much pro-inflammatory cytokines   (reflected by increased sTNFRl, sTNFR2),
154
PREDICTORS OF CYTOKINES IN HEART FAILURE
compared to the levels of anti-inflammatory cytokines that were invariant (i.e., IL-10,
Ill ra)) one year later. Since pro-inflammatory cyfokines are significant predictors of
poor outcome in heart failure [7,551, the findings indeed suggest that there is a
temporal relation between kidney impairment and prognosis in heart failure, and that
this relationship is partly mediated by inflammation.
Although our findings are promising, they should be interpreted sensibly in
the light of some limitations of the study design. Although no significant differences
were found between males and females, the fact that only 25% of the sample was
female, may have precluded finding sex differences. A further limitation to this study
is that only a limited amount of patients had both type-D personality and CKD. It
would be interesting to find out whether the effects of type-D personality and CKD
are additive, since this would specify those CHF patients at high risk even further. The
maiorify of the studies in CHF that have found associations between psychological
distress and cytokine levels have been cross-sectional and based on small sample
sizes [30-341. Our study differs from these reports, as we used a prospective design
and had a relatively larger sample.
Concluding, both type-D personality and CKD independently predict
unfavourable cyfokine profiles in CHF patients. Such alterations in immune processes
may be one mechanism explaining the adverse relationship between these risk
factors and prognosis in heart failure. Whether these type-D and CKD related
alterations in immune balance actually explain adverse prognosis and mortality in
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Clinical predictors of mortality in chronic heart failure (CHF) are established, but less
is known about chronic psychological predicfors. Therefore, we examined the
prognostic value of type-D personality (i.e., the tendency to experience negative
feelings and inhibit self-expression) in CHF patients.
Methods
Consecutive systolic  CHF  patients  (n=232)  filled  in the Type-D Scale  (D514)  at
baseline. Socio-demographic and clinical data were obtained from the patients'
medical records or treating cardiologist/CHF nurse. The primary endpoint was car-
diac mortality after a follow-up of 30.7 months (SD=11.1). Early (56 months} versus
late (>6 months) cardiac mortality were secondary endpoints.
Resu/ts
Type-D patients had a higher incidence of cardiac mortality (15/48=31.3%) as
compared to non type-D patients (32/184=17.4%), OR=2.16;95%Cl: 1.05-4.43,
p=.04. Type-D was a near significant independent predictor of total cardiac
mortality (OR=1.40;95%Cl:0.93-4.29,p=.08). Type-D did not predict early cardiac
mortality (p=.83), but  was a significant independent predictor of late cardiac morta-
lity, adiusting for sex, age and left ventricular eiection fraction (OR=2.34.95%Cl.
1.05-5.26,p=.04).
Conc/usions
Type-D personality was an independent predictor of late cardiac mortality, adiusting
for socio-demographics and disease-severity, but not of early cardiac mortality.
These findings suggest that chronic psychological factors may play less of a role in
short-term CHF prognosis, but are of importance in long-term prognosis. Future
studies are warranted to replicate these findings.
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INTRODUCTION
Worldwide high prevalence and incidence rates of chronic heart failure (CHF) have
been reported; up to 2% of the total population has CHF [1-31. Despite impressive
advances in therapy, CHF still has a poor prognosis [1,2,41. Clinical predictors of
CHF prognosis are established [5-101, and episodic psychological risk factors such
as depression and to a |esser extent anxiety, have also been studied 18,9,11-161.
However, the role of chronic psychological factors, such as personality, in relation to
CHF mortality has largely been overlooked.
Type-D personality, i.e., the tendency to experience negative emotions
combined with the tendency to inhibit self-expression, has been shown to predict
worse prognosis in patients with coronary artery disease (CAD) [17-211. Preliminary
evidence also shows that type-D personality predicts mortality in post-myocardial
infarction (MI) patients with a decreased left ventricular eiection fraction (LVEF) [181,
and in heart transplantation recipients 1221. The prognostic value of type-D perso-
nality in patients with established CHF has not yet been explicitly examined, but
recent research has shown that type-D personality is associated with increased levels
of depressive symptoms and anxiety in CHF patients [23,241. Given the chronicify of
type-D, and that CHF patients with this personality disposition have an increased risk
for the convergence of psychosocial risk factors, may increase the risk of worse
prognosis 11 7,25-29].
The obiedives of this study were to (1) investigate whether type-D
personality predicts adverse cardiac prognosis in patients with CHF, and (2) examine
the role of type-D personality in early (56months) and late (>6 months) cardiac
mortality as secondary endpoints.
METHODS
Patient population
Between October 2003 and March 2006, consecutive CHF patients from the
cardiology unit of the TweeSfeden teaching hospital in Tilburg, the Netherlands, were
included in the current study. Of 305 eligible patients, 232 agreed to participate
(response rate of 76%). No patients were lost to follow-up, but four patients were
excluded from analyses because they died from other than cardiac causes.
Patients were eligible for the current study if they had a diagnosis of systolic
CHF with a LVEF540%, were 580 years of age, and stable on medication for at
least one month prior to inclusion. Patients with a diagnosis of diastolic heart failure,
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who were unable to read, write or understand Dutch, who had life-threatening co
morbidities (e.g. cancer or MI one month prior to inclusion), or severe cognitive
impairments, were excluded. All patients were treated following the most recent
guidelines for CHF [3,30-32}. The study was approved by the hospital medical ethics
committee and carried out according to policies to protect human subiects as
formulated by fhe Word Medical Association, described in the Helsinki Declaration
(2004).
The treating cardiologist or CHF nurse informed patients about the study
and asked them to participate. If they agreed, the investigator called them in the
same week to make an appointment for assessment. During this visit, patients were
given additional information about the study; they provided written informed consent
and were asked to complete a questionnaire at home. All questionnaires were
returned in a self-addressed envelope and were checked for comp|eteness. Patients
who had left open several items were asked to answer those questions. In case the
questionnaire was not returned within two weeks, patients received a reminder
telephone call or letter.
Clinical endpoints
The primary endpoint in this study was cardiac mortality. Information on mortality
(date and cause of death) was collected by checking fhe hospital's electronic
system/the patients' medical records or by contacting the general practitioner.
Secondary endpoints were early (56 months) versus late (>6 months) cardiac
mortality. In previous studies in coronary patients, also in patients with an impaired
pump function, was shown that the cardio-toxic effect of type-D personality was more
prominent on the long term  Il 8,201.  Furthermore, in previous research in cardiac
patients, the endpoint of ma or cardiac events has been split up into early versus late
events, with a cut-off at six months  [331.
Type-D personality
At baseline, the Type-D Scale (DS14) was used to assess type-D personality [341. The
DS 1 4  comprises two subscales of seven items each, measuring negative affectivity
(e.g. "I am often irritated"; "I often find myself worrying about something") and social
inhibition (e.g. "I am a closed kind of person; "I would rather keep other people at a
distance"), respectively. Items are answered on a 5-point Likerl Scale from "false" (0)
to "true" (4). Type-D caseness is defined as a score of 210 on  both DS 14 subscales,
which has been shown to be the most optimal cut-off [34,351. It is the interaction of
negative affectivity and social inhibition that predicts poor clinical outcome in
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coronary patients and not the single traits, with social inhibition moderating the effect
of   negative   affectivity on prognosis   [361.   The   DS14 is internally consistent
(Cronbach's a=.88/.86 for the negative affectivify and social inhibition subscale,
respectively) and stable over time [34,371. Recent studies in post-MI patients showed
that type-D personality is not confounded by disease severity [37,381
Clinical characteristics
Information on sex, age, disease characteristics (LVEF, New York Heart Association
(NYHA) functional class and aetiology), co morbidities (previous cardiac history and
diabetes) and medication Cdiuretics, aspirin, beta-blockers, ACE-inhibitors and
statins) was obtained from the patients' medical records and the treating
cardiologist/CHF nurse at the time of inclusion into the study.
Statistical analyses
Prior to statistical analyses, NYHA-class, aetiology and cardiac history were recoded
into dichotomous variables. For comparison between two groups, we used the chi-
square test for discrete variables and the t test for independent samples for conti-
nuous variables. Logistic regression analyses were used to assess the relationships
between type-D personality and cardiac mortality. In order to obtain reliable
estimates in multivariable analyses, we selected a maximum of three additional




Of all eligible patients, 73 refused participation. Participants and non-participants
differed systematically on some baseline characteristics, with non-participants being
older (69.6 versus 65.5;p=.002), more likely to be female (47.9% versus
25.4%;p<.001), to have non-ischemic CHF (59.7% versus 45.7%;p=.04), and to
use aspirin (66.7% versus 40.1%;p<.001), but less likely fo use ACE-inhibitors
(63.9% versus 76.3%;p=.04), compared to participants.
Of fhe total sample, 48 patients (20.7%) were classified as type-D. Type-D
patients did not differ from non type-D patients on demographic and clinical
variables, although a trend was found for increased use of diuretics among patients
with a type-D personality (p=.06;Table 1)
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Table  1.     Baseline characteristics stratified by type-D personality
Total sample Type-D Non iype-D p-value
fn =48) (n= 184)
Mole sex 75 (173) 79 (38) 73 (135) .41
Age, mean (SDJ 65.5 (9.9) 66.5 (10.63 65.2 (9.8) .44
LVEP', mean (SDJ 30.5 (6.91 30.1 (7.4) 30.6 (6.7) .64
NYHA,2 class 111/IV 48(112) 56 (271 46 (85) .21
Ischemic aetiology 54 (1261 52 (25) 55 (101) .73
Cardiac historyf 57 (133) 56 (27) 58  C 106) .87
Diabetes 27 (63) 25 (12) 28 (51 1 .71
Diurefics 77 (179) 88 (423 75 (137) 06
Aspirin 40 (93f 46 (22) 39 (71) 36
Beta-blockers 66 (154) 69 (33; 66(121) .70
ACE-inhibitors 76(177) 79138) 76(139} 60
Statins 49(113) 50 (24) 48 (89) .84
Data are presented as % (n), unless otherwise indicated
* Previous myocm·dd infacction, coronaty odery bypass sur·gery, and/or percutoneous coronaty
intervention
*Left ventricular election fraction
BNew York Heart Association
Type-D personality and cardiac mortality
The mean follow-up period was 30.7 months (SD-11.1). During this period, 47
patients (20.3%) had died due to cardiac causes. An additional four patients had
died due to other causes (i.e. cancer and chronic obstructive pulmonary disease),
and were excluded from further analyses.
Logistic univariable regression analysis revealed that type-D personality was
a significant predictor of cardiac mortality (OR=2.16;95%Cl:1.05-4.43, p=.04).
Furthermore, higher age (OR=1.05;95%Cl. 1.01-1.09, p=.01) and lower LVEF
(OR=0.92;95%Cl: 0.87-0.96, p<.001) predicted cardiac mortality in univariable
analyses. A trend towards significance was found for male sex (OR=2.23;95%Cl:
0.94-5.30, p=.07). In Figure 1 {left), the incidence of cardiac mortality for patients
with a type-D personality (15/48=31.3%) as compared to patients without type-D
(32/184=17.4%) is provided (p=.04).
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In multivariable analysis, we entered type-D, sex, age, and LVEF. Lower
LVEF (OR=0.93;95%Cl:0.88-0.98, p=.003) and higher age COR- 1.04,95%
Cl:1.00-1.08, p=.049) were independently associated with cardiac mortality,
whereas there was also a trend for type-D personality (OR=1.40;95%Cl:0.93-4.29,
p=.08)
Pm • Type-L)      I Non type.[i
pi 35 p--.0215/48
.-




0                  32/184U




5                                2/48....
Total cardiac mortality   Early cardiac mortality Late cardiac mortality
(·-6 months) C >6 months)
Figure i     Effect of type-D personaltry on card,uc,·norfatify
Type-D personality and early versus late cardiac mortality
As a secondary endpoint, we divided cardiac mortality into early (56 months) versus
late (>6 months) cardiac events. There were  11  early events  (4.7%)  and 36  late
events  (15.596).
Univariable logistic regression revealed that type-D was not associated with
early cardiac mortality (OR=0.85.95%CI:0.18-4.05, p=.83), but it was related to
late cardiac mortality (OR=2.54.95%Cl: 1.1 7-5.52, p=.02). In Figure 1 (centre),
the incidence of early cardiac mortality for CHF patients with a type-D personality
(2/48=4.2%) as compared to CHF patients without type-D (9/184=4.9%) is
provided (p=.83). Furthermore, Figure  1   (right) also shows the incidence  of  late
cardiac mortality for type-D CHF patients (13/46=28.3%) as compared to non type-
D CHF patients (23/175= 13.1%, p=.02)
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In multivariable analysis, type-D remained a significant independent
predictor of late cardiac mortality (OR=2.34.95%(1:1.05-5.26, p=.04), adiusting
for sex, age and LVEF. In addition, LVEF predicted late cardiac mortality (OR=0.95
;95%Cl:0.89-1.00, p=.04), but not as strongly as it predicted total cardiac
mortality. This suggests that CHF patients who died within the first six months are
characterised by a more impaired LVEF. This was confirmed in post-hoc analysis,
comparing the LVEF of patients who died early to those who died late (mean
LVEF„,i,=23.7,mean LVEFi.,«=28.4,t=2.01;df=45, p=.05)
In Table 2, the results for the mulfivariable analyses for early and late
cardiac mortality are provided.
Table 2.    Predictors of early and late cardiac mortality Cmultivoriable analyses)
Odds ratio 95%0 p-value
Early cardiac mortality
Age 1.04 0.9 6 -  1 1 3 .30
Allate sex 2.45 0.29 - 20.56                   .4 1
LVEF' 0.87 0.79 0.96 .006
Type-D personality 0.61 0.12· 3.21 .56
Late cardiac mortality
Age 1.04 1.00 ·- 1.09 .09
Male sex 1.61 0.62 · 4.21 .33
LVEP 0 95 0.89 1.00 .04
Type-D personality 234 1.05 - 5.26 .04
Aleff ventriculor election fraction
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DISCUSSION
We found that type-D CHF patients had a significantly higher incidence of cardiac
mortality as compared to non type-D CHF patients. Type-D personality was a
significant predictor of cardiac mortality in univariable analysis. After adiusting for
sex, age and CHF severity, the relationship was no longer significant, although there
was a trend. When dividing total cardiac mortality into early (56 months) versus late
(>6 months) mortality, we found type-D personality to be significantly associated with
late cardiac mortality, also when adiusting for the mentioned confounders, but not
with early cardiac mortality.
Several episodic psychological and psychosocial variables, such as
depression, anxiety, social isolation and avoidant coping have been identified as
important predictors of mortality in CHF [8,9,11-16,39,401. However, few studies
have examined the prognostic value of personality in patients with diagnosed CHF,
although one study found that neuroticism independently predicted cardiac death
[41], and two studies reported that type-D personality was related to adverse
prognosis in post-MI patients with an impaired pump function [181 and in heart
transplantation recipients [221. To our knowledge, this is the first study investigating
the predictive value of type-D personality on cardiac prognosis in patients with
established CHF.
In the current study, type-D patients did not differ from non type-D patients
on disease severity as assessed by means of LVEF. This result is in line with those of a
recent sub study from the Myocardial Infarction and Depression-Intervention (MIND-
IT) trial, comparing the extent to which type-D personality and depression were
confounded by measures of somatic health [381. De Jonge and colleagues found
that depression, but not type-D personality, was related to impaired LVEF and co
morbidities [381.
In previous studies of patients with CAD, type-D personality has been
shown to predict mortality and re-infarction, with the associated risk being around 4-
fold [17,19-21,361. In addition, type-D personality also independently predicted
cardiac death over 6-10 years in MI survivors with an impaired pump function [181,
and impaired prognosis in heart transplantation recipients [22}. In this study, we
found a significant independent association between type-D and late cardiac
mortality, but not between type-D personality and early cardiac mortality. Thus, it
seems that, at |east in CHF, personality is especially important in long-term
prognosis. Our results are in line with those of the study in coronary patients with an
impaired pump function (but no diagnosed CHF) [18]. In the latter study, the
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influence of type-D personality on cardiac events was more prominent the longer the
follow-up period [18]. Given that in the current study, patients who died in the first six
months after inclusion had a significantly more impaired LVEF compared to patients
who died later, we may assume that these patients had worse heart failure. It is
unlikely that psychological variables, such as type-D personality, are relevant for
prognosis in this very ill subgroup of CHF patients. Next to the already mentioned
study in coronary patients with an impaired pump function [181, results of another
study in post-percutaneous cardiac intervention patients also showed that personality
becomes especially cardio-toxic in the long run [201. It might also be that personality
factors are less cardio-toxic in terms of predicting mortality in CHF patients
compared to CAD patients, as CHF patients tend to have a long history of heart
disease and have often survived several cardiac events. However, this needs to be
confirmed in a larger study with a longer follow-up period.
Mechanisms relating type-D personality to adverse prognosis may be of
physiological and/or behavioural nature. Previously, type-D personality has been
associated with increased cytokine levels in CHF patients [42,431, and cytokines are
related to increased risk of death and CHF in post-MI patients [44]. Of behavioural
mechanisms, compliance and self-care behaviour, such as consultation behaviour,
may be important. A recent study showed that fype-D patients with CHF are less likely
to consult their cardiologist or CHF nurse, despite experiencing relevant cardiac
symptoms and worrying about them [45]. Furthermore, physically healthy type-D
persons also seem to engage in significantly fewer health behaviours as compared to
non type-D persons [461. For clinical practice, this means that efforts should be
concentrated on improving type-D patients' self-care abilities and health behaviours,
as this may help to reduce the cardio-toxic effects of type-D on the long-term.
Limitations and strengths
The sample size of the current study is relatively small and if has a relatively short
follow-up period. Furthermore, the sample could be biased by mobility and younger
age, because participating patients were required to visit the outpatient clinic. There
were also several differences on baseline characteristics between participants and
non-participants. Finally, the sample used in this study was quite heterogeneous, as
end stage CHF patients as well as newly diagnosed CHF patients were included.
However, this is also a strength, as it reflects "the real world" of CHF patients seen in
daily clinical practise. Other strengths of the study include that patients comprised
consecutive, unselected outpatients, that the response rate was quite high, and that
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this is the very first study to examine the prognostic value of type-D personality in
patients with established CHF.
Conc/usions
In this study, type-D personality was associated with cardiac mortality in CHF. Type-D
personality was an independent predicfor of late cardiac mortality, but not of early
cardiac mortality. These findings warrant replication in studies with a larger sample
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Genera/ discussion and summary
CHAPTER 10
This thesis described a longitudinal follow-up study in outpatients with chronic heart
failure (CHF). The aim of the thesis was to examine the associations between type-D
personality and health outcomes in CHF outpatients. Possible behavioural and
physiological mechanisms in explaining the adverse impact of type-D personality on
patient-centred outcomes and prognosis were also investigated. In the present
chapter, the main findings of this thesis are summarised, implications for clinical
practice are described, and methodological reflections are presented.
TYPE-D PERSONALITY AS A PREDICTOR
OF PATIENT-CENTRED OUTCOMES IN CHF
Previous research has examined the associations between type-D personality
(tendency to experience a broad range of negative feelings while not sharing them in
social interaction) and health status, quality of life and psychological distress in
patients with coronary arfery disease (CAD)  Ie.g. 1-91 Until  now, no studies reported
on the influence of type-D personality on these patient-centred outcomes in CHF.
Therefore, the first part of the present thesis (Part A) focused on the impact of type-D
personality on patient-centred outcomes in patients with CHF.
After a general introduction (Chapter 1 1 and an introduction on the type-D
personality construct (Chapter 2), the aim of Chapter 3 was to examine whether type-
D personality was associated with impaired health and mood status, and increased
depressive symptoms in CHF, independent of disease characteristics. Results showed
that CHF patients with a type-D personality were more likely to experience
impairment in health and mood status, and increased depressive symptoms as
compared to non type-D patients. Type-D personality was still associated with
impaired health status, increased depressive symptoms and impaired mood status
(i.e. more negative and less positive affect) when adiusting for severity and aetiology
of CHF, and socio-demographic characteristics.
The aim of the study reported in Chapter 4 was to replicate the above-
mentioned findings in a larger sample of CHF patients, while using a more broad
measure of health status and a prospective design. More specific, this study
investigated whether type-D personality would exert a stable, independent effect on
disease-specific and generic health status in CHF over 12 months, when adiusting
for depressive symptoms, disease characteristics, socio-demographic variables,
relevant medication, and baseline health status. Results showed that there was a
general improvement in disease-specific and mental generic health status over time.
However, type-D patients reported significantly lower disease-specific as well as
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mental health status as compared to non type-Ds. Furthermore, depressed patients
also reported significantly lower health status as compared to the non-depressed.
The negative impact of type-D personality and depressive symptoms on health status
was stable over time and could not be attributed to the severity of CHF. The results
elaborate on findings from previous studies on determinants of health status in CHF
in that is shown that type-D personality is predictive of impaired health status above
and beyond depressive symptoms. In this study, no association between type-D
personality and physical health status was found. An explanation for this may be that
the patients in this study were chronically ill with hardly any options left concerning
invasive interventions; generic physical health status may be largely a function of
CHF severity.
Chapter 5 focused on CHF patients treated with cardiac resynchronisation
therapy (CRT). Although clinical trials have shown that CRT exerIs positive effects on
mortaliW, morbidify, quality of life, functional status and exercise capacity in CHF, a
subgroup of patients still report significant symptoms and high levels of disability
following CRT le.g. 10-141. The study presented in Chapter 5 was the first to
examine the associations between negative affectivity, social inhibition and type-D
personality, and patient-centred outcomes such as health status and symptom levels,
in patients treated with CRT. Results showed general improvements in patient-centred
outcomes over time. However, high negative affectivity patients reported significantly
lower disease-specific health status and more cardiac symptoms and perceived
disability as compared to low negative affectivity patients. When adiusting for
disease-severity, sex and age, high negative affectivity patients still reported lower
disease-specific health status and significantly more perceived disability. The main
conclusion therefore was that CHF patients treated with CRT improved over a 2-
month period in patient-centred outcomes, but also that negative affectivity exerted a
stable, negative effect on these outcomes. In this exploratory study, type-D
personality was not associated with more impaired health status or symptoms,
probably because of the small sample size with only eight patients being identified as
type-D, and the relatively short follow-up period. Hence, replication of these findings
in a larger data set is warranted.
A paucify of studies has focused on anxiety and its determinants in CHF.
Therefore, Chapter 6 examined whether type-D personality and depressive symptoms
would predict clinically significant anxiety at 1 -year follow-up. Hypertension, type-D
personality and anxiety sensitivity, but not depressive symptoms, were significant
predictors in univariable analyses. When adiusting for depressive symptoms, anxiety
sensitivity, socio-demographic and clinical variables, type-D personality remained a
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significant independent predictor of clinically significant  anxiety  at   12  months.
Furthermore, when using a hierarchical logistic regression model comprising
standard and psychological risk factors, type-D personalify enhanced the level of
prediction of clinically significant anxiety substantially.
Taken together, the results of the first part of this thesis showed that type-D
personality and its subcomponent negative affectivity were important predictors of
patient-centred outcomes, such as health status, mood status, depressive
symptomatology, anxiety, cardiopulmonary symptoms and perceived disability in
CHF. Knowledge about determinants of such patient-centred outcomes may help to
identify patients at high risk for adverse prognosis, as impaired health status, and
anxiety and depression have been related to increased mortality in heart patients
le.g. 15-22].
TYPE-D PERSONALITY AS A PREDICTOR OF
PROGNOSIS IN CHF AND MECHANISMS EXPLAINING
THE ADVERSE EFFECTS ON HEALTH OUTCOMES
Type-D personality has been shown to predict worse prognosis in patients with CAD
le.g. 23-271. Although one study examined type-D personality in relation to
prognosis in coronary patients with an impaired pump function [231, and another
focused on type-D and prognosis in heart transplantation recipients [281, no study
has focused on the prognostic value of type-D personalig in patients diagnosed with
CHF per se. Furthermore, although there are two cross-sec:tional studies describing
associations between type-D personality and cylokines in CHF patients [29,301, no
studies have reported on the relationship between type-D personality and cytokines
prospectively. A very recent cross-sectional study evaluated the association between
type-D  personality and health-related behaviours in physically healthy persons  [311,
but, again, no prospective studies have investigated the behavioural mechanisms
that may explain associations between type-D personality and health outcomes.
Therefore, the second part of the present thesis (Part B) focused on possible
physiological and behavioural mechanisms underlying the relationship between type-
D personality and health outcomes in CHF.
Because poor self-management, or self-care, is associated with an
increased risk of adverse clinical outcome in CHF 132], Chapter 7 examined whether
type-D personality would predict poor self-management and failure to consult for
clinically evident symptoms in CHF patients. Results indicated that type-D patients
experienced more cardiac symptoms and more often appraised these symptoms as
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worrisome as compared to non type-D patients. Paradoxically, however, type-Ds
were less likely to report these symptoms to their cardiologist/nurse, as indicated by
an increased risk for inadequate consultation behaviour, adiusting for socio-
demographics, severity/aetiology of CHF, time since diagnosis and medication.
Thus, patients with a type-D personality were at an increased risk for inadequate
consultation behaviour as a specific facet of self-management behaviour. Impaired
self-management behaviour could therefore be a possible behavioural mechanism
explaining adverse effects of type-D personality on health outcomes.
A possible mechanism in the relationship between type-D personality and
prognosis is of pathophysiological nature. Previous cross-seclional studies have
shown associations between type-D personality and the cytokines TNF-a and its
soluble receptors sTNFRl and sTNFR2 [29,301. It has also been shown that the pro-
inflammatory cyfokines IL-6, TNF-a, sTNFRl/sTNFR2, IL-10 and IL-1 ra were related
to increased risk of death and CHF following myocardial infarction [331 Chapter 8
therefore prospectively examined whether type-D personality predicted serum levels
of these pro- and anti-inflammatory cytokines at  1 -year follow-up in CHF patients
while adiusting for traditional prognostic markers, such as left ventricular eiection
fraction (LVEF) and New York Heart Association (NYHA) functional class.
Furthermore, the latter study also examined the association between chronic kidney
disease (CKD) and pro- and anti-inflammatory cytokine imbalance, because patients
with kidney disease are often excluded from cardiovascular research, although CKD
is related to higher IL-6 and TNF-a levels and poor clinical outcomes in CHF [34]. In
the study presented in Chapter 8, type-D personality and CKD were both associated
with pro- and anti-inflammatory cytokine imbalance after  1 -year follow-up, exerfing
an independent effect of similar magnitude. This prospective study presented
therefore evidence for a pathophysiological pathway in the associations between
type-D personality and prognosis.
The study presented in Chapter 9 is the first to report on the relationship
between type-D personality and cardiac prognosis in the context of CHF. Type-D
CHF patients had higher incidence of cardiac mortality as compared to the non type-
Ds. Furthermore, after adiusting for LVEF, sex and age, type-D personality predicted
total cardiac mortality near significant, but was a significant predicfor of late cardiac
mortality. There was no effect of type-D personality on early cardiac mortality in this
study. The relatively small sample size and the short follow-up period may be reasons
for not finding significant associations between type-D personality and tota| cardiac
mortality. Replication of the findings in studies with larger samples and longer follow-
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up periods is therefore warranted. However, the results indicated that type-D
personality is of importance in, at least, late cardiac mortality in CHF.
Overall, the results of the studies presented in the second part of the
present thesis elaborated on results from previous studies on the relationship between
type-D personality and prognosis in patients with CAD, and on studies providing
preliminary evidence that immune-activation and health-related behaviours may
comprise a link between type-D personality and health outcomes.
IMPLICATIONS FOR CLINICAL RESEARCH AND
PRACTICE
interventions aimed at behavioural and physiological mechanisms
The present thesis represents a step towards more attention for patient-centred
outcomes and their determinants in CHF, as strongly recommended by Krumholz
and colleagues [351. Furthermore, the thesis aimed to initiate prospective research
on possible physiological and behavioural mechanisms explaining adverse effects of
type-D personality on health outcomes. Apart from self-management and cytokine
levels, there is also some evidence that the type-D traits are associated with
decreased heart rate variability, increased blood pressure reactivity and increased
cortisol production 136-381. As type-D personality has been associated with
increased cortisol and a greater cortisol awakening response, a role for the
hypothalamic-pituitary-adrenal CHPA) axis has been proposed 136-38] Furthermore,
a recent study indicated that it is important to give attention to the type-D patient's
marital status, as lack of a partner further exacerbated the risk on emotional distress
in type-D patients [391
Further research on this topic of physiological and behavioural mechanisms
is recommended, because of its importance for clinical practice. In particular,
knowing which mechanisms are at play will provide opportunities for (psychological)
intervention in the near future, thereby enhancing secondary prevention in patients
with CHF [401. For instance, in previous research it has been shown that disease
management programmes (DMPs) for patients with CHF have beneficial effects on
hospital readmission and mortality [41,421. One crucial component of DMPs is self-
management [41,431 Furthermore, there is also evidence that self-management
programmes for CHF patients decrease overall hospital readmissions and
readmission for CHF [441. As pointed out by van der Wai and colleagues, patient-
related factors are of importance in compliance, an important aspect of self-
management [45]. These authors also state that results of intervention studies on self-
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care behaviour are rather inconsistent, probably because of the heterogeneify in
content, the difference in disciplines involved and the duration of the intervention
145]. However, it may also be fhat different patients need different interventions, in
other words, that a more personalised approached to the intervention on self-care
behaviours is needed. It might be that patients with a type-D personality need
another type of intervention than non type-D patients.
Apart from interventions aimed at behavioural mechanisms, attention
should also be paid to potential physiological mechanisms. Several studies have
focused on effects of psychosocial interventions on immunologic parameters in both
healthy and physically ill persons. These studies have yielded inconsistent results. It
has been shown that immunologic markers can be influenced by psychological
interventions, such as relaxation and mindfulness training [e.g. 46-49]. In one recent
study, the effect of a home-based cognitive behavioural intervention on immunologic
markers was evaluated in female patients treated with coronary artery bypass (CABG)
surgery. It was found that, among depressed post-CABG women, cognitive
behavioural intervention positive|y affected immunological parameters [491
However, there are also studies indicating no beneficial effect of relaxation training
or other psychological interventions on immunologic parameters [e.g. 50,511. Thus,
results on the effect of psychological interventions on immunological functioning are
rather inconsistent, although some studies show promising results. Further research is
therefore warranted, in particular in the context of type-D personality and immune
parameters.
interventions aimed at fype-D personality
Until now, no intervention study has targeted type-D personality and we can only
speculate about interventions that may reduce the toxic effects of type-D. However, it
is important to emphasise that the fact that type-D refers to a personality construct,
does not imply that type-D patients do not benefit from psychological interventions. It
may be true that changing personality characteristics is very difficult, but this should
not be the primary goal of counselling in the context of type-D; rather health care
professionals should be working with type-D patients on changing behaviours and
enhancing emotional well-being [521. In our opinion, efforts should be directed
towards high-risk patients such as type-Ds, because this subgroup has a substantial
risk of a wide variety of emotional problems and may therefore benefit the most from
counselling. Sher has proposed a series of possible interventions for type-D patients,
including cognitive behavioural therapy, social skills training, interpersonal
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psychotherapy, biofeedback and pharmacological therapy 1371. In our opinion,
efforts should especially be concentrated on:
a.    Improvement of self-management and self-care abilities.
b. Consolidation of the social network. A supportive, stimulating, social
network is of great importance for the socially inhibited type-D patients,
because these patients tend to perceive the social world as threatening and
stressful. For example, type-D patients fear reiection or disapproval while
interacting with other people, although they feel a need for sharing feelings
in interpersonal contact.
c.  Counselling in order to improve emotional coping and to expand on
coping strategies. Type-D patients typically deal with negative emotions by
not sharing them with others. Counselling efforts should be directed
towards teaching type-D patients other ways to deal with their negative
feelings and seek to alter their gloomy view of self and the world.
Specific cognitive behavioural techniques to identify negative and
unrealistic thoughts might be very useful. Another promising treatment option for
patients with a type-D personality is interpersonal psychotherapy CIPT). IPT is a
manualised, time-limited form of psychotherapy, originally designed to treat
depression, but nowadays used to treat various forms of psychological distress
[53,541.  IPT is a practical, present-oriented treatment with a focus on interpersonal
distress, social factors and interpersonal problems. The intervention is tailored to
current interpersonal relations and seeks to modify patterns of social dysfunction
[53,541. Empirical data support the efficacy of IPT in the treatment of depression
[54,55}. A recent study in elderly depressed patients, for example, showed that IPT
was more effective than general practitioners' care 156] However, another study
failed to document a benefit of IPT in comparison with clinical management of
depression in patients with CAD [571. The latter study compared IPT with an
intervention of clinical management given by an IPT-focused therapist [571
Patients with a type-D personality are very much in need for supportive and
stimulating interpersonal contacts, because they feel a need to share their negative
feelings, emotions and thoughts with others, but refrain from doing it, because they
fear disapproval or reiection. Furthermore, this treatment approach might be
especially effective in type-D patients with CHF, because, apart from having
difficulties in establishing valuable interpersonal relationships because of being a
type-D person, the condition of CHF itself may have adverse effects on interpersonal
contacts. For example, the disease may go together with changes in social roles
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because of physical limitations. In particular, for type-D patients this may be very
difficult to manage, leading to increased psychological distress and poor quality of
li fe.
Next to emphasising possible treatment options for patients with a type-D
personality, the importance of screening for type-D personality in CHF has also to be
stressed. Results from studies such as presented in the present thesis indicate that
fype-D personality is associated with a broad range of negative health outcomes in
patients with CHF. Knowing which individuals are at increased risk for impaired
health status, for developing psychological distress and for worse prognosis provides
a window of opportunity to intervene at an early stage. Screening patients for type-D
personality fits well into the personalised approach to medicine that has recently
been advocated [581. The use of the Type-D Scale as a screening instrument for the
influence of psychological and psychosocial factors in clinical practice has also been
advocated by others 159}
LIMITATIONS AND STRENGTHS OF THE PRESENT
WORK
The work presented in this thesis has some limitations. First, all data were collected at
the same hospital, which makes generalisation of the results difficult. Second, not all
eligible patients have participated in the studies. Furthermore, study participants were
required to visit the outpatient clinic to be included in the study, and hence the
sample could be biased by mobility and younger age. Fourth, there were several
differences on clinical variables between patients who agreed to participate in the
study versus those who declined (see Chapters 4 and 9). Fifth, in some studies, the
number of patients was relatively small, which limits the number of variables that
could be controlled for in statistical analyses and the generalisation of the results.
Next, there is an overlap between symptoms of CHF and some forms of
psychological distress, such as symptoms of anxiety. However, we used a clinical
interview to measure anxiety and the assessment of anxiety levels was done by
experienced health psychologists. Seventh, we had no control group, which is of
especial concern in the study presented in Chapter 5.
Despite these limitations, the work presented in this thesis also has a
number of strengths. This thesis reported on longitudinal follow-up research, focusing
on type-D personality as a determinant of health outcomes in CHF. Most chapters in
this thesis were the first in the (psycho) somatic literature on CHF to report on these
issues. Furthermore, participants were consecutive unselected outpatients with CHF
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and response rates were in general high. Finally, this work also comprised research
on mechanisms that may explain the relationship between type-D personality and
health outcomes in CHF.
CONCLUDING REMARKS
Apart from focusing on acute and episodic risk factors in heart disease in general,
and in CHF in particular, it now seems timely to expand our focus to include also
more chronic psychological risk factors. Personality, and more specifically type-D
personality, is a potentially important chronic psychological risk factor that may
explain substantial individual differences in health outcomes in CAD and CHF.
Hence, when studying health outcomes and its determinants in cardiovascular
disease CCVD), future research should not only focus on acute and episodic
determinants of these outcomes, but also on the role of chronic psychological risk
factors.
A challenging task for the near future is designing an intervention for type-
D personality. As with many other psychological risk factors, such as depression, it is
very unlikely that one specific intervention, or monotherapy, is the solution or the
treatment. By analogy, is it very unlikely that type-D personality is the psychosocial
risk factor in CVD or CHF. However, type-D personality can be seen as an umbrella,
capturing several psychological risk factors in hearf disease, thereby increasing the
risk on negative health outcomes. Thus, focusing on personality as a determinant of
health outcomes entails focusing  on  (1 ) chronic emotional distress in addition to
episodic distress, and on (21 clustering of risk factors instead of focusing on single
risk factors 160-621. The findings presented in this thesis indicate that type-D
personality is of special interest in the context of CHF.
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DE EPIDEMIE VAN CHRONISCH HARTFALEN
Hart- en vaatziekten ziln een belangriike doodsoorzaak, niet alleen in Nederland,
maar wereldwiid. Chronisch hartfalen (CHF), het best te omschrilven als een klinisch
syndroom dat bestaat uit een combinatie van klachten die het gevolg ziin van een
tekortschietende pompfunctie van het hart, is het eindstadium van verschillende
vormen van hart- en vaatziekten en gaat gepaard met een hoge mortaliteit. In 2004
overleden in Nederland 5,624 patienten  aan  CHF, wat neerkomt op  12% van  de
fotale mortaliteit voor hart- en vaatziekten in Nederland in dat iaar. In het Verenigd
Koninkriik waren de mortaliteitsciifers voor 2,445 patilanten opgenomen met CHF in
2000,37.3%,  52.9% en 78.5%, respectieveliik  1,2 en 5  iaar na ontslag uit het
ziekenhuis.  In de Verenigde Staten  nam de  mortaliteit voor CHF tussen  1994 en
2004 toe met 28%. De ziekenhuisopnames voor CHF stegen in diezelfde periode
met 175%.
Omdat er sprake is van vergri zing, mensen vaker een hartinfarct overleven
en hoge bloeddruk vaker voorkomt, neemt de incidentie en prevalentie van CHF toe.
Daardoor is er inmiddels sprake van een wereldwiide hartfalenepidemie. Een grote
Nederlandse studie uit 2004 rapporteerde prevalentiecilfers van 6.4% (1997), 6.7%
(1998)  en 7.0% (1999) Dezelfde sfudie vermeldde een incidentie van  14.4/1000
personen-iaar. De Nederlandse Hartstichting vermeldde een prevalentie van
163,800-176,400 en een incidentie van 37,400-43,400 in Nederland in hef iaar
2000. Naast een slechte prognose, gaat CHF ook gepaard met een verminderde
levenskwaliteit en gezondheidstoestand.
PSYCHOLOGISCHE RISICOFACTOREN EN TYPE-D
PERSOONLIJKHEID
Inmiddels is er in wetenschappellik onderzoek meer aandacht voor de rol van
psychologische en psychosociale factoren bil hart- en vaatziekten in het algemeen.
Echter, dit onderzoek richt zich, ook bii CHF, vooral op depressie als risicofactor
voor biivoorbeeld een verminderde prognose of levenskwaliteit, waardoor andere
belangriike psychologische variabelen over het hoofd kunnen worden gezien.
Psychologische risicofactoren kunnen ingedeeld warden in (1) acute, (2) episodische
en (3) chronische risicofactoren. Depressie is een voorbeeld van een episodische
risicofactor, die gedurende een periode van een aantal maanden tot maximaal twee
iaar invloed uitoefent. Een chronische risicofactor echter heeft een impact van langer
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dan twee iaar. Persoonliikheid, het geheel van stabiele gedragingen en affecten van
een persoon, is een voorbeeld van een chronische risicofactor.
Onderzoek naar de relatie tussen persoonliikheid en negatieve gezond-
heidsuitkomsten, zoals een verminderde levenskwaliteit en gezondheidstoestand,
psychologische problematiek (zoals angst en depressie) en verhoogde mortalifeit
heeft de laatste iaren in toenemende mate aandacht gekregen bii patianten met
coronair hartliiden. Echter, bii patianten met CHF is bovengenoemde relatie fussen
een chronische psychologische risicofactor en gezondheidsuitkomsten nog nauweliiks
onderzocht. Onderzoek naar pati6ntgerichte ("patient-centred") uitkomsten, zoals
gezondheidstoestand, en de determinanten wordt door een aantal auteurs echter
sterk aanbevolen.
In dit proefschrift is de re|atie tussen de type-D, ofwel de distressed,
persoonliikheid en gezondheidsuitkomsten, zoals een aangefaste gezondheids-
toestand, angst, depressie, maar ook een verslechterde prognose, bii patianten met
CHF onderzocht. Het type-D persoonliikheidsconstruct bestaat uit twee stabiele en
niet-psychopathologische persoonliikheidstrekken, namelilk negatieve affectiviteit en
sociale inhibitie. Mensen met een type-D persoonliikheid hebben de neiging om een
keur aan negatieve gevoelens te ervaren en een negatieve kiik op de wereld,
anderen en zichzelf te hebben (negatieve affectiviteit). Tegeliikertild ziin ze geneigd
om deze negatieve gevoelens niet te delen met anderen, terwill ze dit weI zouden
willen, uit angst voor afkeuring of kritiek (sociale inhibifie). Onderzoek bii patianten
met coronair hartliiden heeft uitgewezen dat patianten met een type-D
persoonliikheid een hoger risico hebben om vroegfildig te overliiden, en een
verminderde levenskwaliteit en meer psychologische problematiek te ervaren.
Zoals al vermeld, is er nog tot heden geen sfudie gepubliceerd die zich
richt op de relatie tussen type-D persoonliikheid en gezondheidsuitkomsten bii
patianten met CHF. Ook over mogeliike mechanismen die negatieve effecten van
type-D persoonliikheid op gezondheidsuitkomsten zouden kunnen verklaren is weinig
bekend. Dit proefschrift had derhalve tot doel om de impact van type-D
persoonliikheid op patientgerichte uitkomsten bii patienten met CHF na te gaan. Een
tweede focus lag op het exploreren van mechanismen die mogeliike negatieve
effecfen van type-D persoonliikheid op gezondheidsuitkomsten zouden kunnen
verklaren en op de relatie fussen fype-D persoonliikheid en morfaliteit bii CHF.
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SAMENVATTING VAN DE BELANGRIJKSTE
RESULTATEN VAN DIT PROEFSCHRIFT
DEELA
Type-D persoon/4kheid als voorspeller van patisntgerichte uitkomsten
bil CHF
In dit proefschrift is, met uitzondering van Hoofdstuk 3, een longitudinale follow-up
studie bil patienten met CHF beschreven. Alle patianten die aan deze studie
deelnamen, ziin afkomstig van de polikliniek cardiologie van het TweeSteden
ziekenhuis in Tilburg. Nadat eerst een algemene inleiding is gegeven op het
proefschrift (Hoofdstuk   1), is dieper ingegaan   op de kenmerken van type-D
persoonliikheid en welke onderzoeksresultaten er ziin (Hoofdstuk 2). Vervolgens
richfte het eerste deel van dif proefschrift (deel A) zich op de relatie tussen type-D
persoonliikheid en gezondheidstoesfand, klachtenniveau, stemmingstoestand en
angst h ii patianten met CHF (Hoofdstuk 3-6).
In Hoofdstuk 3 is ingegaan op de relatie tussen type-D persoonliikheid
enerziids, en gezondheidstoestand, depressieve symptomen en stemmingstoestand
anderziids. Deze cross-sectionele studie bii 84 patienten liet een significante relatie
zien tussen type-D persoonliikheid en de genoemde uitkomstmaten. Wanneer er in
de analyses gecorrigeerd werd voor belangriike ziektekenmerken (zoals pompfunctie
van het hart), etiologie van het hartfalen, leeftiid en geslacht, bleef type-D
persoonliikheid geassocieerd met een verminderde gezondheids- en stemmings-
toestand, en toegenomen depressieve symptomen.
In Hoofdstuk 4 is bovengenoemde studie gerepliceerd in een grotere
steekproef en in een longitudinale studieopzet. Bii  166 hartfalenpatianten werd zowel
ziektespecifieke als generieke gezondheidstoestand gemeten bii inclusie  en   12
maanden later. Hoewel de ziektespecifieke en mentale gezondheidsfoesfand over de
tild heen verbeterde, rapporteerden Wpe-D patianten een verminderde
ziektespecifieke en mentale gezondheidstoestand in vergeliiking tot niet type-Ds. Ook
patianten die verhoogd scoorden op depressieve gevoelens rapporteerden een
lagere gezondheidstoestand dan patianten die niet verhoogd scoorden op depressie.
Type-D persoonliikheid bleek in deze sfudie een significante en onafhankeliike
voorspeller van verminderde ziektespecifieke en mentale gezondheidstoestand, ook
wanneer gecontroleerd werd voor depressieve gevoelens, baseline
gezondheidsfoestand, medicafie en belangriike ziektekenmerken. Ook depressieve
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gevoelens bleek een onafhankeliike voorspeller van verminderde gezondheids-
toestand fe ziin. In deze sfudie was type-D persoonliikheid echter geen significante
voorspeller voor fysieke gezondheidstoestand, waarschiinliik omdat de fysieke
gezondheidstoestand vooral door de ernst van het hartfalen werd bepaald.
In Hoofdstuk 5 is nagegaan of 31 CHF patianten die behandeld werden
met een biventriculaire pacemaker (resynchronisatie therapie) verbeterden in
gezondheidstoestand, klachtenniveau, waargenomen onvermogen en functionele
capaciteit over een periode van tvvee maanden. In het algemeen was er een
verbetering over de tiid op de genoemde uitkomstmaten. Echter, patisnten die
verhoogd scoorden op negatieve affectiviteit, een van de persoonliikheidstrekken
waaruit het type-D construct bestaat, bleken een lagere gezondheidstoestand en
meer symptomen en waargenomen onvermogen te rapporteren dan patienten die
laag scoorden op negatieve affectiviteit, zowel voor als na implantatie van de
pacemaker.
In het laatste hoofdstuk van het eerste deel van dit proefschrift, Hoofdstuk
6, is de relatie tussen type-D persoonliikheid en klinisch relevante angst (gemeten
met een interview) nagegaan. CHF patienten  (n= 149) vulden  de DS14 (Type-D
Schaal) in op baseline. Een iaar later werd bii deze patitjnten een klinisch interview
afgenomen om het angstniveau vast te stellen. Type-D persoonliikheid bleek klinisch
relevante angst significant te voorspellen, ook wanneer er werd gecontroleerd voor
depressieve gevoelens, angstgevoeligheid ("anxiety sensitivity"), socio-demografische
kenmerken en kenmerken van hef hartfalen, zoals de pompfunctie van het hart.
DEEL B
Type-D persoon/ilkheid als voorspeller van prognose in CHF en
mechanismen in de gevonden relaties fussen type-D en gezondheids-
uitkomsten
Hef tweede deel van dif proefschrift (deel B) richtte zich op de relatie tussen type-D
persoonliikheid en mortaliteit, en mogeliike mechanismen die de gevonden
negatieve verbanden tussen fype-D persoonliikheid en gezondheidsuitkomsten
zouden kunnen verklaren.
In Hoofdstuk 7 is de relatie tussen type-D persoonliikheid en zelfzorg-
vaardigheden  bii 178 patienten  met CHF beschreven. Specifiek werd aandachf
besteed aan consultatiegedrag als een afzonderliike aspect van zel{zorg. De studie
liet zien dat patianten met een type-D persoonliikheid geneigd ziin hun arts of
197
CHAPTER 11
verpleegkundige minder vaak te consulteren dan niet type-D patianten, terwill ze wei
meer gezondheidskiachten rapporteerden en zich daor ook zorgen over maakten.
Type-D patianten hadden dus een grotere kans op het ervaren van relevante
klachten, het zich daarover zorgen maken, maar tegeliikerfild niet de arts of
verpleegkundige raadplegen. Deze studie was de eerste studie die aangeeft dat
verminderde zelfzorg, en dan meer specifiek verminderd consultatiegedrag, een
gedragsmatig mechanisme zou kunnen ziin in de relatie tussen type-D
persoonliikheid en negatieve gezondheidsuifkomsfen.
Hoofdsfuk 8 exploreerde de relatie fussen type-D persoonliikheid en
chronische nierziekte enerziids, en cytokines anderziids bii 125 pati6nten met CHF.
Cytokines ziin proteinen, zogenaamde "boodschapperstoffen" van het
immuunsysteem, vergeliikbaar met hormonen, die een rol spelen in de immuun-
a{weer. Uit de prospectieve studie beschreven in Hoofdstuk 8 bleek dat type-D
persoonliikheid en chronische nierziekten voorspellend waren voor toegenomen pro-
inflammatoire cytokinewaarden en afgenomen anti-inflammatoire cytokinewaarden.
De effecfen van type-D persoonliikheid waren vergeliikbaar met de effecten die
chronische nierziekte had. Deze studie was de eerste prospectieve studie naar de
relatie fussen type-D persoonliikheid en chronische nierziekten enerziids, en
verstoorde balans tussen pro- en anti-inflammatoire cytokines anderzilds. Cyfokines
zouden dan ook een fysiologisch mechanisme kunnen ziin in de gevonden relaties
fussen type-D persoonliikheid en mortaliteit.
In Hoofdstuk 9 worden de resultaten gerapporteerd van een eerste studie
naar de relatie tussen type-D persoonliikheid en cardiale prognose bii CHF
patianten. Type-D persoonliikheid bleek een significante voorspeller voor late
cardiale mortaliteit (6 maanden of langer na inclusie) bii CHF, ook wanneer er
gecontroleerd werd voor pompfunctie van het hart, leeftild en geslacht, maar niet
voor vroege cardiale mortaliteit (binnen 6 maanden na inclusie). De relatie tussen
type-D persoonliikheid en totale cardiale mortaliteit was rand-significant na controle
voor de eerder genoemde variabelen. Omdat de steekproef in deze studie relatief
klein was en de follow-up periode relatief korI, worden studies naar de replicatie van
deze bevindingen aanbevolen.
Hoofdstuk   10  van  dit  proefschrift  omvat een algemene discussie  en
samenvalting, waarin de belangriikste bevindingen van dit proefschrift ziin
geintegreerd. Implicaties voor toekomstig wefenschappeliik onderzoek en voor de




In de Appendix tenslotte, is een Nederlandstalig artikel over de kenmerken
van en het onderzoek naar type-D persoonliikheid opgenomen.
AFSLUITENDE OPMERKINGEN EN CONCLUSIES
Concluderend kan gesfeld worden dat uit de studies beschreven in dif proefschrift is
gebleken dat type-D persoonliikheid een belangriike chronische psychologische
risicofactor is, die voorspellend is voor negatieve gezondheidsuitkomsten bii CHF. In
navolging van eerder onderzoek verricht bii patianten met coronair hartliiden, bleek
hef type-D persoonliikheidsconstruct, dan wei negatieve affectiviteit als belangriike
component van het type-D persoonliikheidstype, voorspellend voor een verminderde
generieke en ziektespecifieke gezondheidstoestand, verhoogde niveaus van
psychologische problematiek, verhoogde klachtenniveaus, meer ervaren
onvermogen en een verminderde cardiale (lange termiin) prognose bil pati6nten met
CHF. Tevens bleek type-D persoonliikheid geassocieerd met verminderde zelfzorg,
meer specifiek met verminderd consultatiegedrag, en verstoringen in de balans
tussen pro- en anti-inflammatoire cytokines. Verminderde zelfzorg en een verstoorde
cytokinebalans zouden mogeliike verklarende mechanismen kunnen ziin in de
gevonden negatieve relaties tussen type-D en gezondheidsuitkomsten.
Dit proefschrift is een eerste aanzet tot meer aandacht voor (1)
patiantgerichte uitkomsten bii CHF, (2) chronische psychologische risicofactoren als
belangriike determinanten van gezondheidsuitkomsten en (3) verder onderzoek naar
mechanismen die de gevonden negatieve relaties tussen type-D persoonliikheid en
gezondheidsuitkomsten zouden kunnen verklaren. Het gegeven dat type-D
persoonliikheid dus niet alleen een belangriike psychologische risicofactor is bii
coronair liiden, maar ook bii CHF, vaak een laatste fase in het proces van een
hartziekte, is indicatief voor de stabiliteit van het construct.
In de klinische praktiik is het van belang om patianten die een verhoogd
risico lopen op negatieve gezondheidsuitkomsten vroeg te identificeren. Deze
pati6nten verdienen, naast optimale farmacologische behandeling, extra aandacht in
de vorm van psychosociale begeleiding of behandeling. Tot nu toe is er nog geen
interventiestudie verricht naar type-D persoonliikheid. Het ontwikkelen van
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De laatste laren wordtin wetenschappelijk onderzoek steeds meer aandachf besteed
aan psychosociale factoren bil hartaandoeningen. Meer en meer bilild dat zil een
belangriike rol spelen. Echter, de rol van persoonlitkheid is, na inconsistentie in
onderzoeksresultaten rondom Type A "persoonlilkheid", in de vergeethoek geraakt.
Type-D persoonlilkheid heeft onderzoek naor de relatie fussen persoonlilkheids-
trekken en hart- en vaatziekten een nieuwe impuls gegeven.
Nog steeds gelden hart- en vaatziekten, met 45.000 gevallen van overliiden per
iaar, als doodsoorzaak nummer 6en in Nederland [11. Maar niet alleen de prognose
is slecht, ook is bil hart- en vaatziekten sprake van een verminderde kwaliteit van
leven [o.a. 21. Psychologische factoren worden geassocieerd met zowel een slechtere
prognose als met verminderde levenskwaliteit bil hart- en vaatziekten [3,41. De
nadruk in wetenschappeliik onderzoek op dit terrein ligt veelal op het verband tussen
depressiviteit  enerziids en prognose en levenskwaliteit anderzlids [51. Daardoor
kunnen andere psychologische factoren, zoals persoonliikheid, over het hoofd
worden gezien. Dif artikel geeft een overzicht van wetenschappeliik onderzoek
verricht naar de rol van de "distressed", ofwel type-D persoonliikheid, op het gebied
van hart- en vaatziekten.
DEFINITIE EN ASSESSMENT
Type-D persoonliikheid bestaat uit twee stabiele en niet-psychopathologische
persoonliikheidsfrekken, nameliik negatieve affectiviteit en sociale inhibitie [6-81.
Negatieve affectiviteit is de neiging om in verschillende situaties negatieve emoties te
ervaren, terwill sociale inhibitie de neiging reflecteert om deze negatieve emoties te
onderdrukken en niet te uiten in sociale interacties uit angst voor kritiek of afwiizing
door anderen [61. Kortom, type-Ds maken zich veel zorgen, hebben een negatieve
kiik op het leven, voelen zich vaak neerslachtig en gespannen, ziin verhoogd
geirriteerd en ervaren minder vaak positieve gemoedstoestanden. Deze negatieve
gevoelens worden niet snel geuit in aanwezigheid van anderen, uit angst voor
sociale afkeuring of kritiek.
Type-D persoonliikheid komt relatief veel voor. In West-Europa ligt de
prevalentie tussen  de   13%  en  32.5%  in de algemene populatie  16,9-111.   De
prevalenfie type-D bil pati6nten met hart- en vaatziekten ligt fussen de 26% en 53%
16,7,121
De oorsprong van Type-D ligt in de klinische setting. Bii evaluafie van een
hartrevalidatieprogramma viel op dat niet alle deelnemers evenveel baat hadden bii
202
TYPE-D PERSOONLIJKHEID EN HART- EN VAATZIEKTEN
de interventie. Deze impressie werd onderbouwd met het gegeven dat emotionele
distress biidraagt aan de progressie van hart- en vaaiziekten [o.a. 131 6n de nofie
dat emotionele distress veelal ontstaat vanuit persoonliikheidskenmerken [14,151.
Vanuif gevestigde persoonliikheidstheorieen werden specifieke kenmerken
geselecteerd [161 en de prognostische waarde van type-D persoonliikheid werd
empirisch aangetoond voor patianten met coronair liiden 11 4,1 71.
Persoonliikheid is een product van zowel omgevings- als
erfeliikheidsfactoren. Tweelingenonderzoek naar persoonliikheidstrekken, zoals
neuroticisme, toonde aan dat deze karaktertrek voor ongeveer 50% erfeliik bepaald
is [181. De overige 50% van persoonliikheidstrekken kan worden toegeschreven aan
omgevingsfactoren, zoals opvoeding. Ook type-D persoonliikheid bevat, conform
andere persoonliikheidstrekken, een belangriike erfeliikheidscomponent (52%) [191
Type-D persoonliikheid is goed te onderscheiden van depressiviteit. Op de
eerste plaats omvat het type-D construct een coping-aspect: met negatieve
gevoelens wordt omgegaan door deze op fe kroppen [201. Op de tweede plaafs is
negatieve affectiviteit (zoals verhoogde irritatie, piekeren) kenmerkend voor type-D,
terwill bii depressie neerslachfigheid of depressief affect het kenmerkende sympfoom
is. Op de derde plaats geldt type-D persoonliikheid als een stabiel, niet-
psychopathologisch persoonliikheidsconstruct en is het geen foesfandsbeeld, zoals
depressie dat weI is [6,211.
De aanwezigheid van type-D persoonliikheid kan eenvoudig vastgesteld
worden. Denollet ontwikkelde hiervoor een korfe, voor de pati6nt gemakkeliik en
snel  (3 tot 5 minuten)  in te vullen vragenliist, de DS 1 4 (Type-D Schaal)  [61. De liist
omvat twee maal zeven vragen, die respectievelilk de persoonliikheidstrekken
negatieve affectiviteit en sociale inhibitie meten, en op een 5-punts antwoordschaal
beantwoord worden [61 Voorbeelden van items ziin: "ik maak me dikwiils zorgen"
Cnegatieve affectiviteit) en "ik ben een gesloten persoon" (sociale inhibitie). Patianten
die op beide schalen tien of meer punten scoren, worden geclassificeerd als type-D.
De DS 1 4 heeft uitstekende psychometrische kwaliteiten (Cronbach's a =0.88/0.86;
test-hertest betrouwbaarheid =0.72/0.82, voor respectieveliik de negatieve affectivi-
teit en sociale inhibitie schaal) 16].
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TYPE A, TYPE-D......IS ER EEN VERSCHIL8
E6n van de mogeliike redenen waarom persoonliikheid relatief weinig onderzocht is
in relatie tot hart- en vaatziekten is de inconsistentie in onderzoeksbevindingen
..„
rondom de Type A "persoonliikheia 1211 Friedman en Rosenman herleidden Type A
van klinische observaties en indrukken, en definieerden het construct als "an action-
emotion complex that can be observed in any person who is aggressively involved in
a chronic, incessant struggle to achieve more and more in less and less time, and if
.required to do so, against the opposite efforts of other things and other persons
[221. Mensen die Type A gedrag vertonen ziin competitief, zeer nauw betrokken bii
hun werk, ongeduldig, agressief, viiandig en hebben een continu gevoel van
gehaastheid en tiidsdruk 14,231. Over het verband tussen Type A gedrag en het risico
op hart- en vaatziekten ziin inconsistente onderzoeksbevindingen gepubliceerd.
Werden er eerst verbanden aangetoond, in latere studies werden deze niet
gerepliceerd [24,251. Een mogeliike verklaring voor deze inconsistentie ligt wellicht
in zogenaamde "derde variabelen", zoals sociale steun [41. Tevens leidden de
inconsistente bevindingen tot de veronderstelling dat niet het complete Type A
gedragspatroon, maar specifieke componenten hieruit, met name viiandigheid
(hostiliteit), een negatieve invloed hebben op het ontsfaan van hart- en vaatzieklen
[261
De term "Type A persoonliikheid" is in feite incorrect, aangezien hef hier
niet gaat om de beschriiving van een persoonlilkheidsconstruct, maar om een
beschriiving van een gedragspatroon [271. Er dient daarom gesproken fe worden
van het Type A gedragspatroon en we kunnen concluderen dat bepaalde
gedragscomponenten uit het Type A gedragspatroon samen liiken te hangen met het
risico op hef ontwikkelen van hart- en vaatziekten. Het type-D construct daarentegen
is, zoals eerder beschreven, niet ontwikkeld als gedragspatroon, maar als
persoonliikheidsconstruct met fundering in bestaande persoonliikheidstheoriean
[14,171. Het verschil met het Type A gedragspatroon is dat type-D een afgebakende
groep mensen definieerf, nameliik de mensen die veel negatieve gevoelens ervaren
en deze niet uifen wanneer ze in gezelschap ziin, terwill Type A, een verzamelnaam
voor verscheidene gedragingen, een meer heterogeen construct is [21].
TYPE-D PERSOONLIJKHEID EN HARTZIEKTEN
De laafste iaren ziin onderzoeksbevindingen gepubliceerd waaruit bliikt dat type-D
persoonliikheid samenhangt met verschillende negatieve uitkomsten bii pati6nten met
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een hartaandoening. Verschillende groepen hartpatienten ziin onderzocht. In deze
paragraaf wordt een overzicht gegeven van de voornaamste onderzoeksbevindingen.
In Tabel 1 wordt, in chronologische volgorde van verschiiningsdatum van de studies,
aangegeven welke sfudies besproken worden.
Type-D persoonliikheid is verschillende malen in verband gebracht met een
verhoogd risico op mortaliteit  bii  hartzieklen.  Zo  werd  in  een  studie  uit  1996
aangetoond dat coronair patianten met een type-D persoonliikheid een beduidend
groter risico op overliiden hadden dan niet type-Ds, na statistische controle voor
biomedische risicofactoren [81 Zoals weergegeven in Figuur  1, was type-D  per-
soonliikheid een voorspeller van mortaliteit, onafhankelilk van eiectiefractie (pomp-
functie van het hart) en vernauwingen in meerdere kransslagaders.
Voorts bleek type-D persoonliikheid mortaliteit of een niet-fafaal myocard
inforct over 6 tot 10 iaar te voorspellen [28}. In een studie uit 2000 bii 319 coronair
patienten toonden Denollet en collega's aan dat type-D persoonliikheid, samen met
iongere leeftiid en een verminderde pompfunctie van het hart, een onafhankeliike
voorspeller voor prognose over 5 iaar was [7]. In een recente studie werd
aangetoond dat type-D een onafhankeliike voorspeller was van het gecombineerde
eindpunt "mortaliteit, non-fataal hartinfarct en bypassoperatie/dotterprocedure" 129]
Type-D pati nten uit een hartrevalidatieprogramma bleken, bezien over een periode
van 5 iaar, een biina driemaal zo groot risico te lopen op hef genoemde eindpunt
danniet type-Ds. Type-D persoonliikheid bleek voorts ook bii pati6nten die gedotterd
waren gerelafeerd aan een viifmaal groter risico op overliiden of het optreden van
een hartinfard wanneer statistisch gecontroleerd werd voor geslacht, leeftiid, eerdere
bypassoperatie, stentl-type, en de interactie persoonliikheid * stent-type [30]
Denollet en collega's [31] bekeken in een volgende studie in dezelfde
patientengroep specifiek de rol van de sociale inhibitie component. Uit de studie
bleek dat hef interactie-effect negatieve affectiviteit * socia|e inhibitie (type-D)
negatief gerelateerd was aan prognose. Te concluderen valt dan ook dat niet enkel
negatieve affectiviteit het negatieve effect op mortaliteit verklaart, maar dat luist het
gecombineerde effect met sociale inhibitie van cruciaal belong is [31}
Naast de genoemde verbanden tussen type-D en "harde" uitkomsten als
mortaliteit, ziin er ook studies in verschillende groepen hartpati*nten, die verbanden
' een stent is een metolen veerfle daf ingebrachf wordt in een slagder bu een dofteringreep en
tot doel heeft de ploque, die door de dotteringreep opzii is geduwd, op ziin plaots te houden.
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le Tabel 1: Type-D persoonfilkheid en negafieve uitkonisten bil hart- en vaotziekfenpaftenten2                                                                                                                                                      -0
-0Auteur Sfeekproef Studie design Eindpunt Risico m
ZDenollet et al.  C 1996) 303 coronair pationten prospectiel mortalifeif OR 4.1                        0
Denollet & Brutsaert (19981 87 coronair patienten prospectief cat"dicile niorfatifert hailinforct RR- 4.7 X
Denoilet el al. (2000) 319 coronair patienten pi ospectiel cardiale mot-faliteit horfinfarct OR  =  8.9
Denollet et al. (2000) 104 coronair patienten piospectiet KvL OR 2.2
Pedersen & Middel {2001) 171  coronair patienten inteive,itiestudie vitale uitputting OR 4.7-6.4
Pedersen et al. (20041 875  PO potunten prospectief nior·fabtest harfinfarct OR - 5.3
Pedersen el al. (2004) 1821CD patienten cross-sectionee/ angst/depressie OR - 4.4-8.7
144 partners
Al-Ruzzeh et af. (2005) 437 CABG patienten cross-sectiorlee/ Kvl OR  2.35.5
Schiffer et al. (2005) 84 Cl-IF potienten cross-sectioneel Kvt/depressie OR- 3.3-7.1
Denollet et al. (2006) 337 coronair pati titen prospectiet cordiaal incident' OR= 2.9
Denotlet et al. (2006) 87 5 PCI patianten prospectief cardiale mortaliteit har·tinforct H R=   1.9
Pedersen et al. 0006) 542 PCI potienten zonder prospectief depressie OR  3.0
depressie
Kvt =Kwal,feit van leven: PCI =Percutaneous coronary intervention; ICD=Implantable cardioverfer defibrillator; CABG=Coronary artery
bypass graff surgery.  CHF= Chronisch haitaleri,· OR   Odds ratio; RR- Relative risk, HR -Hazard ratio.
*cardiale mortaliteit, myocard infract, PCL CABG
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Figuur 1  Morta/ifeit opgesplitst naor pompfunctie en fype-D persoonlitkheid (boven), en
kronssfagoderl,iden en type-D persoonhikheid (onder)
aantonen tussen type-D persoonliikheid en kwaliteit van leven of andere
psychologische uitkomstmaten. Zo werd er een verband tussen type-D en
verminderde kwaliteit van leven bii coronair patianten aangetoond [71 Type-D
persoonliikheid bleek binnen de groep coronair liiders ook gerelateerd aan vitale
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uitputting. Type-Ds rapporteerden meer symptomen van vitale uitputting (dat wil
zeggen uitgesproken vermoeidheid, verhoogde geTrriteerdheid en een gevoel van
demoralisafie) dan niet type-D patianten [32,331. Bil patianten die een
bypassoperatie hadden ondergaan, bleek type-D een iaar na de ingreep gerelateerd
aan een verminderde fysieke en mentale kwaliteit van leven [341. In een groep van
patianten met chronisch hartfalen was type-D geassocieerd met een verminderde
kwaliteit van leven en met toegenomen depressieve symptomen [121. Ook uit een
studie bil patianten bii wie een defibrillator (ICD) geimplanteerd was en hun partners,
bleek dat type-D persoonliikheid een belangriike verklarende factor was voor het
opfreden van angstige en depressieve gevoelens bii zowel de patiant als bii de
partner [351. In een recente studie uitgevoerd bii patianten die een dotterprocedure
hadden ondergaan, bleek type-D persoonliikheid, samen met diabetes mellitus, een
risicofactor voor het ontwikkelen van depressieve symptomen een iaar na de
interventie [361
Binnen de hart- en vaatziektenpopulatie is fype-D persoonliikheid dus
herhaaldeliik in verband gebracht met een verhoogd risico op mortaliteit, een
verminderde kwaliteit van leven en emotionele problemen.
TYPE-D PERSOONLIJKHEID IN ANDERE
PATIENTENGROEPEN
Hoewel het type-D construct voornameliik onderzocht is bii patianten met hartzieklen,
is eveneens onderzoek gedaan in andere patiantenpopulaties. In een case-control
studie van Aquarius en collega's [9] is nagegaan of type-D persoonliikheid invloed
had op de kwalifeit van leven van patienten met perifeer vaatliiden, en of deze
invloed los stond van de ernst van de zielde. Uit de studie bleek dat de ernst van het
perifeer vaafliiden nief samenhing met kwalifeif van leven, maar in de steekproef van
patianten met perifeer vaatliiden werd wei een minder goede kwalifeif van leven
gerapporfeerd dan in de gezonde controlegroep. Daamaast werd er door type-Ds
een minder goede kwaliteit van leven gerapporteerd dan door niet type-Ds, zowel in
de "zieke" groep als in de gezonde controle groep. Na statistische controle voor de
aanwezigheid of afwezigheid van perifeer vaatliiden, bleef type-D persoonliikheid
geassocieerd met een verminderde kwaliteit van leven, waarbii type-Ds een meer
dan zevenmaal verhoogd risico hadden op een aangetaste levenskwaliteit dan niet-
type-Ds (OR=7.4) [91.
Denollet 161 vond een hoge prevalentie (53%) type-D bil pati8nten met
hypertensie. In een andere studie werd gevonden dat type-Ds in vergeliiking met niet
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type-Ds een sterkere bloeddrukreactiviteit hadden [37], maar verder onderzoek naar
type-D en hyperlensie is nog niet verricht.
Onderzoek naar type-D persoonliikheid binnen andere patientenpopulaties
zal in de toekomst verdere aandacht kriigen.
VERKLARENDE MECHANISMEN
Het onderzoek naar type-D persoonliikheid begint zich meer en meer te richfen op
"verklaringen". Hoe kunnen de aangetoonde verbanden fussen type-D en allerlei
negatieve gezondheidsuitkomsten verklaard worden@ Meer duideliikheid over
onderliggende fysiologische en gedragsmatige mechanismen is een belangriike stap
op weg naar mogeliike behandeling van type-D persoonliikheid.
Op de eerste plaats wordt een rol voor de hypofhalamic-pituitary-adrenal-
(HPA)as verondersteld [381. De hypothalamus stimuleert de hypofyse bii confrontatie
met stress. De hypofyse scheidf adrenocorticofroop hormoon (ACTH) uit en prikkelt
hiermee de biinierschors om cortisol af te scheiden. Bii langdurige stress worden er
aldus grote hoeveelheden van hef hormoon cortisol uitgescheiden, waardoor allerlei
negatieve gevoelens in de hand worden gewerkt [391. De beide
persoonliikheidstrekken waaruit type-D bestaaf, negatieve affectiviteit en sociale
inhibitie, bleken in een studie uit 2003 geassocieerd met verhoogde cortisolspiegels
1371
Ten Iweede geeft onderzoek aanwiizingen voor een mogeliik verband
tussen type-D en cytokines [40,41}. Cytokines ziin boodschapperstoffen van het
immuunsysteem, vergeliikbaar met hormonen. Een cytokine is een proteTne, die een
rol speelt in de immuunafweer. Er bestaan verschillende soorten cytokines, die door
verschillende soorten lichaamscellen worden geproduceerd en ook werken op
verschillende lichaamscellen. Bii patienten met chronisch harlfalen worden
verhoogde cytokinewaarden geassocieerd met een verslechferde prognose [421
Vanuit deze onderzoeksbevinding formuleerden Denollet en collega's [411 en
Conraads en collega's 1401 de hypothese dat de verhoogde cytokinewaarden bii
chronisch hartfalenpatianten samenhingen met type-D [40,411. Uit de genoemde
studies bleek inderdaad dat type-D persoonliikheid onafhankelilk geassocieerd was
met de cytokinesoort TNF-a en diens receptoren [40,411
Op de derde plaats ziin er aanwiizingen voor een verband tussen
respectieveliik negatieve affectiviteit en sociale inhibitie, en afgenomen variabiliteit in
de hartslag bii gezonde mannen [37].
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Tenslotte wordt er een relatie verondersteld met gedragsfactoren. Hoewel
nog geen onderzoek hiernaar verrichf is, is hef denkbaar dat type-D
persoonliikheden minder trouw ziin aan medicatievoorschriften, bezoeken aan de
medisch specialist en dergeliike. Bovendien zou type-D persoonliikheid kunnen
samenhangen met ongezonde leefgewoonten als roken en weinig bewegen. Uit
eerder onderzoek is bekend dat verschillende psychologische en psychosociale
risicofactoren geassocieerd ziin met inadequaat gebruik van medische middelen,
zoals biivoorbeeld vertraagd hulp zoeken voor serieuze symptomen en slechte
opkomst bii hartrevalidatieprogramma's 143,44]. Dergeliike risicofactoren kunnen
een belemmering vormen voor het aannemen van een gezonde leefstill en het
vasthouden hiervan 1451. De veronderstelling is dat dit ook voor type-D
persoonliikheid geldt. Overigens toont een recente studie aan dat chronisch
hartfalenpatianten met een type-D persoonliikheid de neiging hebben hun klachten,
waarover ze zich weI grote zorgen maken, niet te melden aan hun arts of
hartfalenverpleegkundige. Deze slechte zelfzorg zou ook een mechanisme kunnen
ziin dat de relatie tussen type-D, en verslechterde prognose en verhoogde morbiditeit
mede verklaard [461
Conctuderend kan gesteld worden dat er nog weinig bekend is over de
fysiologische en gedragsmatige mechanismen die de in onderzoek aangetoonde
verbanden tussen type-D en negatieve uitkomsten verklaren. Onderzoek in de nabiie
foekomst zal zich dan ook hierop dienen te richten.
DE KLINISCHE PRAKTIJK
Voor de klinische prakfilk ziin de behandelingsmogeliikheden van type-D patiianten
met hart- en vaatziekte van belang. Verschillende psychologische en psychosociale
factoren kunnen de ontwikkeling en het beloop van coronaire hartzieklen negatief
beinvloeden 14,43,44,47-491 Aangezien uit onderzoek is gebleken dat type-D
persoonliikheid een belangriike risicofactor is voor verhoogde mortaliteit en
morbiditeit, aangetaste kwaliteit van leven en verhoogde kans op emotionele pro-
blemen, is het een psychologische risicofactor waarmee rekening gehouden dient te
worden. Vroegtiidig opsporen van die patianten met een type-D persoonliikheid en
het bieden van extra aandacht, steun en begeleiding is van belang. De gedachte dat
iemands persoonliikheid toch niet fe veranderen is en dat behandeling van patianten
met een type-D persoonliikheid dan dus zinloos is, moeten we verlaten. Een
dergeliike hoge risicogroep verdient iuist extra aandacht in de klinische praktilk. Bil
de behandeling van type-D patianten moet het doel echter niet het veranderen van
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het persoonliikheidstype ziin, maar veel eerder het veranderen van het gedrag dat
voortkomt uit de persoonliikheid, waardoor negatieve effecten op uitkomstmaten,
zoals biivoorbeeld de genoemde aangetaste kwaliteit van leven of emotionele
problemen, verminderd kunnen worden. Overigens is uit een studie van Denollet &
Brutsaert [501 gebleken dat een inferventie, ook bii type-D patianten, weI degeliik zin
heeft. Een uitvoerig revalidatieprogramma, bestaande uit een combinatie van
beweging, een psychosociale interventie en indien nodig individuele psychologische
begeleiding, leidde tot vermindering van emotionele "distress" (op korte termi n) en
een betere prognose (op lange termiin) bii pati6nten met coronaire harlziekten. De
studie maakte duideliik daf uitvoerige fysieke en psychische revalidatie het
emotionele welbevinden en de overleving van coronaire hartpatianten, 66k patianten
met een type-D persoonliikheid, gunstig kan beinvloeden [7,501.
Naar onze mening ziin een drietal aspecten van belang in de behandeling
en begeleiding van type-D patidnten. Op de eerste plaats liikt, zoals eerder in dit
artikel aangehaald, het verbeteren van zelfzorgvaardigheden belangriik. Uit een
recente studie verricht bii patianten met chronisch harlfalen bleek dat patianten met
een type-D persoonliikheid een vergroot risico hadden op verminderde zelfzorg,
omdat zii de neiging hadden geen contact met hun arts of verpleegkundige fe
zoeken wanneer zii relevante cardiale symptomen bemerkten, waarover ze ook
bezorgd waren 146}. Op de fweede plaats is het belangrilk om de type-D patient te
helpen in het verstevigen en uitbreiden van hef sociale netwerk. Aangezien type-D
patienten niet geneigd ziin hun moeiliikheden en vervelende gevoelens spontaan te
delen met anderen, is het van belong de patiant te begeleiden in het crearen van een
stimulerend, begripvol en sfeunend sociaal netwerk. Type-D patianten willen nameliik
wei hun vervelende gevoelens delen met anderen (in tegenstelling toi sociaal
introverle pati8nten die hieraan geen behoefte hebben), maar durven dit niet uit
angst voor afwiizing of kritiek van hun gesprekspartners. Een derde aangriippunt
voor behandeling en begeleiding van de type-D pati8nt is de copingstrategie die
gehanteerd wordt. Deze patianten gaan met vervelende gevoelens om door deze op
te kroppen en niet te delen met anderen. In de behandeling zou aandacht besteed
moeten warden aan het aanleren van andere copingstrategie8n en het veranderen
van hun negatieve kiik op de wereld. Uit voorgaande studies is overigens ook
gebleken dat lichaamsbeweging kan biidragen aan een verbetering van de kwaliteit
van leven bii hartpatianten 151,521. Onbekend is echter of dit effect ook gevonden
wordt voor type-D pati6nten. Mocht dit het geval ziin, dan zou stimulatie tot meer
beweging een aanvullende interventie op gedragsniveau kunnen ziin. De effecten
van de genoemde interventies of combinaties van interventies bii type-D
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persoonliikheid ziin nog niet onderzocht. Onderzoek naar verschillende
interventiemogeliikheden bii type-D persoonliikheden wordt daarom aanbevolen.
Naast interveni6ren is de stap daarvoor, vroegtiidige herkenning van type-
D persoonliikheid, zoals al eerder aangegeven, zeker ook van belang. Screening van
patienten kan op een eenvoudige, voor de patiant niet belastende, manier door
gebruik te maken van de DS 1 4 [6J. Wanneer type-D patianten sneller geidentificeerd
worden, behoort prevenfief ingriipen nog tot de mogeliikheden. Voorkomen is
immers beter dan genezen!
Concluderend kunnen we stellen dat uit verschillende studies in de
afgelopen iaren gebleken is daf type-D persoonliikheid samenhangt met een
verslechterde prognose, meer morbiditeit, een verminderde kwaliteit van leven en
een verhoogde mate van depressieve gevoelens, angst en vitale uitputting bii
patitbnten met hart- en vaatziekten. Onderzoek richt zich nu met name op de
mechanismen die het verband tussen type-D en de genoemde negatieve uitkomsten
zouden kunnen verklaren. Hoewel er nog geen onderzoek verricht is naar
interventiemogeliikheden, is het vroegtiidig herkennen van type-D patianten in de
klinische praktilk van belang.
SUMMARY IN ENGLISH
Cardiovascular disease, the leading cause of death in the Netherlands, is associated
with high mortality and morbidity rates, as well as impaired quality of life. The
importance of psychosocial variables in heart disease is nowadays recognised.
However, the role of personality in cardiovascular disease has been overlooked.
Recently, there is some research focusing on the distressed, or type-D, personality.
Patients who score high on two stable personality traits, negative affectivity and social
inhibition, are defined as type-D. It has been shown that type-D is related to
mortality, morbidity, quality of life, and psychological distress in cardiovascular
patients. In the near future, research should focus on possible physiological and
behavioural mechanisms that link type-D to negative outcome. In clinical practice,
type-D can be used to identify high-risk patients.
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